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Abstract 
Nitric oxide (NO) is a potent biological messenger known to play key roles in many biological 
processes. Medical conditions such as angina, cancer and some neurodegenerative diseases have 
been shown to benefit from nitric oxide related therapy.  The moderation of in vivo levels of nitric 
oxide is important when considering any lead compounds that exploit NO pathways. It has been 
theorised that conditions such as Alzheimer’s and Parkinson’s disease may benefit from a reduction 
in the levels of NO present in the brain. By inhibiting the nNOS enzyme in brain tissue it is possible 
to reduce the levels of NO and produce an effective way of treating a number of different 
neurodegenerative diseases. A series of novel, and chemically simple NOS inhibitors were sought 
out, building upon evidence alluded from three-dimensional structural docking studies performed 
using pymol and a 3D virtual environment facility. 
 In conditions that could benefit from a higher concentration of NO, such as angina and 
arteriosclerosis, the use of NO-donors is an attractive option. The synthesis of a series of novel NO-
donors, based on a furoxan scaffold, of sufficient stability was achieved allowing NO release and 
vasodilatory studies to be conducted. Compound 94 induced 100% reversal of contraction in rat 
aortic, renal and pulmonary vessels and was able to release NO under both photochemical and 
oxidative conditions with an IC50 0.25μM. The vasodilatory effect of compound 94 and other 
compounds in the series was found to be reproducible and reversible. When compared to the BNF 
listed NO donor, sodium nitroprusside (SNP, 9), compound 94 produced a more sustainable 
relaxation with no fluctuations in vascular tone.  
Mechanistically NO release was confirmed using mass spectroscopy and a nitric oxide analyser 
(NOA) through the application of ozone based chemiluminescence and provided interesting evidence 
towards the decomposition of this novel furoxan. In addition, a second series of novel NO donors 
based on the diazeniumdiolates was successfully synthesised alongside X-ray crystallography data, 
which is pertinent to the debate surrounding the reactivity of both the internal and terminal oxygens 
in the NONO moiety. These diazeniumdiolate based donors were also investigated using the NOA 
to identify the bet conditions for NO release, which were found to be light at 254nm. 
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Chapter 1.0- Introduction 
 
Nitric oxide (NO) is a small, gaseous diatomic radical made up of a single atom of nitrogen and 
oxygen. Before 1987 NO was only considered as a constituent in photochemical smog1. Areas of 
high sun-exposure such as Los Angeles can provide suitable energy for complex radical reactions to 
occur and the production of smog. Alternatively, NO can also be formed as a by-product of 
incomplete combustion in the internal combustion engine.  
In 1987 it was discovered that NO was not just a nuisance to the environment but was also 
biologically active and vital to health. In 1869 Frederick Guthrie reported2 that amyl nitrite when 
inhaled caused “an acceleration in the action of the heart” and induced a “throbbing in the arteries”. 
It wasn’t until 1988 that a major breakthrough in nitric oxide research occurred, when the Nobel 
Prize for medicine was awarded to three scientists, Furchgott, Ignarro and Murad for their discoveries 
concerning nitric oxide as signalling agent in the cardiovascular system.3-6 Robert Fuchgott was 
researching vascular muscle relaxation and how acetylcholine induced this process. Furchgott 
conducted an experiment (shown in Fig.1) using rabbit aorta and found that the relaxation of the 
smooth aortic muscle, upon stimulation with noradrenaline, only occurred when endothelial cells 
were present. In the absence of the endothelial layer, smooth muscle cells continue to contract in the 
presence of noradrenaline. This led Furchgott to conclude that there must be a compound or factor 
inside the endothelial layer that produces this relaxation when exposed to a stimulant such as 
acetylcholine. He named this unknown substance the endothelium derived relaxation factor (EDRF). 
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Figure 1: Furchgott's famous experiment: Using rat aorta with and without the endothelium to 
conclude that the factor EDRF produced vasodialation.3 
 
Ignarro5, who was also researching EDRF, conducted an experiment to see if the effect of      
nitrogylcerin, which has long been used for the treatment of angina, worked by the release of NO. 
By doing UV-Vis spectrophotometry (Fig. 2) on haemoglobin in the presence of EDRF and then in 
the presence of NO he found that the resulting maximum absorbance for the complex formed had 
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Murad’s research6 was concerned with the mechanism by which nitroglycerin relaxed smooth muscle 
cells. He found that nitroglycerin activated an enzyme called guanylyl cyclase (GC), the key enzyme 
in smooth muscle relaxation, which produced cyclic guanosine monophosphate (cGMP), a 
compound known to be involved in the relaxation of smooth muscle.3,6 Murad wanted to determine 
whether nitroglycerin acted via the release of nitric oxide, as suggested by Furchgott in an earlier 
publication, so he bubbled nitric oxide gas through a section of tissue containing the enzyme guanylyl 
cyclase and found that the concentration of cGMP increased thus suggesting that nitric oxide is 
involved in the activation of GC. 
At a similar time it was concluded by a fourth scientist, Moncada, that EDRF was in fact the diatomic 
molecule nitric oxide as he found that the relaxation of endothelium tissue with EDRF was 
indistinguishable from the results produced by nitric oxide and thus EDRF had to be NO.7,8 
1.0.1- Reactions of NO 
 
Nitric oxide is formed from the combination of one atom of nitrogen and one atom of oxygen 
producing a compound with an unpaired electron. Therefore by definition NO is a radical species 
however, it isn’t as reactive some radicals such as the hydroxyl radical.9 
In the gas phase nitric oxide reacts with oxygen to produce nitrogen dioxide as a brown fuming, toxic 
gas (shown in scheme 1). This only occurs at high concentrations, not consistent with those found in 
vivo and as the half-life of NO10 is quite short (approximately five seconds) it is unlikely that this 
reaction occurs in the body to any great extent. 
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A more likely pathway involves superoxide (O2-), a reactive oxygen species, found and produced in 
the electron transport chain in respiration, and produced in macrophages by the enzyme NADPH 
oxidase. Superoxide reacts with nitric oxide to produce a compound known as peroxynitrite (ONOO-
) as shown in scheme 2. Due to superoxide’s being as a cytotoxic compound, the decomposition of 




Scheme 2: Reaction of nitric oxide with superoxide anion: The in vivo metabolism of NO 
 
Peroxynitrite (ONOO-) is a stable anion and is initially produced as the cis isomer due to the creation 
of a ion-dipole interaction. Once protonated at a neutral pH it isomerises to the trans conformer, 
which rapidly decomposes to produce the nitrate anion (NO3-) and is then excreted in urine by the 
body. Peroxynitrite itself has been linked to a number of negative effects in the body and is believed 
to be a main contributor to DNA damage when it’s overproduced. If superoxide concentrations 
increase by 10 fold the levels of peroxynitrite are seen to increase by a 100 fold thus creating quite 
high levels of a fairly strong oxidant. Regulation of this by-product and the constituent compounds 
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1.0.2- Biosynthesis of NO 
 
Nitric oxide is produced in the body at the site of action by a class of enzymes known as the nitric 
oxide synthases which catalyse the conversion of L-arginine 1 to L-citrulline 2 through a five electron 
transfer process resulting in the production of nitric oxide. The L-citrulline 2 is then recycled back 
in to L-arginine 1 by reduced NADP to start the process again as shown below in scheme 311. 
 
 
Scheme 3: Conversion of the simple amino acid L-Arginine to L-Citrulline and the production of 
NO, a reaction catalysed by the enzyme NOS. Adapted from A. R. Butler1 
 
There are three types of NOS enzyme named after where they were originally discovered in the body, 
the endothelium, within neurons and the immune system. The three isoforms of NOS can be further 
divided into two different sub-classes: constitutive NOS and inducible NOS. Their location and 









 Constitutive Inducible 
Properties eNOS nNOS iNOS 
Source Endothelial cells Neurons, cerebral 
tissue, skeletal 




Number of amino acids 1203 1554 1153 
Stimulant required for 
activation 
Acetylcholine Glutamate Cytokines 
Dependence Ca2+ Ca2+ Ca2+ independent 
Primary Function Vasodilation Cell communication Immune response 
 
 
Table 1: Location and function of the three isoforms of the NOS enzyme. Adapted from P. 
Tripathi, 200712 
 
Constitutive NOS is comprised of the endothelial and neuronal NOS enzymes, and are both known 
to be calcium dependent. After either acetylcholine or glutamate has bound the protein calmodulin, 
calcium channels are opened providing an influx of Ca2+ ions into the cell which then activates the 
relevant NOS enzyme to catalyse the production of nitric oxide. NO then diffuses out of the tissue to 
carry out its various actions as described in Fig. 3. The activity of inducible NOS (iNOS) is 
independent of calcium concentration and instead is normally activated in response to an external 
stimulus, such as the initiation of an immune response.12,13,14 Inducible NOS (iNOS) produces a much 
higher concentration of NO compared to the constitutive NOS enzymes and is involved in the ‘flight 











Figure 3: NO production within the endothelial cell that leads to a cascade of different reactions 
 
 
One of the primary uses for nitric oxide in the body is as a vasodilator, increasing vascular blood 
flow by causing the relaxation of smooth muscle cells, as depicted in Fig. 3. Nitric oxide, produced 
by eNOS, binds to the haem centre of soluble guanylate cyclase 3 (sGC). It is the affinity of nitric 
oxide for iron (Fig. 4) that causes the activation of sGC catalysing the cyclisation reaction of 
guanosine-5'-triphosphate (GTP) to cyclic guanosine monophosphate or cGMP, which then initiates 
a cascade of reactions that eventually lead to the relaxation of smooth muscle cells and the reduction 
of blood pressure.1, 15 
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Figure 4: The ferric centre of guanylate cyclase and its activation when NO binds (adapted from 
A. R. Butler, 20031) 
 
 
1.0.3- Biological roles of NO 
 
Blood is essential for transporting oxygen to cells and organs so it can be used in the Krebs cycle to 
produce energy in the form of adenine triphosphate (ATP) so the cell, tissue or organ can carry out 
its plethora of functions. When a cut occurs, and the body starts to lose blood, it is very important to 
stop this bleeding as fast as possible so that homeostasis can be restored. A very complex and 
sophisticated mechanism is in place to repair and fix these problems, of which NO is a major 
component. When damage occurs in an endothelium layer, platelet aggregation acts as a plug and 
stops the blood escaping from the small vessels. NO is produced by both endothelial cells and 
platelets along with a chemical known as the von Willebrand factor, which causes platelets to adhere 
to endothelial cells. Once a platelet becomes stuck, it promotes more to attach and creates a 'plug'. 
With this platelet plug in place, a protein present in the blood plasma called fibrinogen polymerizes 
into the commonly known protein, fibrin. This creates a mesh type structure, trapping blood cells 
and creating a gel-like complex or a clot. This process should only happen when damage has occurred 
to the endothelial cells but it can sometimes happen when unprovoked. 
If a clot forms when bleeding has not taken place for it to be induced, this can cause serious issues, 
such as blocking important blood vessels, which could lead to heart attacks or strokes. NO is also 
key to solving this problem, not only does it promote platelet aggregation but it can also help prevent 
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it. Like in smooth muscle cells platelets contain guanylate cyclase (GC) which NO can readily bind 
to and cause a cascade of biochemical reactions.  
This leads to the internal concentration of calcium ions increasing, affecting the adhesion properties 
of the platelets and preventing them from aggregating in the same manner thus reducing the clots 
size and potential for damage. 1,7 
 
 
Figure 5: Schematic diagram of eNOS increasing levels of NO in smooth muscle cells which can 
decrease blood pressure. Taken and adapted from reference 16.  
 
The human brain is a very complex organ with an unquantifiable amount of neurones, all working 
independently from each other and controlled by simple electrochemical signals being passed 
between synapses. For a signal to transfer across the synaptic cleft, small molecules called 
neurotransmitters are needed to convert the electrochemical signal to a chemical response. Due to 
the size of the nitric oxide molecule it can readily diffuse across membranes, makeing NO an versatile 
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neurotransmitter. NO is formed in the postsynaptic nerve cell following the activation of nNOS and 
readily diffuses outwards to act upon neighbouring cells 17. 
Unlike other neurotransmitters NO is not terminated by re-uptake mechanisms and instead the 
concentration of NO is only terminated by its forward reactions with other substrates like guanylate 
cyclase or superoxide. 
 
 
Figure 6: Schematic diagram showing NO as a neurotransmitter produced by nNOS. Taken and 
adapted from reference 16. 
 
As much as NO plays a positive role within the body, causing vasodilation, nerve responses and 
being embroiled in long term memory development, it has also been found to be heavily involved in 
the regulation of foreign bodies and apoptosis. The body has two main defence cells involved in the 
deletion of harmful substances. Granulocytes and macrophages both of which contain digestive 
enzymes to dispose of their targets through a process known as phagocytosis. Within these cells the 
NO producing enzyme iNOS, the isoform known to produce highest concentrations of NO, has been 
found in high abundance12 especially in cases of inflammation and infection, indicating that nitric 
oxide plays a role in the immune response to these stimuli. Due to the short half-life of NO it is 
unlikely that NO directly causes cell death and it is more apparent that it initiates a cascade of 
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reactions that brings about apoptosis. As already described, NO readily reacts with superoxide to 
form peroxynitrite (ONOO-) a very powerful oxidant. It is thought that it is this reactive molecule 
that causes the cytotoxic effects associated with nitric oxide.1, 13, 14  
 
 
Figure 7: NO produced by iNOS is involved in immune response and is produced in much higher 
concentrations than that seen by the other isoforms. Taken and adapted from reference 16 
 
The production of peroxynitrite can cause amino acid nitration, particularly to tyrosine and thus can 
result in enzymes being denatured.17-21 Peroxynitrite alone may not, however give the whole picture 
of NO’s cytotoxicity towards foreign bodies. NO binds strongly to metal ions as already seen within 
the ferric centre of guanylate cyclase22 (as shown in Fig. 3 and 4). Many enzymes in mammalian 
cells contain metal ion centres for example the enzyme aconitase, an important enzyme used in the 
oxidative phosphorylation process in respiration. This enzyme is known to have a ferric core and 
therefore binds readily to a molecule of NO, which causes enzyme inhibition or denaturation. If this 
was to occur in the cells of an unwanted, foreign body, like a microbe, respiration would be disrupted 
leading to cell death. 
The level of nitric oxide present in a cell or tissue is key to the interaction and effect that will be 
caused. Too little NO can cause an increase in blood pressure and the potential for clots to form as 
well as insufficient polarisation of neurons for the correct signals to be sent within the central nervous 
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system (CNS). On the other hand, if the concentration of NO is too high it can cause cytotoxic effects 
from DNA damage to disease progression. Although this is beneficial in terms of microbe deletion 
and as an anti-inflammatory agent, if the concentration remains high it can cause damage to healthy 
cells. Therapeutically moderating and influencing levels of NO is a useful tool for helping the body 
remain at a homeostatic level. This can be achieved by designing molecules that can either increase 
or decrease systemic levels of nitric oxide. The alteration of these levels in disease systems and states 
could be a successful treatment option and is a viable research area. 
1.1- Enhancement of NO levels 
 
Nitric oxide is involved in several biological processes including blood pressure regulation, platelet 
aggregation, microbe defence and several others as already discussed previously. Medically these 
processes can be affected by increasing the concentration of NO involved in these specific processes 
and could be used as potential therapeutic options in several conditions such as angina, 
arteriosclerosis, erectile dysfunction, cancer, Raynaud’s syndrome and even in vascular stents and 
for wound healing applications.1,7,15,17 
Other than increasing our consumption of foods containing L-arginine, which is the known substrate 
for NO production, there needs to be a method of sustainably increasing systemic levels of NO in a 
controlled way. This can be achieved using donor compounds that have been designed specifically 
to decompose and release a known concentration of NO at the desired site of action. Ever since the 
discovery of NO as a biological messenger molecule, a myriad of different NO donors have been 
investigated and are now grouped into various classes depending on their structures and properties. 
Long before the role of NO in vasodilation was discovered, clinicians have been prescribing drugs 
that produce nitric oxide to combat angina and heart attacks, although their mechanism of action, via 
the release of NO, was not known at the time. One of the oldest known NO-donors is GTN, glyceryl 
trinitrate, 6 or as it’s more commonly recognised nitroglycerin, the explosive ingredient in dynamite.  
It was first discovered in 1847 by Italian chemist Ascanio Sobrero23,24 who was experimenting with 
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glycerol 5 and strong acids (scheme 4). GTN, 6 is a very explosive liquid that can be detonated just 
by vibrations so at first Sobrero kept his discovery secret for more than a year, as he was afraid of its 
potential for harm and militarisation from his government. 
 
 
Scheme 4: The nitration reaction of glycerol to form the powerful explosive nitroglycerin or GTN. 
 
Famous chemist and founder of the Nobel Prize, Alfred Nobel, a student of Sobrero’s was the first 
person to find a commercial use for GTN 6 when he stabilized it by mixing it with silica (clay) to 
form what we now know as dynamite.24 However GTN 6 is not limited to being used as an explosive. 
It was first used medically by the physician William Murrell in 1878 for the treatment of angina. 
Murrell25 found that a 1% solution of GTN 6 in ethanol reversed the symptoms of angina. At the time 
this was a fantastic discovery as it was a topical treatment for quite a series illness, patients could put 
a patch of GTN 6 under the tongue and have the symptoms reversed within minutes. However this 
was not without its short comings, excessive GTN 6 use can lead to temporary tolerance of the drug. 
This phenomenon was described as the ‘Monday morning headache’. Workers at the factory that 
produced GTN 6 would find that after the weekend that they would have a terrible headache on their 
return to work. This was attributed to the rapid onset of vasodilation when they became exposed to 
GTN once returning to work after a two day break. 
Nitroglycerin 6 is a potent vasodilator belonging to the class of compounds called organic nitrates, 
due to the nitrate groups contained in its structure. Essentially it is a pro-drug, as upon absorption it 
is rapidly broken down to release nitric oxide which then proceeds by the mechanism highlighted 
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(Fig. 3 and 4) earlier to induce relaxation of smooth muscle cells. Other organic nitrates (Fig. 8) have 
been developed with similar effects to GTN 6 but are not as regularly prescribed1,26. Isosorbide 
dinitrate 7 (ISDN) is a more stable version than GTN26 and therefore has a much slower release of 
NO. It is therefore used for long term treatment and is applied as a sublingual medicine; however the 
issues of tolerance still occur with this compound. Pentaerythrityl tetranitrate 8 (PETN) is also an 
organic nitrate, very similar to GTN in structure and has the ability to release NO rapidly, and does 
so without building up tolerance. Although a good NO-donor compound, due to the extra nitrate 
group and the ratio of nitrogen to oxygen PETN 8 is classed as being highly explosive and has been 




Figure 8: Modern alternatives to GTN for use as NO-donors. 
 
Clearly having compounds that are good NO-donors but also high explosives is not very 
pharmaceutically viable. This major drawback led to the development of a number of different 
classes of NO-donors, with different structural features and stabilities either through structural design 
or serendipity. The vast majority of NO donors are organic based compounds, however there are a 
few compounds, one of which can be found in the BNF (British National Formulary26) that are 
classed as inorganic NO donors or metallic nitrosyls. The most commonly recognised compound in 
this class is sodium nitroprusside 9 (SNP) a bright red cyanoferric compound (Fig. 9). 
Introduction 
15 | P a g e  
 
 
Figure 9: Sodium nitroprusside, an example of a metallic nitrosyl. 
 
SNP 9 rapidly releases nitric oxide in the presence of both thiols and light. Several theories surround 
the actual mechanism of release but it is commonly reported that SNP binds to oxyhaemoglobin and 
in doing so produces NO, cyanide and methemoglobin. The production of the by-product hydrogen 
cyanide (HCN) is associated with most of SNPs side effects, from intracranial bleeds to cyanide 
poisoning and is one reason for its more limited use nowadays.27 Another theory on its release is that 
endogenous thiols such as glutathione or cysteine react with SNP form an S-nitrosothiol 10 as an 
intermediate compound which then decomposes to release NO into the bloodstream. Studies have 
shown that a thiol-iron complex is detectable, using UV-Vis spectrophotometry at a wavelength of 
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Scheme 5: Proposed28 mechanism of SNP decomposition by cysteine resulting in the formation of 
an S-nitrosothiol and a cysteine-iron (II) complex as shown by the asterik.Another compound from 
the inorganic NO-donor class is an intensely black, crystalline solid first discovered by a French 
army scientist named Francois-Zacherie Roussin, and is aptly known as Roussin’s black salt29 11 
shown in Fig. 10. 
 
 
Figure 10: Roussin's black salt, a potent inorganic NO donor29. 
 
Produced from the reaction of nitrous acid, potassium hydroxide, potassium sulphide and iron (II) 
sulphate, Roussin’s black salt 11 is a known NO-donor and has even been linked to having anti-
bacterial effects. Roussin’s discovery was made by mere accident when investigating nitrous acids 
ability to make azo dyes when treated with various amines. This crystalline black salt served as a 
novel way of ‘storing’ NO at the time of its discovery and could be forced to release NO readily by 
addition of different copper salts.29 
1.1.1- S-Nitrosthiols (SNOs) 
 
S-Nitrosothiols, also known as thionitrites, are organic compounds that have a nitroso group attached 
to a sulphur atom of thiol group. Their general formula is written as R-SNO. The synthesis of these 
compounds is relativity straightforward and was first conducted in 1909 by H.S. Tasker30 through 
the reaction of nitrosyl chloride (12) with thiophenol (13) to yield a ‘red-wine’ coloured compound, 
14 (scheme 6). Tasker reported that the new thiol compound rapidly gave off nitric oxide at room 
temperature, indicating how unstable these RSNOs are under mild conditions.31 
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Scheme 6: First described synthesis of an S-nitrosothiol by Tasker in 190930. 
The first synthesis of S-nitrosothiols, opened up a gateway to the production of more stable versions 
of the RSNO structure. Historically these compounds are brightly coloured with primary and 
secondary thiols, producing red or pink crystals whilst tertiary thiols yield green compounds.32 The 
intensely coloured properties of these compounds can be exploited analytically, especially using  
UV-Vis spectrophotometry, as the evolution of NO can be monitored by the loss of colour. The 
current, classic way of making substituted RSNOs is to react the thiol of choice with a form of NO+, 
which is usually generated as N2O4 under acidic conditions.30-34 
NO has a relatively shot half-life, and measurable concentrations in tissues have been found in the 
nanomolar range meaning that the body has a way of chemically ‘storing’ it in the blood plasma. 
This is done in vivo by the nitration of endogenous thiols (shown in Fig. 11) such as cysteine (16) 
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Figure 11: Two common endogenous thiol compounds 16, 17 and their S-nitrosothiol counterparts. 
 
Once an S-nitrosothiol has been formed in vivo it can readily diffuse throughout the tissue and 
essentially ‘deliver’ NO to other sites in the tissue and act as a reservoir of nitric oxide. Trans-
nitrosation (scheme 7) can also occur, where nitric oxide is exchanged from one thiol compound to 
another.37 This enables the nitrosation of a variety of compounds such as proteins and even serum 
albumin38 and allows the body to maintain a relatively constant level of NO when not producing it 
through the NOS catalyzed reaction. 
 
Scheme 7: General reaction of transnitrosation of an endogenous thiol S-nitrosothiol where R≠R’. 
 
S-Nitrosothiols decompose readily to afford NO and the corresponding disulphide via a homolytic 
bond cleavage as shown in scheme 8.39 Heterolytic cleavage can also occur but this does not produce 
the desired form of NO, as it instead produces either the positively or negatively charged NO ion 
depending on the movement of electrons.40-41 
 
 
Scheme 8: General decomposition reaction of RSNOs, usually via homolytic cleavage and the 
formation of radicals34. 
 
RSNOs can undergo three different types of decomposition to produce nitric oxide.40 Thermal 
decomposition, where temperatures as mild as room temperature can sometimes be sufficient, is 
believed to be a two-step process, which firstly involves the homolytic S-N bond cleavage to produce 
the two corresponding radicals and is then followed by two thionyl radical dimerizing to give the 
disulphide. Literature indicates that the rate of thermal decomposition depends of the stability of the 
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starting thiol, for instance primary and secondary thiols decompose more rapidly than tertiary ones 
due to stabilising steric and inductive effects42. 
A second type of NO release is photochemical decomposition. As the name suggests this is the 
breakdown of the RSNOs due to light, especially UV light. When a RSNO is irradiated with light, 
particularly at a wavelength of 340 or 545 nm, the RSNO decays to give NO.43 
A third method of RSNO decay is via metal ion catalysed decomposition and is shown in scheme 9. 
The breakdown of RSNOs can be catalysed by certain d-block metals such as iron, mercury, silver 
and copper.43-45 Copper, found in relatively high concentrations in the body has had the most focus 
in terms of research. It is thought that copper in the form of Cu2+ is reduced by the RSNO primarily, 
and initiates a chain reaction in which the Cu+ ion reacts with another RSNO to yield the disulphide 
and nitric oxide.41 
 
 
Scheme 9: Decomposition of RSNOs is catalysed by copper producing NO and free thiol.41, 46 
An example of this type of decomposition is illustrated by S-nitroso-1-thio-2,3,4,6-tetra-O-
acetyl-β-D-glucopyranose 19 (SNAG) which binds to copper ions and breaks down by the 
pathway shown in scheme 10. This decomposition occurs via the formation of a new seven 
membered intermediate, 20, involving the copper ion and the lone pairs available on both 
the sulphur and oxygen atom.41,44  
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Scheme 10: Copper catalysed decomposition of SNAG 19, a carbohydrate based S-nitrosothiol. 
The reaction proceeds via a 7 membered intermediate compound, 20. 
 
SNAG 19, as well as the majority of other S-nitrosothiols, is known to cause vasodilation and 
relaxation of smooth muscles in vivo through the release of nitric oxide upon decomposition. Butler47 
and researchers found that treatment of the human forearm with SNAG 19 produced significant, 
dose-dependent vasodilation in a reproducible manner. Graph 1 shows a summary of their data, 
showing that as you increase the dose of SNAG 19 the Laser Doppler Flux increases in a positive 
correlation. The Laser Doppler Flux is used to measure the blood flow in the skin. This is done by 
scanning the surface with a laser beam (2 mW) and measuring the resulting back scattering of light 
from erythrocytes, whose velocity will change depending on the rate of blood flow. The faster the 
flow (increased vasodilation) the greater the Laser Doppler flux.47 
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Graph 1: Vascular responses to three doses of SNAG 19 applied to the forearm skin of 
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1.1.2- NO-hybrids 
As previously mentioned, nitric oxide plays a key role in vasodilation and immune response, but 
producing viable NO-donors is a relatively new research area over the past 40 years. One strategy 
many researchers use is to combine an already proven drug with a NO donating group, to form a NO-
hybrid; such hybrids represent an expanding area in the NO-donor work. These ‘dual-action’ 
compounds can work symbiotically to either promote more than one response or reduce associated 
side effects. The rationale behind these compounds is to promote an existing drug compound, with a 
proven track record of effects, and increase its activity by having an additive effect when coupled to 
a NO-releasing group, as well as incorporating nitric oxide’s cytoprotective nature48. A common 
series of compounds linked to NO are the non-steroidal anti-inflammatory drugs (NSAIDs) such as 
aspirin 21, nicorandil 22, naproxen 23 or ibuprofen 24 49-53 (Fig. 12). It has been found that the 
introduction of NO into these existing drugs has reduced the side effects associated with them such 
as GI disturbances and ulcer formation. A study by Gasco49 found that having the NO moiety present 
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Nitric oxide has also been coupled to a plethora of different drug compounds, to create dual action 
compounds with enhanced biological profiles. Examples range from β2-agonists 25 for treating 
pulmonary disease,54 anti-malarial compounds 26,55 and calcium channel blockers 2756 to 
bisphosphonate drugs 2857 that treat osteoporosis and has even been seen to reverse multidrug 
resistance (Fig. 13). This wide array of examples shows the enormous potential for NO-donors in 
pharmaceutical research and their varied applications. 
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1.1.3- Furoxans 
The furoxans, also known as 1,2,5-oxadiazole-2-oxides 29 (Figure 14)  have the NO moiety ‘locked’ 
in a five membered heterocyclic ring system which improves stability allowing the release of NO in 
a more controlled manner compared to S-nitrosothiols and the metallic nitrosyls. 
 
 
Figure 14: The general structure and numbering system of 1,2,5-oxadiazole-2-oxide compounds 
also known as furoxans. 
 
Furoxans are known to decompose to give nitric oxide via several different mechanisms.  The usual 
manner of decomposition (scheme 11) is via a photochemical reaction but they can also ring open in 
the presence of thiols. Glutathione 17 can attack the ring system at the three position, to give an 
alkyne and NO.  Depending on the substituents, such as a carbonyl group (see scheme 12), this can 
cause the furoxan ring to convert into an isoxazole ring, 31, which is brightly coloured, and releases 
NO2 (a characteristic brown gas) which is then converted into water and nitric oxide.58-60 
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Scheme 11: The general decomposition pathways for furoxans58-60.  
 
The mechanistic differences in release can be utilised when monitoring NO release from furoxan 
compounds and therefore the stability of the parent compound. The isoxazole, 31, by product formed 
by production of NO can easily be monitored using UV-Vis spectrophotometry, yielding peaks at 
254 nm (the yellow region of the electromagnetic spectrum). 61, 62 
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Furoxans were first synthesised in 1845 from the oxidation of anethole 32, a common aromatic 
flavouring, by a chemist called Tonnies (scheme 13). Tonnies reported63-64 that treatment of anethole 
with sodium nitrite produces ‘a compound that has gained two atoms of nitrogen and oxygen’. 
Following this first ever production of a furoxan ring there have been several different procedures 
and conditions developed to produce a library of 1,2,5-oxadiazole-2-oxide compounds. 
 
 
Scheme 13: The first synthesis of a furoxan, 33, starting from anethole, 32, using acidic conditions. 
 
The site of reactivity of the first synthesised furoxan is the double bond in anethole 32, so it’s not 
surprising that the majority of chemistry producing the desired furoxan ring involves manipulation 
of this double bond. In 1903, it was reported64 that a reaction between styrene, the aromatic alkene 
commonly known for its polymerised form, produces a 1,2,5-oxadiazole-2-oxide upon reaction with 
sodium nitrite. However as well as forming the furoxan product it was noted that a side reaction was 
forming the nitrated styrene, instead of the desired product. 65 It was concluded that this happened 
due to the steric hindrance of the aromatic substituents in proximity to the double bond which in their 
orientation prevented the ring closure process and thus only nitrated the starting material much like 
34 in scheme 13. More recently an equivalent reaction using very similar chemistry to Tonnies was 
performed by Italian chemist Alberto Gasco, who documented that the conversion of the alkene 
double bond to the 1,2,5-oxadiazole-2-oxide heterocycle occurred via a ‘pseudonitrosite’ 
intermediate 35.66 This intermediate compound is produced via an ‘ionic’ mechanism (depicted in 
scheme 14). When combined, acetic acid and sodium nitrite form the reactive species NO+ and NO2-
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, which initiates the nucleophilic addition to the alkene bond. This then causes the adjacent olefinic 





Scheme 14: Gasco's ionic mechanism for the production of the furoxan ring using the reactive 
species NO2- and NO+ formed from the decomposition of nitrous acid.66 
 
Several reactions have been carried out using this alkene chemistry58,66-69, most, if not all the starting 
materials have had an alcohol or a carbonyl group adjacent to the double bond. This suggests that an 
oxygen species or at least an electronegative atom is needed for the generation of the 
‘pseudonitrosite’ intermediate 35. It is possible that an amine or even a halogen adjacent to the alkene 
double bond could also generate this intermediate, but the question remains as to whether this 
interaction is needed for the reaction to take place. This chemistry has also been frequently used to 
generate the NO-hybrid compounds mentioned earlier such as compounds 25 and 28 (Fig. 13). 
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Furoxan compounds can also be synthesised from other simple starting materials and the 
acetophenone 36 is just one of the many options. The acetophenones, of which there are many, are a 
series of aromatic compounds that have been a widely used in furoxan research due to their relatively 
inexpensive nature. It has been reported that when exposed to concentrated nitric acid, acetophenones 
can form furoxans (scheme 15) with aromatic rings (from the starting material) flanking the carbons 
of the heterocycle 3761. A combination of acetic acid and concentrated nitric acid has been reported 
to produce the reactive N2O3 species required for the formation of the furoxan ring as already shown 
in scheme 14. 70-72 
 
 
Scheme 15: Two synthetic routes to the furoxan ring starting from a simple, cheap starting material 
36. Both routes require acidic conditions to generate the reactive species NO2- and NO+. 
 
A major drawback of using an acetophenone starting material and the procedure outlined in scheme 
15 is the formation of unwanted by-products, shown in scheme 16. If too much water is present in 
the reaction, the corresponding benzoic acid 38 can form instead of the furoxan ring 37. It has also 
been reported that the benzoylformic acid 39 can also be produced. Additional side products formed 
from nitration of the aromatic ring is also a problem with this chemistry and can produce highly 
coloured compounds,73 which can be used as an identifier of by product formation. 
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Scheme 16: Reaction to form the furoxan compound 37 from an acetophenone. Depending on the 
reaction conditions various by-products can form such as 38 and 39. (Taken and adapted from 
reference 73) 
 
An alternative starting material for the synthesis of the furoxan heterocycle is the oxime motif,  
C=N-OH. Many different derivatives of oximes have been reported for the formation of furoxans 
29.58,59,74-76 The dioxime starting material 40 is a popular starting point in furoxan synthesis as it 
already contains the desired nitrogens and oxygens for the oxadiazole heterocycle, therefore a simple 
dehydration or oxidative reaction (scheme 17) is all that is needed to generate the product.  
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This conversion can be completed using a variety of strong oxidants such as potassium ferricyanide77 
and sodium hypochlorate, but these are sometimes avoided due to their handling issues. 59  
 
 
Scheme 17: The formation of a furoxan involving the oxidation of a dioxime 40.77 
 
To avoid these more toxic reagents other methods have been developed, such as direct exposure to 
nitrogen tetroxide (N2O4), stirring in concentrated nitric acid or conversion to the oxime-chloride and 
then ring closure by treatment with a strong base. An interesting procedure, making use of ligand 
and inorganic chemistry is the treatment of a substituted dioxime compound 41 with copper (II) 
chloride in the presence of copper perchlorate, shown in scheme 18.78 Unlike other oxidative 
reactions, this produces the furoxan compound 42 as a ligand complexed to the copper. The authors 
then report that by utilising simple ligand exchanged chemistry, the furoxan can then be ‘freed’ from 
the copper by treatment with ammonia.78 Although an interesting method for the production of the 
desired heterocycle, the publication is contradictory, stating on numerous occasions that a strong 
base is required to formulate the furoxan as a ligand, but then indicate that no base is needed for the 
ligand formation. The lack of analytical data on the final compounds produced by this copper 
mediated route, bring into question how pure and repeatable the published synthesis is. 
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Scheme 18:  Conversion of a dioxime to the furoxan ring in the presence of copper: The furoxan is 
generated as a ligand and is isolated through ligand exchange chemistry77. 
 
The standard way of producing the furoxan seems to be in a one pot process by reacting the oxime 
(43) or dioxime directly under oxidative conditions.74 However a popular method found in the 
literature involves converting the acidic proton of the oxime compound to a halogen atom (scheme 
19), to essentially produce a good leaving group for the second step of ring cyclisation.77 Treating 
the oxime compound with either N-chlorosuccinamide or hydrochloric acid produces the chlorinated 
oxime (44) in high yield (90%). Exposure of this to a strong base leads to the ring closure and the 
loss of HCl and the formation of the desired furoxan product 29. 
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1.1.4- Diazeniumdiolates 
An alternative class of NO donors that are synthetically interesting and of reasonable stability are the 
NONOates. Recently renamed to the diazeniumdiolates after several arguments amongst researchers, 
these compounds all share a common feature, the NONO moiety, shown in Fig. 15. 79 The name 
diazeniumdiolate can be broken down in to three parts to explain its origin. Firstly the ‘diazen’ part 
refers to the two sp2 hybridised nitrogens and the ‘ium’ denotes the nitrogen’s formal positive charge. 
Finally the ‘diolate’ can be attributed to the negatively charged oxygens attached to each nitrogen. 
 
 
Figure 15: Schematic diagram explaining the nomenclature for these compounds.79 
 
This class of NO-donors can be split again in to further subclasses depending on what the atom 
directly attached to the NONO moiety is. This can either be a carbon, nitrogen, oxygen or sulphur. 
The latter two are the most uncommon elements to be attached to the NONO structure (as shown in 
Fig. 16).  Oxygen is more predominantly used when compared to the sulphur subclass and is formed 
as an inorganic salt, known as Angeli’s salt 45 and is primarily used in biomedical research as a 
source of NO-, however it can also release NO under acidic conditions or in the presence of copper.79, 
80 Only one S-diazeniumdiolate 46 has been isolated and was prepared by passing NO gas over 
potassium sulphite. This compound decomposes to give nitrous oxide (N2O) and sulphate ions so has 
never been of much interest as an NO-donor.  
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Figure 16: The four isolated derivatives of diazeniumdiolate structure. The NONO motif is either 
connected to an oxygen, a sulphur, a nitrogen or a carbon atom. 
 
The nitrogen 47 and carbon 48 bound diazeniumdiolates are by far the most researched derivatives79 
in the NONO class. N-bound diazeniumdiolates (47) were first synthesised in the 1960s by Drago81 
by directly exposing NO to diethylamine 49 (scheme 20). Even though they were first made over 50 
years ago the NO donating ability of this class of compounds has only been thoroughly investigated 
since the discovery of NO’s biological importance.  
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Since the Drago work81, several variants of N-bound diazeniumdiolates 47 have been synthesised for 
use as NO donors in the biomedical industry. Due to the stability of the compounds formed most are 
produced by treatment of the relevant amine with NO gas to produce the NONO functionality. 
However additional chemistry can be done at either end of the N-diazeniumdiolate 47 structure to 
generate an entire compound library. The amine group can be introduced into other molecules as a 
linker (for example as an amide) between biologically active molecules82 and the NO-releasing unit. 
The oxygen on the NONO terminus can be alkylated (scheme 21) using various aromatic or alkyl 
halides to produce a ‘protected’ version of the N-diazeniumdiolate.  
  
 
Scheme 21: Potential sites of derivatisation proposed by Keefer 2002.79 
 
Although several different N-diazeniumdiolates have been synthesised81,83 the mechanism of their 
release comes with some disadvantages that can be argued to be detrimental for their use as safe NO 
donors in a pharmaceutical setting. In the presence of acid or light N-diazeniumdiolates decompose 
to release nitric oxide and the free amine 53, this amine can then react with oxygen to produce a 
nitrosamine 54 (scheme 22).84 Nitrosamines are known to have carcinogenic properties and have 
been linked to several types of cancer when exposed to high concentrations of them.85-87  
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Scheme 22: General decomposition route of the N-bound diazeniumdiolates when exposed to acid 
or light. 
 
As with other diazeniumdiolates, nitrogen bound derivatives can form bi-dentate ligands with metals 
and therefore act as chelators of copper, iron, colbolt and zircon amongst others.88 An example of 
this complexation is shown with copper 55 in Fig. 17. 
 
 
Figure 17: Diazeniumdiolates can coordinate to metal ions forming a bi-dentate ligand. 
 
The last diazeniumdiolate subclass of the four and by far the most researched are those where the 
NONO moiety is directly attached to a carbon atom 48. These were first synthesised by Traube in 
1895 by the reaction of NO with a carbanion79. Since then several different carbon bound 
diazeniumdiolates 48 have been produced utilising a range of starting materials including oximes, 
alkenes, alcohols, nitriles and ketones.79, 89 The wide range of possible starting materials gives this 
class of diazeniumdiolates 48 a lot of scope for research as there are many derivatives that can be 
synthesised at a later stage of a synthetic route (scheme 23). 
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Scheme 23: Various synthetic routes for the production of C-diazeniumdiolates starting from an 
array of different functionalities 
 
One compound in particular, that has seen a lot of research in terms of synthesis and derivatization, 
is the aromatic diazeniumdiolate called cupferron 56. Named after its strong affinity for copper and 
iron, it is routinely used as an industry grade metal chelator, particularly in the purification of 
plutonium.79 
Cupferron compounds are generally synthesised from the nitrosation of N-hydroxyamines (58) in the 
presence of ethyl nitrite and ammonia gas89 (scheme 24). However, exposure of nitrobenzene 57 to 
gaseous NO will also afford the cupferron structure, but as this is a fairly expensive method due to 
the need for pure NO gas, the former method is more commonly seen. 
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Scheme 24: Synthesis of the common metal chelator and NO-donor cupferron 56. 
 
As mentioned before in terms of the N-diazeniumdiolates, you can also alter the stability of the 
cupferron 56 compound by performing chemistry at the terminal oxygen in the NONO group. 
Alkylation chemistry at this terminus (shown in scheme 25) can be performed with a variety of 
reagents, depending on the desired final product. Alkyl halides, sulfates, acid halides and even 
epoxides have seen purchase in the past. However there is some argument amongst researchers as to 
which oxygen, out of the two available is best able to support the alkylation chemistry. After some 
dispute from Russian chemists,79 who argued that the O1 position (depicted in scheme 25) is the more 
nucleophilic site, it is now widely agreed79,90,91  that any alkylation would occur preferentially at the 
O2 site and any O1 alkylation would be a side reaction producing an unstable product and isolated. 
Interestingly, the O1-alkylation product was recently observed (see scheme 25) and isolated during 
the reaction of neocupferron, the naphthalene derivative of cupferron, with alkyl halides but was 
verified as a low yielding side reaction.91 
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Scheme 25: Alkylation of cupferron is shown to occur favourably on the O2 alkylation site rather 
than at O1 site. 91 
 
Alkylation at the O2 terminus can act like a protecting group for the diazeniumdiolate in terms of NO 
release and tends to increase the stability of the parent cupferron compound89. Compared to the 
cupferron derivatives where the aromatic ring had been decorated in either the para or ortho 
positions, the O-alkylated cupferrons were intrinsically more stable to decomposition and NO 
release.91,92 
As a metal chelator, cupferron compounds are excellent, but the same cannot be said for its use as 
NO-donors. Cupferron 56 is inherently unstable at room temperature and can release NO in the 
presence of mild oxidants, enzymatically or in the presence of light.11,79 It has been found that 
substituents placed in the ortho position on the aromatic ring caused the decomposition rate to 
increase due to the substituent position preventing the cupferron molecule 56 becoming planar.93 
Substitution in the para position of the ring alters the sensitivity of these compounds to oxidants and 
enzymatic decomposition but having an electron withdrawing group para to the NONO functionality 
appears to increase the stability of the compound.92  
It is worth noting however that upon decomposition (scheme 26) the C-diazeniumdiolates produce 
benign compounds and are therefore more biologically appropriate compared to the N-
diazeniumdiolates. 
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Scheme 26: Proposed decomposition routes for C-diazeniumdiolates in the presence of an oxidant, 
heat or light. All resulted in the production of NO. 
 
The azoxy compound 59 produced through exposure to temperature or light can be easily detected 
by UV-Vis spectrophotometry and can be a used as an indicator for successful NO release94. 
Currently the measurement of the compounds produced upon NO release has been the most common 
method for monitoring decomposition rates, however this doesn’t give any clue about relative release 
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1.2- Reduction of NO levels 
 
Nitric oxide is produced at the site of action, by the NOS class of enzymes. As already mentioned 
these can be split in to inducible and conservative NOS depending on their dependence on calcium 
ions (Ca2+) for their activation. It has just be shown that the levels of nitric oxide can be increased by 
using a variety of different compounds to act as NO-donors, producing one or two equivalents of NO 
per mole of starting material. This is therapeutically beneficial for conditions such as arteriosclerosis 
where the blood vessels become thicker and drastic expansion is needed for relief, but what happens 
if there is too much NO within a system or tissue. 
Some medical conditions such as Alzheimer’s (AD), Huntington’s (HD)94and Parkinson’s (PD)95,96 
disease, are classed as neurodegenerative diseases due to the degeneration of a selected population 
of neurons, and this is thought to be effected by high levels of NO. It is theorised that either NO alone 
or in combination with superoxide and peroxynitrite (ONOO-) are predominant effectors of 
degeneration of neuronal pathways. Figure.18 shows the relationship between peroxynitrite, NO and 
cytotoxicity.98 The exact mechanism of how NO contributes to neurodegeneration is not yet fully 
understood but multiple theories and evidence exist, suggesting that it occurs through DNA damage 
and protein modification. Reactive oxygen species (ROS) react with nitric oxide to form the 
peroxynitrite. This oxidant has the potential to react with other compounds and produce toxic 
peroxide like species that can cause DNA damage.97 
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Figure 18: The production of NO can lead to oxidative damage via its metabolite peroxynitrite 
(ONOO-).98 
 
NO has also been linked to neuronal damage caused by stroke, due to the high levels of NO that can 
build up and the oxidative damage it can propagate. A stroke occurs when a blood vessel to the brain 
becomes blocked, this causes oxygen starvation in the brain and increases the stimulation of the 
glutamate receptor, causing large amounts of calcium ions to be released which then stimulates the 
nNOS enzyme to produce NO and as described before in large concentrations it can be 
cytotoxic1,99,100. NO has also been implemented in cerebral ischemia, a condition where there is 
insufficient blood flow to the brain to meet metabolic demand.101,102 In cases of cerebral ischemia 
high levels of nitrotryosine have also been detected. Nitrotyrosine is a marker for peroxynitrite 
metabolism, and an indicator of NO production. NO has also been linked to cases of rheumatoid 
arthritis, inflammation disorders and cerebral palsy.103 
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As there is now increasing evidence that nitric oxide may play a destructive role in the brain96-100, 
ways of reducing in vivo levels of nitric oxide are needed. There are two such ways in which these 
high levels can be affected. One involves halting or reducing enzymatically produced NO by NOS. 
Nitric oxide is produced at the synapse upon stimulation of the glutamate receptor NDMA and 
activation of nNOS enzyme by Ca2+ ions. The substrate for this reaction is the common, simple 
amino-acid, L-arginine 1. It is this substrate that holds one of the keys to the inhibition of the nitric 
oxide synthase enzyme. By mimicking the binding interactions that occur between the NOS enzyme 
and the substrate a potent and selective inhibitor could be produced to help alleviate the high levels 
of NO in the aforementioned conditions. 
L-Arginine, being an essential amino acid, has a very simple structure; due to this there is a large 
amount of synthetic scope in terms of compounds that can mimic its binding potential. The 
highlighted guanidine terminus on L-arginine (Fig. 19) is the main point of interaction with the NOS 
enzyme and it is this motif that reoccurs in current NOS inhibitors work.   
 
 
Figure 19: L-Arginine, the substrate for each isoform of NOS. Highlighted is its guanidine 
terminus, the used to design active NOS inhibitors. 
 
Several quantitative structural activity relationship (QSAR)104,105 studies have explored the structural 
and docking profiles and identified the optimal requirements for the binding of inhibitor molecules 
to the NOS enzyme. They found that although active sites of each NOS enzyme are practically 
identical they differ in a single amino acid between the nNOS and eNOS protein structures. As each 
isoform’s active site catalyses the same reaction a key feature must be the involvement of a 
guanidinium biostere to mimic the terminus of L-arginine 1 as highlighted in red in Fig. 19. This 
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interaction is key as docking relationships show the guanidine group in L-arginine hydrogen bonds 
to a Glu592 residue in NOS, shown in Fig. 20104.  
The difference in the single amino acid plays a large part in selectivity as the alpha amino nitrogen 
of L-arginine interacts with both Glu-592 and Asp-597 in nNOS and Glu-592 and Asn-368 in eNOS 
(Fig. 20). This difference in amino acid interactions causes compounds docked in nNOS to adopt a 
curled conformation within the active site and thus increases the electronic stabilisation of the 
compound, while in eNOS it remains flatter.104 
 
 
Figure 20: NOS substrate L-arginine (shown in yellow and labelled L-Arg) docked into the NOS 
active site. Key interactions from the haem group and Glu-592 account for L-Arginine's binding 
ability. The structure highlighted in magenta represents the haem centre of NOS. Taken from 
reference 104. 
 
The main problem with this method of inhibition is that each NOS enzyme has the same substrate 
and therefore drug compounds that mimic L-arginine 1 too closely will not be selective for a 
particular enzyme. Selectivity is key if a viable therapeutic treatment is going to be produced from 
the inhibition of NOS, as all three isoforms are found throughout the body, especially in the brain. 
Cerebral tissue contains eNOS for essential cranial blood flow, glial cells are known to produce iNOS 
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for immune responses and nNOS is present for neuronal function. Without selectivity there is a high 
probability that the wrong NOS enzyme will be inhibited which could cause more drastic problems, 
especially if occurring in the brain. For example if nNOS is over producing NO in the brain and a 
non-selective inhibitor is applied, eNOS may halt production of NO in cerebral tissue, which may 
lead to a stroke or cerebral ischemia. This is a current challenge and concern as without potent 
selectivity no inhibitor will be pharmaceutically viable.106, 107  
 
Several nNOS inhibitors have been synthesised as arginine analogues, the most noteworthy are L-
nitroarginine methyl ester (L-NAME 60) and asymmetric dimethyl arginine (ADMA 61) which have 
chemical structures that are almost identical when compared to the original substrate108 (Fig.21). 
Other inhibitors that are commercially available are Spermidine 62 and Melatonin 63. All are potent 
and selective inhibitors of nNOS.109  
 
 
Figure 21: L-NAME, 60, ADMA, 61, Spermidine 62 and Melatonin 63. Four marketable NOS 
inhibitors with various selectivity’s for nNOS. The potency (IC50) and inhibition constant (Ki) for 
nNOS is stated below the chemical structure. 
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Once L-arginine has docked within the NOS active site, it is converted to L-citrulline through the 
five electron transfer mechanism previously depicted in scheme 3. L-Citrulline is then reused in the 
catalytic cycle to generate more L-arginine. Due to the production of NO being a catalytic procedure, 
interfering with the concentrations of L-citrulline could also affect the levels of nitric oxide produced. 




Figure 22: Two potent NOS inhibitors that are both derived of L-citrulline. Thiocitrulline, 64, and 
S-methyl-L-thiocitruline, 65.103  
 
Professor Silverman from Northwesten University has performed an extensive research on nNOS 
inhibition.110,111 Initial work in the area allowed him to conclude that the poor selectivity of some 
NOS inhibitors was because the same reaction is occurring at the active site of each isoform of NOS 
and therefore to obtain selectivity a compound needed to extend further from the active site into the 
second sphere of amino acids within the binding site. By focusing on one isoform of NOS his research 
group managed to find the one amino acid difference in the second sphere of amino acids between 
nNOS and eNOS.110 Silverman developed a lead compound 66 (Fig.23), through exploration of 
evidence from Glaxo-Smith-Klein that L-nitroarginine was a selective inhibitor of nNOS and eNOS. 
Additional amino acid chains were coupled to L-nitroarginine to extend the ‘reach’ out of the active 
site. This process lead to the development of the lead compound shown in Figure 23.  
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Figure 23: Silverman's lead compound for inhibition of NOS, derived from L-Nitroarginine. 
 
The development of this lead compound 66 and the corresponding computer modelling promoted a 
new type of approach dubbed ‘fragment hopping’. This new approach applied small changes in the 
pharmacophoric element of the molecule to create a new library of compounds based on fragment 
binding and bioisosters that kept to the pharmacophore’s rules. This de novo method of lead 
compound formation enabled the synthesis of a new non-peptide based compound 67 and with 
further optimisation produced the lead compound 68, which was potent in the nanomolar (nM) region 
and is shown in Figure 24. 
 
 
Figure 24: After fragment hopping, a new lead compound was found, 67. The aminopyridine ring 
showed enhanced binding in the active site. Compound 68 is post optimisation to make it more 
lipophilic. 
 
Problems still arose with the new lead compound 68 in the fact it had poor blood brain barrier 
diffusion. This issue was solved by crystal structure docking (Fig.25) of lead compound (68) into the 
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nNOS active site. The aminopyridine ring was concluded to interact with the haem section in nNOS 
through π-π stacking interactions, while the pyridinium nitrogen interacts through hydrogen bonding 
with Asp-597 in the amino acid sequence of the enzyme. It is this particular interaction that induces 
the selectivity for nNOS, as eNOS has a different amino acid residue at that part of the sequence111 
and therefore doesn’t have the same binding interaction at that point. For a successful inhibitor of 
nNOS, a molecule needs to adhere to the pharmacophoric rules seen by Silverman; it must contain a 
guanidinium type group for selectivity and also be large enough to ‘reach’ out of the active site and 






Figure 25: Lead compound 68 (shown in grey) docked within the active site for nNOS. The 
aminopyridine ring interacts with the glutamate group of the haem centre (shown in pink) of NOS 
and the haem centre itself through π-π interactions and hydrogen bonding.110 
 
Inhibiting the enzyme that produces NO is only one way to reduce the in vivo levels. An alternative 
method is employing scavenger molecules to essentially ‘mop’ up excess nitric oxide. A scavenger 
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molecule is one that can be added to a reaction or system to remove or deactivate unwanted 
compounds before they cause damage or side reactions. The ability of a molecule to be an effective 
radical scavenger comes from the compounds capability to rapidly donate a hydrogen atom and the 
possibility of radical stabilisation, usually due to conjugate electronic effects. The compound class 
known as the flavonoids are well-known anti-oxidant scavengers and are constantly mentioned by 
the world media as the new ‘holy grail’ in diet management.  
 
Flavonoids 69 are essentially ‘built’ to be radical scavengers112-114 and are successful due to the high 
amount of phenolic hydrogens coupled with the large amount of conjugation that exists in their 
structures. The general mechanism for action is proposed as follows: A hydrogen atom from the 
hydroxyl group (19) is donated to the radical, producing in the process a phenoxyl radical at positon 
19. This is then stabilised by the adjacent α,β-unsaturated ketone, which moves the radical to carbon 
9 (Fig. 26).  Movement of the radical to the 9 position creates a tertiary radical and therefore creates 
a more stable compound, due to the fact that tertiary radicals are inherently more stable than primary 
and secondary ones. The other hydroxyl groups positions around the A and C rings have been 
highlighted (Fig. 26) by researchers to be essential for effective radical scavenging due to electron 
donating ability and their ‘attractiveness’ to radical compounds, in particular the OH groups on the 
C ring at C14 and C15.114 
 
 
Figure 26: General structure 69 for the flavonoid class of compounds. 
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Curcumin 70 is the main compound found in the spice turmeric (Fig.27) and has recently been linked 
to having medical potential against a variety of conditions, from cystic fibrosis115 to cancer116-118 and 
Alzheimer’s disease119. Although not a true flavonoid, curcumin, 70 contains most of the same key 




Figure 27: Curcumin 70, the biologically active compound found in turmeric. Shown existing in its 
enolated form but can also be found as the diketal tautomer under some conditions. 
 
Due to the high amount of conjugation present in the curcumin 70 structure it can stabilise radicals 
fairly well, producing many resonance structures and therefore acting as a successful scavenger115 as 
shown below in scheme 27 with its reaction with a DPPH radical, a common scavenger testing 
compound. Once in its reduced form it (DPPH-H) it changes colour from purple to orange. 
 
 
Scheme 27:  Curcumin 70, acting as a radical scavenger with DPPH, a radical tester compound. 
Curcumin easily stabilises the radical through three resonance forms shown in the square brackets. 
Adapted from reference 115 
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1.3- Rationale and Target Compounds 
As described previously there are numerous medical conditions that involve nitric oxide in one way 
or another. Conditions that need an increase in the systemic levels of NO such as angina have a 
limited arsenal of compounds that can be used to treat them, as many of the currently prescribed 
options could be considered to be outdated due the timeline of their discovery coupled with the 
adverse effects they cause, notably the potential cyanotoxicty from SNP.27 It is quite apparent that 
there is a need for a compound or class of compounds that can act as nitric oxide donors in a 
conservative and predictable manner and whose metabolites or mechanism does not lead to toxic or 
damaging consequences. Producing a compound that can provide a known amount of NO could be 
greatly beneficial for the pharmaceutical industry let alone have a huge impact on patients living with 
one of the aforementioned conditions. On the other hand, there are also several conditions, 
Huntington’s, stroke and Alzheimer’s to name but a few that could be benefited from the reduction 
in nitric oxide levels through the use of NOS inhibitors or radical scavengers. Developing and 
synthesising compounds that can reduce the amount of NO being produced at the site of these 
diseases could go a long way to treat the symptoms if not help underpin the mechanism behind their 
causation. To address the need for the moderation of NO levels within the body a series of compounds 
will be designed and synthesised to separately enhance or reduce levels of nitric oxide. 
Combretastatin is a small natural product isolated from the bark of the Africa bush willow tree, the 
Combretum caffrum.120 Whilst being one of the smallest natural products of interest to researchers, 
it has also been used for many years by the San people of Africa as a ‘well-being’ tonic in addition 
to being used as a coating for their spear tips.119 When isolated from the bush willow bark it was 
found to be a mixture of compounds, three of which are noteworthy (Fig. 28) with combretastatin A-
4, 73, being the most potent against cancer cell lines. 121-123 
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Figure 28: The three isolated compounds from African bush willow. Combretastatin A-4 (73) is 
the most biologically active.120-122 
 
It was concluded that combretastatin A-4 73 was potent due to its pharmacophoric similarity to 
another natural product, colchicine 74124 which is known to have a specific binding site in tubulin 
and is routinely used to treat gout. Figure 29 shows the similarities125 between the two natural 
products, with the trimethoxy unit on both benzene rings as well as the two aromatic rings being 
bridged by an aliphatic bond (shown as a bold outline in Figure. 29).  
 
 
Figure 29: Colchicine, 64, and combretastatin, 63, have many key structural similarities explains 
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Cancerous growths125 are caused by uncontrollable division of cells and can be classified as being 
blood or organ cancers. Organ cancers are found between the endothelial cells of an organ and are 
usually solid structures. One such structure prone to over polymerization is the protein tubulin, the 
precursor to the microtubule structures found throughout the body. Combretastatin 73 has been found 
to be potent against cancer cell lines and in particular as a vascular disrupting agent (VDA).  
Combretastatin has shown to be quite prevalent against solid tumours, as for a tumour to survive it 
needs a strong vascular structure and blood flow supporting it. Combretastatin 73 works by attacking 
the immature endothelial cells in tumours and forcing the shape of the cell to change to a more 
spherical one, this then acts as a ‘plug’ and prevents blood flowing through the capillary bed thus 
causing oxygen deprivation inside the tumour, leading to apoptosis and tumour death.126-127  
Combretastatin 73 binds within the colchicine 74 binding site124,128 and halts replication as shown in 





Figure 30: How combretastatin (shown here as an anti-tubulin ligand) disrupts cellular division 
preventing tumour growth. Taken from reference 129 
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You might be thinking where does nitric oxide fit into all of this? Due to its simplicity, combretastatin 
(73) has had several QSAR studies conducted on its structure to determine any key interactions taking 
place that would account for its potency. It was revealed that the trimethoxy motif on the A ring and 




Figure 31: Combretastatin A-4's, 73, key structural features for anti-tubulin activity.124,130,131 
  
The cis conformation has also been shown to be essential for binding due to its resemblance to key 
portions of colchicine (Fig. 29 and 31), but it is prone to isomerisation in vivo, therefore there needs 
to be a way to maintain this orientation so that activity doesn’t diminish. The way we are proposing 
to solve this is by implementing the furoxan ring, mentioned earlier, into the structure by replacement 
of the olefinic bond. This will essentially ‘lock’ the structure in the cis orientation and keep the 
rigidity needed for activity. Another reason for the employment of the five membered heterocycle, 
is that clinical trials have shown that combretastatin 73 is not very water soluble due to the high 
amount of hydrophobicity present in the structure, therefore causing it to have poor bioavailability. 
By introducing the 1,2,5-oxadiazole-2-oxide 29 structure it should increases the potential for 
hydrogen bonds due to the electronegative nature of the heterocycle and the presence of both nitrogen 
and oxygen as hydrogen bond acceptors. 
Rationale and Target Compounds 
54 | P a g e  
 
Two different analogues of combretastatin (shown in Figure 32) fused with a furoxan ring (from 
herein known as combretafuroxan compounds) will be synthesised by adapting synthetic routes 
already mentioned in section 1.1.3.1. The first class (‘Series 1’, 75) will resemble the parent 
combretastatin by having two decorated aryl rings directly attached to the furoxan, this will enable 
direct comparison with the parent compound (due to similar tether lengths) in terms of anti-cancer 
activity and water solubility. The second class (‘Series 2’, 76) of combretafuroxans will by 
synthesised with a ketal unit effectively bridging the aryl rings and the furoxan ring. The addition of 
two extra oxygen atoms may help to increase hydrophilicity further by increasing the number of 
potential hydrogen bonds that can be formed.  
 
 
Figure 32: Planned combretafuroxan compounds to assess the ability substituents positioned around 
the aromatic rings have on the effect of NO release and anti-cancer activity. 
 
An additional reason for using the furoxan structure is that within NO donor research, stability is a 
key issue. Furoxans tend to be the more stable of the NO-donor classes, compared with the  
S-Nitrosothiols and metallic nitrosyls, as the NO portion of the molecule is trapped within a five 
membered ring. By incorporating the furoxan within an already stable natural product (effectively 
producing a fused NO-hybrid) it may produce a symbiotic relationship between NO and 
combretastatin in a way that stabilises the furoxan and also combretastatin. The release of nitric oxide 
from the combretafuroxan (75 or 76) can also act as way to alleviate the cardiotonic side effects 
experienced with combretastatin. 
The 3,4,5-trimethoxy substituents located on the ‘A’ ring of combretastatin are thought to be essential 
for binding130 within the tubulin structures (Fig. 29) and this motif was incorporated into the early 
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work of combretafuroxans from our own research group132. Combretafuroxan compounds, 
symmetrically substituted with a tri-methoxy group on both the A and the B rings, were found to be 
highly potent against a variety of ovarian cancer cell lines with IC50 values ranging from 3.64 μM to 
8.04 μM for the A2780 cell line and 4.64 μM to 10.19 μM for the cisA27 cell line.132 The difference 
in these values can be attributed to the different positions that the methoxy compound was substituted 
in, the most potent compound was a 2,4,6-trimethoxy substituted combretafuroxan (adhering to series 
2 motif in Fig. 32) producing a low μM range across the eight cell lines it was tested on. Changing 
the substitution pattern to 3,4,6-trimethoxy arrangement led to a slight loss in activity in all cell lines 
suggesting that the relative position of substitution on the A and B rings are key to its activity.  
Combretafuroxans that adhere to the series 1 motif in Fig.32 and are decorated with a tri-methoxy 
units will be synthesised (their structures can be seen in Fig. 33) by exploiting the alkene double 
bond chemistry developed by Gasco (as shown in section 1.1.3.1). The 3,4,5 the 2,4,6 and the 2,4,5-
trimethoxy combretafuroxans compounds have previously been synthesised131 and their anticancer 
properties tested against ovarian cancer cell lines with interesting results (sub 20 µM activity). 
  
Figure 33: Planned combretafuroxan compounds within in the series 1 model. To be synthesised 
from simple stilbene starting materials. 
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Interestingly at the same time as this work, a publication arose in the literature from Steve Ley’s 
research group.133 This publication stated that halogenation of the ‘A’ ring in replacement of two of 
the methoxy groups, increased the activity of their tetrazole combretastatin (83-85) analogues 
fivefold in comparison to the trimethoxy version as it induced ‘optimal packing’ in the colchicine 
binding site.An abstract of their findings is shown in Figure. 34. The findings by the Ley group (Fig. 
34), interested us and partially influenced the substituents we chose to decorate our A and B rings 
with in the combretafuroxan model.   
 
 
Figure 34: Graph showing the increase in cell apoptosis on human umbilical vein endothelial cells 
(HUVECs) when OMe is exchanged for a halogen atom. (Adapted from reference 133) 
 
A plan of symmetrically para substituted combretafuroxans was devised, to find a correlation 
between substituents and anti-cancer activity through small subtle structural changes to the A and B 
rings. These structural modifications should also have an effect of on the relative nitric oxide release 
from the furoxan ring due to the different electronic effects atoned to each group as mentioned before 
in section 1.1.3 (page 28) on furoxan decomposition. Fig. 35 shows the twelve compounds (86-97) 
that will be synthesised based on the series 2 motif shown in Fig.32. 
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Figure 35: Planed combretafuroxan compounds 86-97 with varying substituents in the para position 
as well as a trimethoxy substituted analogue. 
 
The mechanism of NO release from furoxan compounds is well established (scheme 11 and 12) and 
researched especially by Gasco.66 Furoxan compounds can be fairly dependable that they will release 
nitric oxide when exposed to thiol or thiolate compounds, however, there isn’t always a viable source 
of these inductors for NO release. Therefore alternative compounds that produce NO via a different 
mechanism, but at the same time are stable compounds, unlike some S-nitrosothiols, is a desirable 
goal. One such class of compounds, stable under these conditions and whose mechanism of NO 
release is not fully understood, are the diazeniumdiolates and in particular, the carbon based 
diazeniumdiolate, cupferron 56.  
Cupferron 56 is described as being able to release NO under numerous conditions such as light and 
temperature but at a rate far too unpredictable for therapeutic application. Therefore the stabilisation 
of this compound could produce a range of potentially tuneable NO-donors, which can release nitric 
oxide in a more conservative controlled fashion. Research has already been carried out on whether 
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substituents on the aromatic ring of cupferron alter stability,79, 91 however alkylation of the terminal 
oxygens is a relatively untouched area. We aim to systematically alkylate (Fig. 36) at the terminal 
oxygen (O2 site) increasing by two carbon units 98-101 each time to assess whether chain length of 
the ‘protecting’ group effects the rate of NO release and if there is a trend amongst this. Along with 
mono alkylated cupferron derivatives, a series of compounds that contain two cupferron molecules 
102-105 will also be synthesised using the same chemistry and assessed to see if using an alkyl chain 
as a synthetic ‘bridge’ effects the rate of NO release. 
 
 
Figure 36: Planned cupferron derivatives synthesised by alkylation chemistry at the O2 site. Both 
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The compounds 98-105 produced from within the cupferron series (Fig. 36) will be tested for their 
nitric oxide releasing capabilities under physiological conditions as well as irradiation with 
ultraviolet light. It is the hope with this type of chemistry the stability of the parent compound will 
be increased and therefore produce a series of more effective NO-donors.  
As aforementioned, nitric oxide levels are finely balanced by homeostasis. We have hypothesised 
methods to increase the level of NO if it should be required to treat various vascular-related diseases, 
however when levels of nitric oxide are too high and at risk of becoming toxic we need an alternative 
approach. We therefore aim to design and synthesise a class of novel and selective neuronal nitric 
oxide synthase (nNOS) inhibitors for potential therapeutic relief of these severe conditions. Our 
rationale is to expand on the work conducted by Silverman,103, 110-111, 134-136 by using the 4-
aminopyridine unit to mimic the guandinium group of L-arginine 1 and build upon key observations 
had while studying their current research.  
 
 
Figure 37: The most potent compound post optimisation for the Silverman group. The crystal 
structure for this compound docked in nNOS was obtained and used for computational studies. 
 
Whilst looking at the most potent compound 106 studied by Silverman during docking studies (Fig. 
38) using the Keele Active Virtual Environment (KAVE) and Pymol software an interesting 
observation was found. Looking at the 3D profile of the docked molecule it appears that the back 
bone of 106 and other analogues ‘over hang’ several amino acid residues within the active site of 
nNOS. This provided an area that could potentially be exploited to increase the binding potential of 
the inhibitor in the active site of the nNOS isoform. 
Rationale and Target Compounds 




Figure 38: Compound 106 (shown in yellow), Silverman's potent inhibitor, docked within the 
active site of nNOS showing interaction between the haem groups of nNOS with the aminopyridine 
ring. Circled in blue is a propionic acid group identified as a possible unexplored interaction.  
NB: Three aminopyridine rings are shown due to the crystal structure being unresolved. The two 
aminopyridine rings on top of each other show two possible conformations they can adopt. 
 
The yellow structure shown here is the crystal structure for compound 106 (Fig. 38). The 
aminopyridine ring is interacting with the haem portion of nNOS through π-π stacking. This 
interaction forces the alkane linker out of the plane and contorts it slightly. It is the twisting of the 
structure that highlighted the propionic acid (circled in blue in Fig. 38) group of the haem residue 
positioned directly above the centre of the 5 carbon chain linking the two aminopyridine rings. The 
propionic acid group, existing as the carboxylate (COO-) could potentially become a strong hydrogen 
bond acceptor (HBA) as well as offering potential ion-dipole interactions with appropriate groups. 
Fig. 39 part A, again shows compound 106 docked in nNOS, with the propionic acid group ‘hanging’ 
over the second carbon in the linker chain.  
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The distance from the carboxylate group to the hydrogen of the inhibiter was measured to be 2.6 Å, 
suggesting that with the correct hydrogen bond donator in place a viable and successful hydrogen 




Figure 39: Part ‘A’ shows compound 106 (shown in magenta) docked in the nNOS active site. The 
distance between the carboxylate on the haem group (shown in green) and the hydrogen on the 
inhibitor (magenta) was found to be 2.6 Å suggesting that a hydrogen bond interaction could be 
exploited at this site. ‘B’ shows compound 106 can interact with two amino acid residues present in 
the nNOS structure. The amino group on the aminopyridine ring can hydrogen bond with both 
asparagine (1.9Å) and glutamic acid (1.6Å). 
 
Fig. 39 part B shows the interaction of compound 106 with two amino acid residues present within 
the backbone of the nNOS enzyme. The hydrogen bonding interactions with asparagine (top left of 
Fig 39-B) and a glutamic acid residue (bottom right) validate the need for the aminopyridine moiety 
and the terminus of the inhibitor. The π-π interaction of the pyridine ring with the pyrrole rings that 
make up the haem group of nNOS can also be seen in part A and B of figure 39. 
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This observation suggested that there was a site of unexplored derivatisation that could be taken 
advantage of if the correct substituents could be placed along the alkane chain. Computational studies 
has led to the design of five new linkers (Fig. 40) to replace the pentane chain separating the 
aminopyridine rings as seen in compound 106 and produce five novel nNOS inhibitors (Fig. 40) 
 
 
Figure 40: Proposed linker compounds to synthetically implement between two aminopyridine 
rings. Linkers offer difference in HBD ability and allow for further chemistry at a later date. 
 
The diol 109 and the propanol 110 linkers can act as hydrogen bond acceptors and donators Linker 
B 108 is a diketone linker and has the potential to form ion dipole interactions with the negatively 
charged oxygen present when the propionic acid group is existing as the carboxylate. The alkene 107 
and the xylene 111 linkers can be utilised as synthetic building blocks, which can be reacted with 
further once in place to add additional functionality. Inhibitors 107 and 111 also have the potential 
to provide hydrophobic interactions, similar to the one the parent molecule had using the pentane 
chain. 
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A further goal in the NO reduction work and also related to the NOS work and increasing the HBD 
potential is making use of the radical scavenger curcumin 70 as a potential inhibitor of NOS. 
Curcumin already has the HBA and HBD motifs situated within the molecule and therefore is a great 
candidate as a NOS analogue 112 under our current proposed hypothesis (see Fig. 38/39) Not only 
can curcumin act as a radical scavenger, by implementing an L-arginine 1 motif into its structure it 
has the potential to have dual functionality of acting as a NOS inhibitor and a scavenger. 
 
 
Figure 40: Natural product curcumin, 70, and the objective dual function inhibitor 112. 
 
1.4- Overall objectives  
Due to the plethora of applications nitric oxide has within the body, both beneficial and detrimental 
there is a real need for compounds that can potentially aid in these processes, by either increasing or 
decreasing levels of nitric oxide in vivo. My research aims to synthesise two separate types of NO 
compounds, ones that can enhance levels of nitric oxide and ones that can work on reducing levels 
of NO. 
To enhance the levels of NO, two types of NO-donor compounds that can release nitric oxide under 
differing conditions and thus can be made tailorable to specific disorders will be synthesised. Furoxan 
compounds (77-82 and 86-97) will be synthesised in a systematic way, by varying the para 
substituent attached to the phenyl ring or manipulating the trimethoxy units positioning around the 
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aromatic ring. Their relative NO release will be monitored using a NO analyser in the presence of 
thiol/thiolate. Cupferron analogues (98-105) will also be synthesised through a series of systematic 
alkylations at the preferential O2 site. The stabilisation effect of these alkyl chains on the parent 
compound will be assessed under various conditions including light and heat. To further test furoxan 
compounds 77-82 and 86-97’s ability to release nitric oxide, vasodilatory tests will be performed by 
collaborators at Kingston University (UK). The vasodilatory work will establish how effective each 
furoxan is at releasing NO and its ability to bring about relaxation of smooth muscle cells. 
The reduction of NO levels requires a different approach and therefore a series of novel NOS 
inhibitors will be synthesised, building on the work of Silverman. Various linkers, exploiting the 
potential HBD/HBA and electronic interactions, will be implemented between two aminopyridine 
rings, which will be mimicking the guanidinium terminus of L-arginine 1.   
References 
 
1. A. Butler and R. Nicholson, “Life, Death and Nitric Oxide”, RSC paperbacks, The Royal 
Society of Chemistry, Cambridge UK, 2003. 
2. F. Guthrie,  J. Chem. Soc., 1859, 11, 245-252 
3. http://nobelprize.org/nobel_prizes/medicine/laureates/1998/illpres/index.html  
4. R. F. Furchgott, Angew. Chem. Int. Ed. 1999, 38 (13-14), 1870-1880 
5. L. J. Ignarro, Angew Chem. Int. Ed. 1999, 38 (13-14), 1882-1892 
6. F. Murad, Angew. Chem. Int. Ed. 1999, 38 (13-14), 1857-1868 
7. S. Moncada, M. Randomski, and R. M. J. Palmer, Trends in Pharm. Sci, 1991, 12, 87 
8. R. M. J. Palmer, A. G. Ferrige and S. Moncada, Letters to Nature, 1987, 327, 524-526 
9. A. R. Butler, F. W. Filtney, D. Lyn. Wiliams, Trends in Pharm. Sci, 1995, 16, 1, 18-22 
10. T. S. Hakim, K. Sugimori, E.M. Camporesi, and G Anderson, Physiol. Meas, 1996, 17, 267–
277 
11. Y. C. Hou, A. Janczuk and P. G. Wang, Curr. Pharm. Des., 1999, 5, 417-441 
Introduction References 
65 | P a g e  
 
12. P. Tripathi, Indian J. Biochem. Biophys., 2007, 44, 310-319 
13. W. K. Alderton, C. E. Cooper, and R.G. Knowles,  J. Biochem, 2001, 357, 593-615 
14. D. Stuehr, S. Pou, and G. Rosen,  J. Biol. Chem, 2001, 276, 14533-14536 
15. C. Napoli, and L. J. Ignarro, Nitric Oxide, 2001, 5, 88-97 
16. R. G. Knowles and S. Moncada, J. Biochem., 1994, 298, 249-258 
17. A. R. Butler, D. L. H. Williams, Chem. Soc. Rev. , 1993, 233- 241 
18. F. Y. Liew, and F. Cox, Immunol Today, 1991, 12, 17-18 
19. S. L James, Microbiol. Rev., 1995, 59, 533-547 
20. V. L. Dawson and T. M. Dawson, J. Chem. Neuroanat.,1996, 10, 179-190 
21. S. Moncada and J. O. Bolanos, J. Neurochem., 2006, 97, 1676-1689 
22. J. Kerwin, J. Lancaster, and P. Feldman, J. Med. Chem. Perspective., 1995, 38, 22, 4343-
4362 
23. A. Sobrero, Liebigs Annalen der Chemie, 1847, 64, 398 
24. N. Marsh and A. Marsh, Clin. Exp. Pharmacol. Physiol, 2000, 27, 313-319 
25. W. Murrell, Lancet, 1879, 80 
26. Joint Formulary Committee. British National Formulary. 64 ed. London: BMJ Group and 
Pharmaceutical Press; 2012 
27. J. A. Friederich and J. F. Butterworth IV, Anesthesia and Analgesia, 1995, 81, 152-162 
28. L. Grossi and S. D'Angelo, J. Med. Chem., 2005, 48, 2622-2626 
29. F. W. Flitney, I. L. Megson, D. E. Flitney and A. R. Butler, Brit. J. Pharmacol., 1992, 107, 
842 
30. H. S. Tasker, and H. O. Jones, J. Chem. Soc. Trans, 1909, 1910-1918 
31. N. Hogg, Annu. Rev. Pharmacol. Toxicol., 2002, 42, 585-600 
32. D. L. Williams, Acc. Chem. Res., 1999, 32, 869-876 
33. V. G. Kharitonov, A. R. Sundquist, and V. S. Sharma, J. Biol. Chem, 1995, 270, 28158 
34. P. Wang, M. Xian, X. Tang, X. Wu, Z. Wen, T. Cai, and A. Janczuk, Chem. Rev, 2002, 102, 
1091-1134 
35. B. Gaston, Biochimica et Biophysica Acta, 1999, 1411, 323-333 
Introduction References 
66 | P a g e  
 
36. I. Kluge, U. Gutteck-Amsler, M. Zollinger and K. Quang Do, J. Neurochem., 1997, 69, 6, 
2599-2607 
37. Y. Zhang and N. Hogg, Free Radical Biol. Med, 2005, 38, 831-838 
38. J. S. Stamler, O. Jaraki, J. Osborne, D. I. Simon, J. Keaney, J. Vita, D. Singel, C. R. Valeri 
and J. Loscalzo, Proc. Nat. Acad. Sci, 1992, 89, 7674, 7677 
39. S. C. Askew, D. J. Barnett, J. McAninly, D. L. H. Williams, J. Chem. Soc, Perkin Trans 2, 
1995, 4, 741-745 
40. R. J. Singh, N. Hogg, J. Joseph and B. Kalyanaraman, J. Biol. Chem., 1996, 271, 31, 18596-
18603 
41. D. L. Williams, Chem. Commun., 1996, 1085-1091 
42. H. M. S. Patel and D. L. H. Williams, J. Chem. Soc. Perkin Trans 2, 1990, 37-42 
43. H. Al-Sa’doni and A. Ferro, Clin. Sci., 2000, 98, 507–520 
44. A. Butler, J. McAninly, L.H. Williams, S. Askew, and C. Russell, J. Chem. Soc., Chem. 
Commun, 1993  
45. Q. Timerghazin, G.H. Peslherbe, and A.M. English, Org. Lett, 2007, 9, 16, 3049-3052 
46. D. R. Noble and D. L. H. Williams, Nitric oxide, 2000, 4, 392-398 
47. F. Kahn, R. J. Pearson, D. J. Newton, J. J. F. Belch, and A. R. Butler, Clin. Sci., 2003, 105, 
577-584 
48. C. M. Turnbull, P. Marcario, T. A. Sheldrake, L. Lazzarato, C. Cena, R. Fruttero, A, Gasco, 
S. Fox, I. L. Megson and A. G. Rossi, J. Inflammation, 2008, 5, 1-10 
49. A. Gasco, and P. Tosco, Pure Appl. Chem., 2008, 80, 8, 1693-1701 
50. A. Gasco, and A. Rossi, J. Inflammation, 2008, 12, 1-10 
51. L. Megson, and A. Gasco, Br. J. Phamracol., 2006, 148, 517-526 
52. D. Ding, and L. Fang, Bioorg. Med. Chem. Lett., 2007, 1062-1066 
53. A. Gasco, J. Med. Chem., 2001, 44, 3463-3486 
54. M.L. Lolli, B. Rolando, P. Tosco, S. Chaurasia, A. Di. Stilo, L. Lazzarato, E. Gorassini,  
R. Ferracini, S. Oliaro-Bosso, R. Fruttero and A. Gasco, 2010, Bioorg. Med. Chem., 18, 
2428-2438 
Introduction References 
67 | P a g e  
 
55. M. Bertinaria, S. Guglielmo, B. Rolando, M. Giorgis, C. Aragno, R. Fruttero, A. Gasco,  
S. Parapini, D. Taramelli and Y. C. Martins, Eur. J. Med. Chem., 2011, 1-11 
56. A. Di Stilo, S. Visentin, C. Cena, A. M. Gasco, G. Ermondi and A. Gasco, J. Med. Chem., 
1998, 41, 5393-5401 
57. R. Fruttero, M. Crosetti, K. Chegaev, S. Guglielmo, A. Gasco, F. Berardi, M. Niso,  
R. Perrone, M. A. Panaro, N. and A. Colabufo, J. Med. Chem., 2010, 53, 5467-5475 
58. R. M. Paton, Comprehensive Heterocyclic Chemistry I, 1984, 393-426 
59. R. M Paton, Comprehensive Heterocyclic Chemistry II, 1995, 229-265 
60. G. N. Nikonov, and S. Bobrov, Comprehensive Heterocyclic Chemistry III, 2008, Vol.5, 
315-394 
61. W. F. Nirode, J. M. Luis, J. F. Wicker and N. M. Wachter, Bioorg. Med. Chem. Lett., 2006, 
16, 2299-2301 
62. P. G. Wang, T. B. Cai, N. Taniguchi, Nirtic oxide donors: For Pharmaceutical and Biological 
Applications, Science, John Wiley and Sons, 2005 
63. P. Tonnies, Chem. Ber, 1903, 13, 1845-1880 
64. H. Wieland, ANN., 1903, 329, 225-268 
65. H. Takayama, S. Shirakawa, M. Kitajima, N. Amimi, K. Yamaguchi, Y. Hanasaki, T. Ide, K. 
Katsuura, M. Fujiwara, K. Ikichi, K. Konno, S. Sigeta, T. Yokota and M. Baba, Bioorg. Med. 
Chem. Lett, 1996, 16, 1993-1996 
66. A. Gasco, R. Fruttero, B. Ferrarotti, A. Serafino, and A. Di Stilo, J. Heterocyclic. Chem., 
1989, 26, 1345  
67. H. Takayama, Bioorg. Med. Chem. Lett., 1996, 1993- 1996 
68. A. Gasco,  ANN, 1991, 1211-1213 
69. X. Dong, and Y. Hu, Eur. J. Med. Chem., 2010, 40, 3986-3992 
70. E.R. Alexander, M. R. Kinter and J. D. McCollum, J. Am. Chem. Soc, 1950, 72, 2, 801-803 
71. H.R.Snyder and N. E. Boyer, J. Am. Chem. Soc, 1955, 77, 16, 4233-4237 
72. D. A. Shirley, B. H. Gross and M. J. Danzig, 1958, J. Org. Chem., 23, 7, 1024-1026 
73. H. Tezuka, M. Kato and Y. Sonehara, J. Chem. Soc. Perkin. Trans. 2, 1985, 1643-1647 
Introduction References 
68 | P a g e  
 
74. V. N. Yarovenko, S. A. Kosarev, I. V. Zavarzin and M. M Krayushkin, Russ. Chem. Int. Ed., 
2002, 51, 8, 1504-1509 
75. M. Curini, Tet. Lett, 2000, 8817-8820 
76. Kwang-Jin Hwang ,Y. C. Park, H. Jin Kim, J. H. Lee, J. Biochem, 1998, 62, 9, 1693-1697  
77. R. L. Willer, J. Org. Chem., 1985, 50, 5123-5127 
78. J. V. Burakevich , J. Org. Chem., 1971, 36, 1, 5-7 
79. J. A. Hrabie and L. K. Keefer, Chem. Rev, 2002, 102, 1135-1154 
80. A. Angeli, Samml. Chem. Chem-Tech. Vortr, 1908, 13, 1-50 
81. R. S. Drago, E. F. Paulik, J. Am. Chem. Soc, 1960, 82, 96-98 
82. J. E. Saavedra, M. N. Booth, J. A. Hrabie, K. M. Davies and L. K. Keefer, J. Med. Chem., 
1999, 64, 5124-5131 
83. R.S. Nyholm and L. Rannitt, J. Inorg. Syn., 1957, 5, 117-118 
84. P. G. Parzuchowski, M. C. Frost and M. E. Meyerhoff, J. Am. Chem. Soc, 2002, 124, 12182-
12191 
85. M. J. Hill, G. Hawkswort and G. Tattersall, Br. J. Cancer, 1973, 28, 562-567 
86. K. Straif, S. K. Wieland, M. Bungers, D. Holthenrich, D. Taeger, S. Yi and U. Keil, Brit. 
Med. J., 2000, 57, 180-187 
87. E. V. Arnold, B. G. Doleski and R. E. Raulli, United States Patent. Patent No: US 7,569,559 
B2, 2009 
88. J. Brown, J. Am. Chem. Soc., 1917, 2358-2366 
89. T.A. Balaban, E. R. Garfield, M. J. Lesko and A. W. Seitz, Org. Prep. Pro. Int., 1998, 30, 
439-446 
90. Y. Hou, W. Xie, N. Ramachandran, B. Mutus, A. J. Janczuk and P. G. Wang, Tet. Lett, 2000, 
41, 451-456 
91. Y. Hou, W. Xie, A. J. Janczuk and P. G. Wang, J. Org. Chem., 2000, 65, 4333-4337 
92. A. D. McGill, W. Zhang, J. Wittbrodt, J. Wang, H. Bernhard Schlegal and P. G. Wang, 
Bioorg. Med. Chem. Lett., 2000, 8, 405-412 
Introduction References 
69 | P a g e  
 
93. E. R. Garfield, T. A. Bablaban, A. W. Seitz, J. D. Klein and M. Lesko, International Patent, 
WO: 96/36326, 1996 
94. J. R. Hwu, C. S. Yau, S-C Tsay and T-I Ho, Tet Lett. 1997, 38, 52, 9001-9004 
95. A. W. Deckel, J. Neurosci. Res., 2001, 64, 99-107 
96. S. Hunot, F. Boissiere, B. Faucheux, B. Brugg, A. Mouatt-Prigent, Y. Agid and E. C. Hirsch, 
Neuroscience, 1996, 72, 2, 355-363 
97. L. Zhang, V. L. Dawson and T.M. Dawson, Pharmacol. Ther., 2006, 109, 33-41 
98. J. B. Schulz, R. T. Matthews and M. F. Beal, Curr. Opin. Neurol., 1995, 8, 480-486 
99. V. L. Dawson and T. M. Dawson, Prog. Brain Res., 1998, 118, 215-29 
100. R. Shukla, Ann. Neurosci., 2007, 14, 1-14 
101. http://dictionary.reference.com/medical. Date accsessed 18/06/2015 
102. P.E. Chabrier, C. Demerle-Pallardy and M. Auguet, Cell. Mol. Life Sci., 1999, 55, 1029-1035 
103. H. Ji, S. Tan, J. Igarashi, H. Li, M. Derrick, P. Martasek, L. J. Roman, J. Vasquez-Vivar, T. 
L. Poulos and R. B. Silverman, Ann Neurol., 2009, 65, 2, 209-217 
104. H. Matter, P. Kotsonis, O. Klingler, H. Strobel, L. G. Frohlch, A. Frey, W. Pfleiderer and  
H. H. H. W. Schmidt, J. Med. Chem, 2002, 2923-2941 
105. J. Vitecek, A. Lojeck, G. Valacchi and L. Kubala, Mediators of Inflam. Rev., 2012, 1-22 
106. http://www.rcsb.org/pdb/101/motm.do?momID=133. D. Goodsell: Molecule of the Month 
review 2011. Date accssesed 18/06/2015 
107. T. Fischmann, A. Hruza, X. D. Niu, J. D. Fossetta, C. A. Lunn, E. Dolphin, A. J. Prongay, P. 
Reichert, D. J. Lundell, S. K. Narula and P.C. Weber, Nat. Strut. and Bio., 1999, 6, 233-242 
108. S. Pfeiffer, E. Leopold, K. Schmidt, F. Brunner and B. Mayer, Br. J. Pharmacol., 1996, 118, 
1433-1440 
109. www.scbt.com Date accessed 18/06/2015 
110. R. B. Silverman, Acc. Chem. Res., 2008, 42, 439-451 
111. F. Xue, J. Fang, S. L. Delker, H. Li, P. Martasek, L. J Roman, T. L. Polous and  
R. B. Silverman, J. Med. Chem., 2011, 54, 2039-2048 
112. K. E. Heim, A. R. Tagloaferro and D. J. Bobilya, J. Nutr. Biochem., 2002, 13, 572-584 
Introduction References 
70 | P a g e  
 
113. C. A. Rice-Evans, N. J. Miller and G. Paganga, Free Radical Bio. Med., 1996, 20, 933-956 
114. D. Amic, D. Davidovic-Amic, D. Belso and N. Trinajstic, Croatica Chemia Acta., 2003, 76, 
55-61 
115. T. Ak, I. Gulcin, Chemico-Biologcal Interactions, 2008, 174, 27-37 
116.  H. Tezuka, M. Kato and Y. Sonehara, J. Chem. Soc. Perkin Trans 2, 1985, 1643-1647 
117. D. I. Batovska and I.T. Todorova, Curr. Clin. Pharmacol., 2010, 1, 1-4 
118. W. V. Farrar, J. Chem. Soc, 1964, 904-906  
119. Y. Hou, W. Xic, A. Janczuk and P.G. Wang, J. Org. Chem., 2000, 65, 4333-4337 
120. D. Thompson, Molecule of the month, 
http://www.chm.bris.ac.uk/motm/combretastatin/combv.htm 
121. R. G. Pettit, M. G. Cragg, L. D. Herald and M. J. Schmidt, Can. J. Chem, 1982, 60, 1374-
1376 
122. R. G. Pettit and B. S. Singh,  Can. J. Chem., 1987, 65, 2390-2396 
123. R. G. Pettit, C. Temple (Jnr), L.V. Narayanan, R. Varma, K. M. Simpson, Anti-Cancer Drug 
Des., 1995, 10, 299-309 
124. G.C Tron, F. Paglial, E. Del Grosso, A. A. Genazzani and G. Sorba, J. Med. Chem., 2005, 
48, 3260-3268 
125. World Health Organisation, http://www.who.int/topics/cancer/en/ 
126. G. Nagaiah and S.C. Remick, Future Oncol., 2010, 6, 8, 1219-1228 
127. Oxigene pipeline drugs- How combretastatin works. - 
http://www.oxigene.com/our_science/how_our_drugs_work/ 
128. E. Hamel, Pharmac. Ther., 1991, 51, 377-401 
129. K. G. Pinney, M. P. Mejia, V. M. Villabos and G. R, Pettit, Bioorg. Med. Chem.,2000, 8, 
2417-2425 
130. S. Ducki, G. Mackenzie, N. J. Lawrence and J. P. Snyder, J. Med. Chem, 2005, 48, 457-465 
131. T. McGown, J. Org. Biomol. Chem., 2003, 1, 3033-3037 
132. M. E. Richardson, PhD thesis, Keele University, 2012 
Introduction References 
71 | P a g e  
 
133. T. M. Beale, D. M. Allwood, A. Bender, P. J. Bond, J. D. Brenton, D. S. Charnock-Jones, S. 
Ley, R. M. Myers, J. W. Shearman, J. Temple, J. Unger, C. A. Watts and J. Xian, Med. 
Chem. Lett., 2012, 3, 177-181 
134. P. Mukherjee, M. A. Cinelli, S. Kang and R. B. Silverman, Chem. Soc. Rev., 2013 
135. H. Huang, H. Li, P. Martasek, L. J. Roman, T. L. Poulous and R. B. Silverman,  
J. Med. Chem, 2013, 56, 3024-3032 
136. Q. Jing, H. Li, J. Fang, L. J. Roman, P. Martasek, T. L. Poulos and R. B. Silverman, Bioorg. 














Results and Discussion- Synthesis 
 
72 | P a g e  
 
Chapter 2.0- Results and Discussion 
 
The results and discussion chapter will be split into three sections. The first comprising the 
synthetic routes used in the generation of NO-donors and inhibitors. The second will contain details 
concerning the measurement of NO release including background and. The final section will 
contain the biological results generated by collaborators at Kingston University (UK). 
2.1 Synthesis 
2.1.1- Combretafuroxan compounds  
The rationale for developing a series of substituted combretafuroxan compounds within either series 
1 or 2, allows for a large amount of research scope. For each combretafuroxan series to have any 
potency against cancer cell lines, better or comparable to the parent compound, combretastatin A-4, 
it will need to have key structural similarities, notably the cis conformation. The structural back bone 
of the parent compound combretastatin is essentially a Z-stilbene1 which makes synthetic analogues 
relatively straight forward to make. Petitt2, who first isolated combretastatin from the bark of the 
African willow, used standard Wittig chemistry to synthesise the substituted stilbene. The rationale 
for the inclusion of a furoxan ring within the combretastatin structure is an easy one and it is all down 
to orientation, sterics and solubility. The cis orientation that combretastatin A-4 adopts is one of the 
reasons for its high potency.3 The double bond forces the two phenyl rings to be an optimal distance 
apart for binding with in the tubulin site4,5. However in vivo, the parent compound is prone to 
isomerisation and readily converts to the less active trans conformer. The furoxan ring forces the 
combretastatin to remain in the most optimal orientation while also having the dual action of 
improving water solubility. 
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2.1.1.1- Synthesis of Stilbene compounds 
 
The general reaction scheme for the production of the substituted stilbene compounds (120-125) is 
shown in scheme 1. Classic Witting chemistry6 was utilised in the production of the stilbene 
compounds 120-125 (shown in scheme 28), these were then treated with sodium nitrite under acidic 
conditions, comparable to those used by Gasco7,8, to generate the combretafuroxans 77-82. 
 
Scheme 28: Standard Witting reaction6 to produce a mixture of E/Z stilbene compounds. These can 
then be reacted on to generate the desired combretafuroxan compound, 42. 
 
Adapting a method found in the literature9 mono-substituted iodo phosphonium bromides, in the 
meta and para positions 117 & 118 and para-bromo phosphonium bromide 119 were synthesised 
from their corresponding benzyl bromides and triphenylphosphine (scheme 29). These were 
synthesised in high yields (86-88%) for use in the later Wittig reaction and creation of the required 
stilbene compounds 120-125 E/Z as shown in scheme 30.  
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Scheme 29: Reaction of bromobenzyl compounds with triphenylphosphine to produce the 
phosphobium bromide compounds 117-119 for scheme 28. 
 
The synthesis of the stilbene compounds was initially straight forward route using standard Witting 
chemistry by reacting substituted aldehydes with phosphonium bromides to create the desired 







Scheme 30: Reaction of substituted phosphonium bromides with benzaldehydes to produce a 
mixture of E and Z stilbenes 120-125. 
Compound 
Number 
R R1 R2 R3 R4 R5 R6 
120 E/Z OMe H OMe OMe H I H 
121 E/Z OMe H OMe OMe H H I 
122 E/Z OMe H OMe H OMe H I 
123 E/Z H Br H Br H I H 
124 E/Z H Br H Br H H I 
125 Z H H Br H H H Br 
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Diagnostically, 1H NMR spectroscopy and specifically J couplings were used to determine if the 
production of the stilbene compounds were successful. Literature9 indicates that the E isomers have 
a J coupling of 16 Hz compared to 12 Hz for the Z isomers, although due to the mixture of isomers 
not all J couplings were isolated.  
The appropriate halogenated phosphonium bromide 117-119 was sparingly dissolved in dry THF 
and deprotonated using n-Buli at -78⁰C, creating the reactive ylide species that are famous to the 
Wittig reaction. To this solution trimethoxy substituted aldehydes 156-158 (scheme 30) were added 
and left to stir at room temperature for 1 hour before being worked up, by the addition of water, to 
yield the E/Z stilbene analogues in various yields (2.3% to 22%). Of the isolated E/Z stilbenes, ratios 
of cis:trans isomers were found at 1:4 E/Z. The production of phosphonium oxide 160 is the driving 
force for this reaction as production of the oxygen-phosphorous bond is highly energetically 
favourable and its formation is shown in scheme 31.  
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Scheme 31: Mechanism for the Wittig reaction between the phosphonium bromide 117 and 
trimethoxybenzaldehyde 157. The driving force for this reaction is the formation of the very strong 
P-O bond and generation of phosphonium oxide 160 and the alkene. 
 
The purification of these compounds proved to be a very challenging. Both E and Z isomers were 
almost inseparable using thin layer chromatography (TLC) and column chromatography. Several 
solvent systems were tried, ranging from 1:1 to 100:1 petroleum ether:ethyl acetate, none of which 
managed to produce a successful separation of the isomers, expect for one compound (122).. During 
the synthesis and purification of these stilbene compounds (120-125 E/Z), it was discovered that 
isomerisation was occurring rapidly and the ratio of E/Z (1:4) was changing. Compound 122, the 
stilbene that was successfully separated, was used to test this change in olefinic bond orientation. A 
1H NMR study was conducted were a sample of compound 122 E and 122 Z (cis and trans stilbene) 
were either exposed to light or kept under dark conditions. Using diagnostic olefinic 1H peaks 
between 6 and 7 ppm the ratio of cis to trans was determined and showed that over time there was a 
slow conversion to the trans conformation as the preferred isomer. This phenomenon only occurred 
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when compound 122 E/Z was kept under dark conditions. In the presence of ambient light compound 
122 E/Z began to isomerise but then rapidly degraded and decomposed. These findings led to all 
compounds being protected from light and stored at a low temperature to slow down the 




Graph 2: Isomerisation graph showing the change in conformation over time for compound 122 
E/Z.  
 
Although stilbenes 120-125 E/Z could not be separated by conventional chromatography techniques, 
this didn’t affect the forward synthesis and the reaction to generate the furoxan ring. This is due to 
the ‘ionic’ mechanism7 that is undergone to form the 1,2,5-oxadiazole-2-oxide ring previously shown 
in scheme 14 (chapter 1, page 30). The orientation of the double of bond should not alter the reaction 
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82 was preceded without further purification. Stilbene’s 120-125 E/Z were dissolved in acetic acid, 
to which dilute HNO3 was added in a dropwise fashion. To this solution a catalytic amount of solid 
sodium nitrite (NaNO2) was added causing the evolution of a brown gas, noted as being nitrogen 
dioxide (NO2) gas. However the synthesis of furoxans from the substituted stilbenes proved to be 
unsuccessful on several attempts. High purity sodium nitrite was also used (99.9995%) but this 
yielded no desired product. The number of equivalents of sodium nitrite was also changed in relation 
to what is reported in the literature.7,9-11 Sodium nitrite was used in both three and seven fold excess 
to that of the stilbene staring materials (120-125 E/Z), however all reactions returned unreacted 
starting material, with no isolation of the desired furoxan product. When several attempts at 
converting the substituted stilbene compounds to their corresponding furoxan derivatives 77-82 
appeared not to be giving the desired product and only produced unreacted starting material, the 
validity of the procedures being adapted were discusssed7,10. Various theories about temperature 
control were considered, as Gasco states7 that addition of sodium nitrite should be done at exactly 
14°C, which appeared to be quite a strange option. To understand Gasco’s procedure in a more in-
depth way, so any further alterations to his method could be done logically and through direct 
observations, it was decided that the synthesis of furoxans from alkenes reported in the literature7, 12 
should be repeated using the identical starting materials and conditions quoted in the publication, as 
this should give an indication of the validity of the procedure and provide key experimental 
observations that could be applied to our stilbene compounds.  The two most common starting 
materials for the majority of Gasco’s furoxan work used were but-2-enal 161 and cinnamyl alcohol 
162. Reactions of these compounds with sodium nitrite have been reported to successfully produce 
the furoxan ring 126 from the alkene double bond, as shown in scheme 32.  
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Scheme 32: Two historic reactions from the literature converting an alkene double bond to the 
furoxan ring7 
 
1,2-Diphenylethene, 155, the unsubstituted stilbene compound most directly linked to the work with 
the combretastatins, was converted to the furoxan ring by Vellaquez10 using the a similar procedure 
to Gasco7 (NaNO2 and acetic acid) but with the addition of the solvent 1,4-dioxane, this was probably 
to increase the solubility of the reagents and to ensure all reaction intermediates stayed within 
solution.  
 
Scheme 33: Reaction of trans stilbene with NaNO2 to produce the furoxan ring in the place of the 
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Using the historic synthesises found in the literature7,10,12, compounds 3-acetyl-4-methyl-1,2,5-
oxadiazole 2-oxide 126 and 1,2-Diphenyl furoxan 128, were successfully synthesised. 
Crotonaldehyde, or but-2-enal 161, was dissolved in acetic acid and cooled to 14°C while aqueous 
NaNO2 was added dropwise. After an hour, an aqueous work up was completed and after purification 
through flash column chromatography the desired furoxan was recovered in 23%. Diagnostic peaks 
for the imine (C=N) and the N-oxide bond were sought out in carbon NMR spectroscopy and were 
found respectively at 154.3 and 110.3 ppm indicating the successful conversion of the double bond 
to the furoxan ring, 126. 
The trans stilbene compound, (1,2-diphenylethene, 155) was dissolved in a combination of 1,4-
dioxane and acetic acid. In contrast to the Gasco method7, this reaction10 was then heated to between 
50 and 60°C before solid sodium nitrite was added. This reaction was successful in producing the 
desired furoxan compound, but also produced with it an inseparable by-product which was found to 
be the nitrated starting material, 129 as shown in scheme 34. Diagnostic peaks for the furoxan ring 
128 were found at 156.2 and 114.3ppm by 13C NMR spectroscopy for the new imine bond (C=N) 
and the N-oxide (C=N+-O-) respectively. The by-product was confirmed as the nitrated stilbene 
through mass spectroscopy, yielding a peak of 226.0862 m/z, corresponding to compound 129. 
Repeating the literature reaction of cinnamyl alcohol 162 with sodium nitrite in acidic conditions, 
performed by Gasco12 and researchers, failed to produce any desired furoxan compound 127 and only 
starting material was recovered upon multiple attempts. 
 
Scheme 34: Reaction of trans stilbene with NaNO2 following a procedure highlighted in the 
literature, successfully producing the desired furoxan compound as well as the nitrated by-product. 
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With viable conditions in place for the formation of the furoxan ring, these were applied to the 
substituted stilbene compounds 120-E/Z 125-E/Z. Vellaquez’s procedure10, of seven equivalents of 
sodium nitrite and a temperature of 60°C was used but again to ill effect, as no reaction appeared to 
have occurred. Steric hindrance was thought to play a factor in why the furoxan ring is failing to 
form, especially for the 2,4,6-trimethoxy compounds (121 E/Z and 122 E/Z),. Due to the position of 
the 2 and 6-methoxy group on the aryl rings, they may be large enough to prevent the alkene initiating 
a nucleophilic attack with the nitrosonium ion, by blocking one face of the alkene bond. A 
representation of compounds 122 E/Z’s three-dimensional orientation is shown in Fig. 41. The 2-
methoxy group appears to sit directly above the alkene bond’s hydrogen atom at C7 and C45 (cis and 
trans respectively) and may be close enough to cause steric hindrance and prevent the initial reaction 
with the NO+ ion.  The trans stilbene’s three-dimensional structure 122 E indicates a that there isn’t 
a lot of ‘space’ for the alkene bond to orientate itself to behave as a nucleophile as the stilbene exists 
as a much more planar structure. This may explain why the methoxy substituted stilbene compounds 
121 E/Z and 122 E/Z were unsuccessful in the forward synthesis and didn’t produce the desired 
furoxan ring. 
 
Figure 41: 3D representation of compound 121 E/Z showing the steric hindrance caused by the 2-
methoxy group adjacent to the double bond. Three-dimensional model created using Chembio3D 
Ultra 13.0. 
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With the trimethoxy compounds not producing the desired furoxan product (121-122), it was 
thought that the position ortho to the double bond was causing the reaction to fail due to steric 
hindrance coupled with the ring activation and possible loss of aromaticity induced by the methoxy 
groups; as the oxygen of the methoxy group (in the ortho position) donates its lone pair into the 
ring, movement of electrons towards the olefinic bond would cause a loss in aromaticity and is 
therefore energetically un-favoured, a paradigm which would cause a high barrier to overcome. 
These electronic effects prompted the synthesis of another stilbene compound 123 E/Z. Starting 
from 3,5-dibromobenzaldehyde, with the rationale that replacing the 2-methoxy group with the 
much smaller hydrogen atom should remove the steric hindrance issue as shown in Fig.42. As 
bromine is much less electronegative than oxygen, the aromatic ring should be less activated and 
therefore enable the double bond to engage in nucleophilic attack with the NO+ species produced in 
the furoxan reaction. 
 
Figure 42: 3D representation of compound 123 E/Z without a substituent in the 2 position 
reducing the steric effects over the double bond. Three-dimensional model created using 
Chembio3D Ultra 13.0. 
 
Our theory of enhanced reactivity towards heterocylic ring formation with the 3,5-dibromo 
stilbene, also failed to produce the desired combretafuroxan compound. Reacting the (Z/E)-3,5-
dibromo-5-(3-iodostyryl)benzene 123 with sodium nitrite in the presence of acetic acid only 
returned starting material after several attempts. Increasing the number of equivalents of sodium 
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nitrite towards an excess (1 equivalents to 7 equivalents) also had no effect on the success of the 
reaction and continued to yield only starting material. This suggests that steric hindrance was not 
the only issue. It is possible that the electronic effects of the chosen substituents are making the 
addition of the NO+ electrophile unfavoured.  
Returning to the literature procedures11,12 highlighted the need for an oxygen atom in the starting 
material to be adjacent to the double bond. This prompted the inclusion of an oxygen atom within 
our structures to study their ability to produce the desired furoxan ring. Literature indicates13 that 
caffeic acid, a cheap and relatively available starting material, had been successfully converted to a 
furoxan derivative in 50% yield (scheme 35) from the reaction with acidified nitrite.  
However further reading14 indicated that the conversion was not a clean one, producing multiple by-
products. To test this reaction and minimise the amount of by-products formed, caffeic acid phenyl 
ester (CAPE, 158), a derivative of caffeic acid was instead reacted in the presence of acetic acid and 
NaNO2 in an attempt to yield the furoxan (scheme 35). Several attempts at this reaction failed to 
produce the desired product, returning unreacted starting material each time. 
 
Scheme 35: Caffeic acid 156 reaction from the literature producing the furoxan ring13 and the 
reaction of CAPE 158 with acidic nitrite. 
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Due to caffeic acid 156, and CAPE 158, not yielding the desired products, attention turned to the 
chalcones. These are common organic compounds consisting of a α,β-unsaturated ketone, whose 
synthesis15 is relatively straight forward. The reaction of two readily available starting materials, a 
benzaldehyde and a acetophenone, in the presence of a base affords the chalcone motif. Due to the 
presence of an oxygen atom, in the form of a ketone group, adjacent to the double bond we theorised 
that it may be possible to generate the furoxan ring from the α,β-unsaturated ketone 130 (shown in 
scheme 36). If successful, the chalcone derived furoxan would be able to act as a synthetic scaffold 
for combretafuroxan series with the addition of an unsymmetrical ketone group between the furoxan 
ring and the A and B ring. 
 
 
Scheme 36: Reaction of 2,4,5-trimethoxybenzaldyde, 160, with 4-bromoacetophenone, 161, to 
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2,4,5-Trimethoxybenzaldeyde 160 and 4-bromoacetophenone 161 were dissolved in methanol and 
stirred with 5% sodium hydroxide for 24 hours. Addition of water led to a yellow precipitate to form 
which was then recrystallized from hot ethanol to give a luminous yellow powder of 130. The next 
reaction to generate the furoxan compound 162 followed the Velaquez procedure,10 using NaNO2 
(99.999%) in acetic acid and dioxane at 60°C. However the desired reaction did not occur and only 
starting material 130 was recovered. 
Direct furoxan synthesis from substituted stilbene compounds using the double bond chemistry by 
Gasco7,12 and Velaquez1o was not producing the desired product and therefore a different approach 
was sought out. After scouring the literature for a different methodology, it was decided that two 
different procedures4,16 should be combined in the hope that a viable route for successful production 
of the combretafuroxan compounds77-82 would be developed. An interesting publication4 that could 
be applied to our work on both combretastatin analogues and furoxan synthesis provided a possible 
synthetic route to explore. The authors converted a stilbene compound to a dioxime derivative which 
was then cyclised to form the furazan ring. A furazan ring is very similar to the furoxan ring as both 
are oxadiazoles but the former lacks the ability to release nitric oxide as it does not possess the N-
oxide bond. Adapting the procedure4 to produce the furoxan ring 80 from the oxime starting material 
132 can be done using coordination chemistry found in the literature.16 
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Scheme 37: Reaction of stilbene 122 E/Z to the furoxan 80 via a diketone 131 and dioxime 132 
intermediate4,16. NB: Compounds 122 E/Z, 132 and 80’s 6-OMe bond is distorted due to its 
positioning in the 2D plane. 
 
A test reaction was implemented on compound 122- E/Z to see how viable this new proposed route 
was. Compound 122-E/Z was successfully treated with potassium permanganate to yield the diketone 
compound 131 in 37% yield as shown in scheme 10. The diketone 131 was then converted, without 
any further purification to the dioxime 132 by reacting it with hydroxylamine hydrochloride 
producing a 5.5% yield. Following the second publication16 the dioxime compound 132 was 
dissolved in acetonitrile and treated with copper (II) chloride and sodium perchlorate causing an 
intense green solution to form, indicative of ligand formation. After 12 hours a green oil was 
separated from the reaction mixture and immediately treated with aqueous ammonia. A further colour 
change was noted at this point, changing the green oil to a deep blue solution, this was also an 
indication that ligand exchange had occurred forming the copper-ammonia complex which is 
historically known to be a deep blue coloured compound. Liquid-liquid extraction of the furoxan 
complex was completed using chloroform and gave the desired furoxan 80 compound in a 16% yield. 
Although this reaction did produce the desired furoxan compound 80, it was decided that due to the 
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number of steps and low yield (0.3% overall) that it wasn’t a feasible option for progression with the 
stilbene compounds. 
2.1.1.2 -Synthesis from oxime starting materials 
 
A positive result from the stilbene work was that successful conversion to the furoxan was possible, 
but it wasn’t until the double bond had been converted to the dioxime moiety that the furoxan 
formed. As aforementioned ( chapter 1.1.3, page 40), the oxime moiety already has the correct 
stoichiometric amount of nitrogen and oxygen present and therefore is a much simpler, easier route 
for ring closure and production of the oxadiazole-2-oxide ring. Building on the use of oximes as a 
starting material, a convenient procedure was found that produced the desired furoxan ring in a 
one-pot synthesis (scheme 38). A Russian group,17 led by Krayushkin, reacted substituted amino-
oximes with sodium nitrite in the presence of sulphuric acid and produced the furoxan  ring in high 
yield (60-91%) and as a collectable precipitate. Giving that the yield for our dioxime work only 
gave a 16% yield and involved a three step process, this alternative synthetic route was a very 
attractive option. 
 
Scheme 38: Reaction of aminooxime compounds with sodium nitrite yields the furoxan ring. 
Taken from reference 17. 
 
Adapting Krayushkin’s procedure17 to use benzoximes as our starting material, to synthesise 
symmetrical combretafuroxans that adhere to the ‘series 1’ model (chapter 1.3, page 61), 
trifluromethyl and trifluromethoxy benzyl oximes were purchased. The CF3 group strongly 
deactivates aromatic rings and therefore may amend some of the possible electronic interactions that 
may have been occurring with the stilbene to the furoxan synthesis. The starting material was 
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suspended in 20% sulphuric acid, to which sodium nitrite was added while the temperature was 
maintained between -5 and -15°C. After several attempts at this reaction, no furoxan product was 
isolated either as a precipitate as stated in the literature or when an organic extraction was carried 
out. 
 
Scheme 39: Reaction of benzoaminoximes with acidic NaNO2 produced the desired 
combrefuroxans 96-97. 
 
The main problem with this reaction is that, two molecules of oxime starting material are needed to 
combine and expel NH2 as a leaving group. Here is where it was theorised the problem might lie. 
Strong bases are notoriously bad leaving groups and therefore the amino (NH2) group isn’t going to 
want to be removed from the oxime molecule and hence ring closure and the formation of the 
oxadiazole-2-oxide isn’t going to occur. To overcome this, we aimed to convert the amino group into 
a better, less basic leaving group such as a halogen atom. It would seem that the Russian researchers 
also explored this17 and again provided a straight forward method to the synthesis of the desired 
furoxan ring, this time in a two-step method, first converting the carbamoylformamide oximes 
165/166 to their corresponding carbamoylformamide oxime-chloride 135 and then treating the new 
improved leaving group with a base to generate the furoxan ring with expulsion of the chlorine group 
as the salt as depicted in scheme 40. 
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Scheme 40: Two step synthesis of furoxan compound 96. Reaction of aminooxime with HCl and 
NaNO2 provides a suitable leaving group for the second step. 
 
Reaction of 165 with 18% hydrochloric acid and sodium nitrite successfully produced the desired 
chlorinated oxime in a 24% yield. Column chromatography was used to purify this intermediate (7:3 
petroleum ether:ethyl acetate) and was notably easier than the stilbene columns due to the very decent 
separation on TLC. The next step of the forward synthesis was to react the chlorinated oxime 135 in 
the presence of a base to initiate the ring closure mechanism. The first attempt of this reaction used 
trimethylamine as a base and caused no reaction, it was thought the reaction failed due to 
trimethylamine not being a strong enough base. The second attempt at this reaction proved to be 
fruitful, this time using pyridine as a base. Pyridine has a pKb of 5.2 compared to 11.1 of 
trimethylamine and hence is a stronger base. Using pyridine afforded the desired substituted furoxan 
compound 96 as a precipitate (5.8%) with no further purification needed.   
With the successful generation of the furoxan ring 96 from the chlorinated oxime intermediate 135, 
all be it in relatively low yield (24%), attention was turned to the oxime starting material, which was 
fairly expensive, to be producing a 5% yield of furoxan. This led to a literature search being 
conducted for an alternative synthetic route to the required oxime starting material, from chemicals 
that were more readily available to us, such as benzaldehydes. A 2006 publication by a group of 
Serbian chemists18 stated that the desired oxime compounds could be produced in very high yields 
(72-100%) in a solvent-less reaction solid with hydroxylamime hydrochloride and sodium hydroxide 
by grinding the starting materials together in a pestle and mortar as depicted in scheme 41. 
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Scheme 41: A unique procedure for the production of benzoxime compounds 136 in a solventless 
reaction using just a pestle and mortar. 
 
4-Chlorobenzyaldehyde 167 was chosen due to its inexpensive nature and relative abundance within 
our laboratories and the added advantage that it was a solid starting material. The benzaldehyde 167, 
hydroxylamine hydrochloride and sodium hydroxide pellets were added in a 1:1.2:1.2 ratio. To this 
powdered mixture, silica was added to act as a ‘binding’ agent while the four ingredients were ground 
together intermittently using a pestle and mortar for 120 minutes before being washed with water to 
remove any inorganic salts remaining. Although initially sceptical about this method, the oxime 
compound 136 was isolated in an 83% yield. The authors18 stated that the silica was present due to 
the ‘unreactive’ nature of aromatic ketones to this kind of chemistry. This led us to repeat the 
reaction, to test this statement without the addition of silica. The same reactants were used in the 
same 1:1.2:1.2 ratio and ground in the usual manner for the same duration as outlined above. The 
consistency of this mixture was notably different to the first attempt; it produced a dough like 
consistency and was much harder to efficiently grind. However in contrast to the literature, the 
desired oxime compound was isolated but in a lower yield of 59% suggesting that the silica perhaps 
plays a role in providing a surface on which the reaction occurs, much like an inorganic catalyst 
would.18 As a comparative procedure19 the same reaction was carried out, but this time introducing a 
solvent. 4-Chlorobenzyaldehyde 167 was dissolved in diethyl ether and to it aqueous NH2OH.HCl 
and NaOH were added at room temperature before being left to stir vigorously for 2 hours. After an 
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aqueous work up and the removal of the ether, a white solid corresponding to the 4-
chlorobenzaldehyde oxime 136 was recovered in 87% yield (scheme 42). The addition of a solvent 
seems to only offer a slight improvement of yield compared with the solvent-less reaction and 
therefore both routes appear to offer viable options to the synthesis of the desired oxime 136. 
 
 
Scheme 42: Alternative route for the generation of benzooximes, used as a comparative tool to the 
solventless reaction. 
 
The next step for this oxime route is the generation of a good leaving group by replacing the acidic 
hydrogen of the oxime with a chloride. In contrast to the first step of the two step synthesis used 
earlier17 (scheme 40) the oxime compound (derived from the solventless procedure18 scheme 41) was 
dissolved in THF and introduced to N-chlorosuccinimide at room temperature.20 This product was 
isolated in a 88% yield, as pale yellow flakes and was determined to be the desired chloro-oxime 
compound 137 as shown in scheme 43. 
To compare the products from two synthetic routes used to produce the oxime moiety the oxime 136 
isolated from the aqueous procedure19 (scheme 42) was reacted with N-chlorosuccinimide under the 
same conditions resulting in the isolation of a yellow solid in 96% yield. This suggests that both 
routes to the formation of the oxime-chloride compound (137) work effectively and give comparable 
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Scheme 43: The chlorination reaction using N-chlorosuccinimide to produce the oxime-chloride 
compound 137, which is the intermediate compound in the generation of the furoxan ring. 
 
Unfortunately the forward synthesis from the p-chlorobenzooxime chloride 137 failed to produce the 
furoxan ring under the basic conditions quoted in the literature17. Krayushkin reported a 50% 
recovery of furoxan compound using this procedure, however when p-chlorobenzooxime chloride 
137 was refluxed in the presence of an equimolar amount of trimethylamine, no furoxan product was 
isolated. Increasing the equivalents of trimethylamine to two and four returned unreacted starting 
material. Theoretically with the better leaving group in place like the chloride in 137, the simple ring 
closure reaction should be successful, however this was not the case. The fact that Krayushkin only 
isolated a 50% yield suggests that the production of the furoxan ring is not very favoured. 
2.1.1.3- Synthesis from an acetophenone 
 
The second series (Fig. 43) of combretafuroxans contains a two ketone groups acting as a bridge 
between the aromatic rings and the oxadiazole-2-oxide centre ring while still maintaining symmetry. 
 
 
Figure 43: Combretastatin analogue. 
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The starting material for this series is the relatively inexpensive acetophenones. Two acetophenone 
molecules combine under acidic conditions and in the presence of sodium nitrite to produce the 
furoxan ring at the heart of the structure. The reason for this second series (Fig. 43) is to increase the 
number of hydrogen bond acceptors and therefore to improve solubility1,2 since this is an issue with 
the parent compound combretastatin A-4. This series allows comparison of the NO releasing abilities 
and anti-cancer properties when two ketones are inserted, causing the structure to ‘bend’ slightly in 
comparison to the combretastatin’s predominantly cis orientation. This increase in tether length 
between the A and the B ring may also cause ‘series 2’ to dock differently within the colchicine 
binding site and therefore potentially improve its binding potential. 
 
 
Figure 44: Combretastatin A-4 and series 2. Both contain two A and B aryl rings. Series 2 contains 
a carbon linker bridging the two rings in addition to the furoxan ring for increased rigidity. 
 
As aforementioned (chapter 1.3, page 63)  the Ley group21, 22 found that halogenation of one of the 
aromatic rings increased anti-tumour activity five-fold of compounds similar to combretastatin A-4 
73 and this observation influenced the initial work. Preparations to modify our acetophenone starting 
materials to include a halide on the aromatic ring were sought out from the literature. The trimethoxy 
substituents are known to be of fundamental importance for a potent binding activity of 
combretastatin4,5,23, therefore starting with substituted methoxy acetophenones, it was planned to 
halogenate in the 3 and the 5 positon on the acetophenone ring as shown in scheme 44) 
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Scheme 44: Halogenation of trimethoxyacetophenones under various conditions. 
 
Bromination of 2,4,6- trimethoxyacetophenone 166 was attempted by exposing the acetophenone to 
a solution of bromine. The reaction was carefully monitored using TLC in a 4:1 petroleum ether: 
ethyl acetate eluent and then was purified using column chromatography. 1H NMR analysis showed 
that no reaction had occurred, so a sample of 166 was analysed using GC-MS to exploit the unique 
isotopic properties of bromine. It was discovered that bromination at the 3 or the 5 position on the 
acetophenone ring had in fact occurred but on a very small scale and (shown as compound 167 in 
Fig.45) providing a mass peak of 353 m/z. This mass peak corresponds to the dibromonated version 
of 166 but with the loss the aceto group. 
 
Figure 45: Isolated product from failed bromination reaction of trimethoxyacetophenone. 
 
Iodination of 2,4,6-trimethoxyacetophenone was also attempted using sodium iodide in the presence 
of sodium hypochlorate (NaOCl) at 0°C. Addition of sodium thiosulphate and acidification with HCl 
during the work up procedure produced a brown solid which was recrystallized from boiling water. 
The resulting chocolate brown solid was analysed and found to be unreacted starting material. 
Additional attempts at this reaction were attempted by increasing the volume of sodium hypochlorate 
but no desired iodinated acetophenone was isolated from either reaction. A different approach to 
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generate the halogenate acetophenone compounds was to start from the triol compound (168) and 
halogenated the ring under the same conditions to give the 3,5-subsituted iodo/bromoacetophenone.  
Introducing the methoxy group can then be done once halogenation has been completed, as a second 
step using methyl iodide in the presence of potassium carbonate24 with a reported literature yield of 
98%. However this alternative route to halogenated trimethoxy acetophenones was not successful, 
as the first step would not produce the desired product and gave either no reaction or a degraded 
version of the starting material on multiple attempts. 
 
Figure 46: Planned two step synthesis of halogenated acetophenones building on the work by the 
Ley group21,22 where halogenated combretastatin has heightened activity compared to the parent 
compound. 
 
After unsuccessful attempts at iodinating and brominating in the meta position of the acetophenone, 
attention turned to synthesising combretafuroxan compounds with varying substituents in the para 
position. The position of the substituents in this series was partly chosen as Nirode25 had made some 
successful headway in synthesising para-substituted furoxans by reacting acetophenoens with acetic 
acid and sodium nitrite. The literature provides two different routes to the production of 
combretafuroxan compounds from the acetophenone starting material. One method developed by 
Nirode and co-workers25 uses the combination of acetic acid and sodium nitrite to form the 
oxadiazole ring, by producing the reactive NO+ and NO2- species in situ from of nitrous acid. The 
second route26,27 involves using concentrated nitric acid, usually at around 50°C and sodium nitrite 
to produce the desired heterocycle. To give the best success rate for the production of a series of para 
substituted combretafuroxan compounds both procedures were attempted in tandem, each of which 
had varying success. 
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Scheme 45: Two alternative routes to the production of the furoxan ring starting from the readily 
available acetophenone starting material. 
 
It was found that the concentrated nitric acid procedure26, 27(route (ii) in scheme 45) which was 
conducted at 50, 60 and 80⁰C often produced no desired product, and was a very violent reaction 
producing plumes of NO2 gas upon addition of sodium nitrite. It is likely that this very rapid evolution 
of NO2 caused the reaction to fail or produce the un-wanted by products, possibly due to the 
energetics of the reaction and that nitration of the ring is more favourable than addition to the 
carbonyl carbon. Using and adapting Nirode’s procedure25, several combretafuroxan compounds 
were successfully synthesised in varying yields (2-29%). Reaction of the para substituted 
acetophenone with combination of acetic acid and nitric acid and a catalytic amount of NaNO2 
produced a range of products (as seen in scheme 46), as shown by TLC and crude NMR analysis. 
Notably the nitrated product (scheme 46), where a NO2 group has replaced the aceto portion of the 
acetyl group, was produced as a highly coloured compound and was successfully isolated from any 
furoxan product through column chromatography. The corresponding benzoic acid by-product was 
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Scheme 46: Reaction of acetophenone produces the furoxan ring and two by-products, the 
corresponding benzoic acid and a nitrobenzene compound. 
 
Tezuka et al28 reported that the formation of by-products, such as benzoic acid, are produced due to 
too much water in the reaction, which as the formation of the oxadiazole ring requires aqueous acid 
is a challenging hurdle to overcome. The carbonyl peak (C=O) and the missing C=N and C=N+O- 
peaks at 154 and 112 ppm respectively, from the 13C NMR spectrum were key indicators of side 
product formation (Fig. 47).The ability to form the furoxan ring seemed to be heavily dependent on 
the substituent(s) on the benzene ring. Functional groups that encouraged crystallisation from the 
Figure 47:13C NMR spectrum showing a carbonyl peak at 166.5 ppm, a peak this low is diagnostic for 
the formation of the benzoic acid by-product.  
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reaction, seemed to be more preferential at forming the furoxan ring compared to either their 
corresponding benzoic acid or nitro by-products. In particular the halogen series and the more 
lipophilic substituents were better at precipitating out of the reaction and yielding the correct product. 
Substituents that were more water soluble failed to precipitate on the addition of ice water and 
therefore required an aqueous work up to obtain the furoxan. The various conditions used and the 
relative by -products and furoxan rings formed are summarised in table 2. Using the combination of 
acetic acid and nitric acid (route (i) in scheme 18) was by far the preferred route for producing 
furoxans in addition to by-products. The use of neat concentrated nitric acid gave no furoxan ring 
instead only by-products were isolated. 
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Table 2: Table comparing both routes to the furoxan ring, the conditions used and by-
products formed. * Trace evidence from LRMS found evidence of nitro and benzoic acid by-
products after initial 1H and 13C NMR spectroscopy was inconclusive of their formation. 
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From the variety of starting materials used and the differing conditions utilised to generate the series 
of combretafuroxan compounds 86-95, the key factor on whether the desired product forms appears 
to be substituent dependent. Functional groups that either promote crystallisation, or precipitate from 
the reaction solution, notably the halogenated compounds, tend to produce the furoxan product in a 
higher yield and in a much cleaner process due to the ease of isolation. This is perhaps due to the 
compounds precipitation from the reaction mixture; no work up procedure is required and therefore 
may prevent some by-products, such as the benzoic acid, from forming as there is less chance of 
exposure to an aqueous environment. The alkyl substituted acetophenones all required an aqueous 
work-up, extraction with organic solvents (DCM) and vacuum distillation. This exposure to excess 
solvents and steps may have contributed to the presence of the benzoic acid by-product27. Purification 
by column chromatography and recrystallization was also needed for all furoxan compounds before 
any pure furoxan product was obtained.  
The mechanism (scheme 47) for the generation of the furoxan ring from the acetophenone starting 
material is fairly straight forward and utilises the reactive species NO+ and NO2- that are generated 
in situ by the action of sodium nitrite on acetic acid as aforementioned in chapter 1 (page 37). The 
acidic medium of the reaction provides optimal conditions to initiate the reaction by protonating the 
acetophenone. This allows the enolate resonance structure to form and promotes the coupling of the 
enolate and the nitrosonium ion (NO+). Proton transfer forms the oxime moiety which is then attacked 
by the nitrite anion (NO2-). The nitrite ion has an unpaired electron so can be considered a radical, 
which then attacks the oxime carbon-nitrogen double bond. Movement of electrons causes the oxime 
nitrogen to become a radical. This can then attacks another nitrite ion to generate structure 179 in 
scheme 20. Two simultaneous reorganisations leads to the loss of two molecules of nitrous acid 
(HNO2) to form the nitrile oxide, which then combines with another nitrile oxide in solution to ring 
close and form the furoxan ring 37.26-28 The product determining step of this reaction is generation 
of the nitrile oxide form 179, as reaction of H3O+ with compound 179 produces the benzoyl acid and 
reaction with another nitrite ion leads to the assembly of the benzoic acid by-product. Once the nitrile 
oxide is formed, ring closure and generation of the desired furoxan ring 37 is more likely.  
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Scheme 47: Mechanism proposed by Tezuka28, for the generation of a furoxan ring from an 
acetophenone starting material. 
 
Looking at the mechanism (scheme 47) involving the acetophenone starting material, generation of 
the desired product appears to be in a delicate balance with the production of by-products such as 
benzoic acids. The more water present in the system the more the reaction is pushed in the direction 
of the acid by-product as described by Tezuka28, who found that with 50% water content in the 
solution the yield of corresponding benzoic acids was close to 50%. Removal or reduction of the 
water drives the yield of furoxan compounds back towards the 60% mark.  
With generation of by-products a likely outcome from this reaction, distinguishing the success of the 
reaction became of paramount importance and was helped greatly by 1H and 13C NMR analysis 
coupled with high resolution mass spectroscopy (HRMS). 
2.1.1.4- Analysis of furoxan formation 
 
The beauty of synthesising furoxans from acetophenones is the ability to distinguish at an early stage 
if the reaction has been successful. Due to the loss of methyl group on the acetyl part of the molecule, 
integration in 1H NMR spectroscopy can be utilised to determine the reduction or loss of any methyl 
character, however the crude mixture is often very complex and direct conclusions from this evidence 
tend not to be made. Instead a crude 13C NMR spectrum can usually indicate the production of the 
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furoxan, due to the appearance of four diagnostic peaks (depicted in Fig. 48). If we look at the general 
structure of the series 2 combretafuroxan (Fig. 48) compounds, four diagnostic peaks can be 
recognised for the easy identification of the desired product.  
 
Figure 48: Diagnostic peaks for the successful synthesis of furoxan compounds. Peaks present in 
13C NMR spectroscopy in these regions provide good evidence of furoxan production. 
 
The two carbonyls produce two separate peaks between 179 and 180 ppm and lie very close together. 
If the benzoic acid by product has been produced its carbonyl bond is found slightly further upfield 
between 166-175 ppm (as already seen in Fig.47). Arguably the most important diagnostic peaks in 
furoxan formation come from the two sp2 hybridised carbons of the oxadiazole heterocycle. The 
imine type carbon (C=N) is shifted downfield towards a chemical shift value of around 156 ppm, one 
side of the aromatic carbons peaks. The C-N-oxide (C=N+-O-) bond is pushed further upfield due to 
the electronic effects from the formal charges present on the heteroatoms. This N-oxide bond usually 
appears around 111-114 ppm, meaning essentially the oxadiazole’s carbon atoms lie either side of 
the aromatic carbons from the acetophenone rings. This distinct separation pattern in 13C NMR 
spectroscopy is characteristic of all furoxan compounds synthesised from acetophenone starting 
materials and is a very useful diagnostic tool. 29-31  
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Figure 49: 13C NMR of combretafuroxan compound 90. Diagnostic peaks are the imine bond 
(green), the N-oxide bond (blue) and the two carbonyl peaks (red). 
 
Formation of the nitro by-product could also be obtained using 13C NMR spectroscopy. Synthesis 
of this by-product removes the carbonyl group and replaces it with a NO2 substituent, this causes 
the loss of the diagnostic C=O peaks as seen in Fig. 50. The absent peaks, combined with the 
addition of a C-NO2 peak at 129 ppm confirms the presence of the unwanted by-product as shown 
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In summary, synthesising 1,2,5-oxadiazole-2-oxide compounds can be a synthetic challenge but as 
shown in section 2.1.1.3 it is possible to isolate the furoxan ring. Synthesis from an acetophenone 
starting material was by far the most lucrative method for generating the desired products and 
afforded compounds 86-95.  Of the two synthetic routes explored, it was found that the use of a 
combination of acetic acid and dilute nitric acid with the addition of a catalytic amount of solid 
sodium nitrite was the preferred route in the production and isolation of combretafuroxan compounds 
86-95. The main issue with furoxan production using this style of chemistry is controlling the 
formation of by-products that are readily produced. The more likely a substituted acetophenone (169-
178) is to precipitate from the aqueous media, the easier isolation of furoxan product. This is 
representative in the relative yields obtained from these reactions. Compounds with lipophilic groups 
such as halogens produced the highest yields of furoxan (20-23%). Almost every reaction led to the 
recovery of benzoic acid by-products (10-25%) confirming what is found in the literature28, that the 
formation of the 1,2,5-oxadiazole-2-oxides is not a clean one. Minimising the amount of water in the 
reaction appears to be key in avoiding the benzoic acid by-products forming as shown in scheme 47.  
Figure 50: 13C NMR of nitro by-product 143. The diagnostic peaks for the characterisation of these 
compounds is the missing carbonyl peaks and the new C-NO2 bond 
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Generation of combretafuroxan compounds from an alkene bond provided the largest synthetic 
hurdle. Stilbene precursors, both cis and trans isomers, 120 Z/E-125 Z/E were synthesised using 
classic Wittig chemistry in varying yields (2.3-22%) and although the isolation of each single isomer 
was not possible, the forward synthesis to the furoxan ring should not of been affected by this. Steric 
hindrance appeared to play a key role in the initial experiments as outlined in Fig. 41 and 42 in section 
2.1.1, with the face of the alkene bond blocked from any forward reaction with a nitrosonium ion. 
Removal of the steric hindrance caused by the ortho positioned methoxy group in compound 121 
E/Z and replacing it with two bromine substituents in the meta positions of the benzene ring still did 
not elude the desired furoxan ring. This suggests that factors other than steric hindrance are involved. 
It has been previously observed32 that the nitrosonium ion generated from the use of NaNO2 can cause 
inefficient conversion to the furoxan ring. The use of a much more electrophilic source of NO may 
increase the likelihood of a successful reaction. 
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2.1.2- Cupferron compounds  
 
The diazeniumdiolates are the second class of nitric oxide donor compounds that were synthesised. 
Attempts were made to improve the stability of the parent compound, cupferron 56 (Fig.51) so that 
the release of NO could be better regulated. Cupferron 56, is a cheaply available, industrial chelator. 
 
Figure 51: Parent compound cupferron, which is inherently unstable and releases NO 
 
Synthetically the diazeniumdiolate analogues were much easier to produce compared to the furoxans 
due to the more simplistic alkylation chemistry involved rather than the ring closure reaction 
described previously. Cupferron 56 was dissolved in dry DMF under anhydrous conditions; the 
turbid solution was then cooled to 0⁰C before 3 equivalents of alkyl bromide were added as shown 
in scheme 21. 
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Upon removal of the DMF, using a cold finger apparatus, each reaction produced a black tar 
substance; the intense black colour could be due to some mild decomposition of the parent compound 
and its possible complexation with DMF. The crude gum was absorbed on to silica and purified using 
flash column chromatography using a 4:1 petroleum ether: ethyl acetate eluent to give the desired 
mono alkylated cupferrons 98-101 in reasonable yield (10-36%).  Confirmation that the alkylation 
chemistry had been successful was straight forward. 1H NMR spectroscopy showed the introduction 
of alkyl chains in the aliphatic region of chemical shifts between 1-4 ppm as expected, but it was 13C 
NMR analysis that provided the diagnostic peaks. The methylene carbon that is directly attached to 
the terminal oxygen (labelled ‘a’ in Fig. 52) in cupferron is shifted considerably downfield compared 
to the rest of the alkane chain. Typically the O-CH2 group was found between 69 and 75 ppm. The 
rest of the alkyl chain remained upfield between 10 and 40 ppm. The synthesis of compounds 98-
101 was also confirmed using high resolution mass spectroscopy (HRMS) and all mass peaks were 
found within a precision of ±1.0 ppm. 
 
 
Figure 52: 13C NMR spectra of compound 99 showing the separation of peak 'a' due to the 
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To produce the series of compounds where the alkane chain acts as a linker between the two 
cupferron molecules (depicted in scheme 49), the same chemistry1 was exploited. Dibromoalkyl 
compounds (2, 4, 6, and 8 carbons long) were reacted in the same manner as the mono alkyl bromides, 
except this time in a 3:1 ratio of cupferron to alkyl bromide.  
 
Scheme 49: O-alkylation of cupferron with dibromo alkanes to produce the di-cupferron 
compounds 103-105 and the monoalkylated by-products 113-116.  
 
Much like the mono alkyl series, once the DMF had been removed a dark black tar was left at the 
bottom of the flask. Upon purification with column chromatography, using 8:1 petroleum ether: ethyl 
acetate as an eluent, the desired di cupferron compounds 103-105 were isolated in varying yields 
(1.8-7.7%). The low yield of this reaction, 1.8-7.7%, could be attributed to the by-product that was 
isolated during column chromatography. During the reaction, upon initial alkylation of one molecule 
of cupferron, the second cupferron molecule failed to displace the second bromide and resulted in 
mono alkylation. This resulted in the mono alkylated-bromo products 113-116 shown in scheme 49. 
These compounds 113-116 were confirmed through 1H NMR spectroscopy as the methylene group 
bonded directly to the bromide appears at around 3.2 ppm as shown in Fig. 53. When compared with 
the di-cupferron product from the same reaction, the 1H NMR spectra looks completely different 
with the loss of the peak at 3.2 ppm and the change of integration for the peak labelled ‘b´’ at 2 ppm.  
These half alkylated products 113-116 were also confirmed using high resolution mass spectroscopy 
(HRMS), taking advantage of bromine’s unique isomeric characteristics.. 
Results and Discussion- Synthesis 




Figure 53: 1H NMR spectra comparing the by-product 114 and the desired di-cupferron 103. 
 
Apart from producing the initially undesired half alkylated products 113-116, the synthesis of the of 
di cupferron compounds produced some other interesting results. The reaction of cupferron with 
dibromoethane did not produce the desired di-cupferron compound 102 but instead produced the 
mono-bromo alkylated compound 113. It was thought that this could be due to the alkyl chain 
bridging the two cupferron molecules not being long enough for the second cupferron to orientate 
itself in such a way to displace the second bromide. Electronic repulsion may also play a role in the 
reaction failure, as the formal charges surrounding the cupferron molecule may repel another 
cupferron if it is sitting in the wrong orientation for the SN2 reaction to take place. 
Results and Discussion- Synthesis 
112 | P a g e  
 
 
Scheme 50: Reaction of cupferron with dibromoethane did not produce the desired product, 102, 
instead produced two interesting by-products 113 and 180.  
 
As well as the mono-bromo alkylated compound 113, an additional compound was also isolated from 
the reaction of cupferron with dibromoethane. Compound 180 was isolated post column 
chromatography and its structure confirmed by HRMS. This is thought to have formed from the 
initial O-alkylation of cupferron, generating compound 113. Upon work-up, the reaction is exposed 
to moisture, by the removal of DMF, this may enable a free bromide ion present in the solution to 
attack an available water molecule forming hydrogen bromide. The formation of hydrogen bromide, 
leads to the production of hydroxide, which can then attack compound 113 as shown in scheme 51 




Scheme 51: Possible mechanism for the generation of compound 180 as a by-product of the 
reaction of cupferron with dibromoethane. 
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2.1.2.1- Determining of alkylating position 
 
Within cupferrons structure there are two available sites that any alkylation chemistry could occur 
at. There is the terminal oxygen attached to the non-charged nitrogen and the oxygen directly attached 
to the nitrogen with a formal positive charge. 
There has been some argument from researchers2,3 as to what oxygen any alkylation would occur at. 
Only one compound in the cupferron series produced a solid product and was formed upon standing 
at room temperature over two days. The di-cupferron compound 103 produced large needle like 
crystals which enabled single crystal analysis. This single crystal structure determination (Fig. 54) 
gives strong evidence that it is the terminal oxygen (labelled O8 in Fig.54) that the alkylation 
chemistry occurs at. The single crystal study of compound 103 matched a primitive triclinic cell with 
the following cell parameters:  a = 7.23 Å, b = 7.83 Å and c= 8.46 Å with corresponding angles of 
α=64.6°, β= 66.84° and γ= 73.147. The full crystallography data can be found in appendix AP01. 
 
 
Figure 54:  The single crystal structure of compound 103, showing that O-alkylation occurs at the 
terminal O8 and O8i position. 
 
The crystal structure of compound 103, shown in Fig. 54 confirms that the O-alkylation occurs on 
the O8 terminal oxygen and it therefore can be assumed that this is the case for the non-crystalline 
produced compounds 98-101 and 104-105. The two aryl rings sit in an offset planner relationship 
allowing for π-π stacking, and alignment of charges within the packing structure (Fig. 55). Literature4, 
5 has indicated that it is possible to form the O1 alkylated derivative but they tend to be an unstable 
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by-product and do not affect the formation of the O8 alkylated product seen in Fig. 54. 15N NMR 
spectroscopy was also performed on compound 103, confirming the structure presented in Fig.54 
through correlation of proton to nitrogen environments (see experimental section 4.0 for full data). 
 
Figure 55: The crystal packing of compound 103 showing that a 103 stacks using hydrophobic 
interactions and π-π stacking.  
 
However some minor evidence was found that the intramolecular cyclisation reaction to produce the 
8 membered ring (Fig. 57) had also occurred during the reaction. 13C NMR spectroscopy highlighted 
a compound with very different peaks to the previously observed mono-bromo alkylated cupferrons 
113-116 and the di-cupferron compounds 103-106. A new peak occurring at 73 ppm alongside the 
usual peak at 75 ppm was isolated indicating that a different compound had been synthesised as 
shown in Fig. 56. This was thought to be the intramolecular cyclised product where instead of another 
cupferron molecule’s terminal oxygen displacing the second bromide on the alky chain, the oxygen 
attached to the positive nitrogen (labelled O1i in Fig. 54) attacks the methylene group (depicted as 
‘d’ in Fig. 56) and displaces the bromine to form a 8 membered ring 181. 
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Figure 56: The 13C NMR spectrum of compound 181, presenting a new peak at 73ppm, labelled d, 
indicating that the intramolecular reaction has occurred. 
 
The formation of the (Z)-2-phenyl-5,6,7,8-tetrahydro-1,4,2,3-dioxadiazocin-2-ium, compound 181 
was further confirmed by mass spectroscopy, however only low resolution was obtainable, possibly 
due to the instability of the compound. A mass of 193 m/z corresponding to the formula C10H13N2O2 
was isolated and the corresponding spectrum is shown in Fig 57. 
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Figure 57: LRMS of a compound confirming the formation of the intramolecular ring product 181. 
Spectrum produced by the NMSF. 
 
Interestingly when analysing the HRMS for both the hexyl and octyl compounds, 104 and 105, 
evidence was also found corresponding to the intramolecular ring formation in these reactions as 
well, although not in an isolatable yield but enough to provide accurate mass information. Compound 
104, synthesised with the hexyl linker produced a 10 membered ring 182 (Fig. 58) with a m/z of 
221.1287 and compound 105 with the octyl chain produced a 12 membered ring 183 with a m/z of 
251.1757. This appears to be the first isolation of any data consistent with the formation of these 




Figure 58: The two intramolecular products isolated from the HRMS generated from the reaction 
of cupferron with dibromohexane and dibromooctane respectively. 
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Mass spectroscopy also isolated another interesting compound from the reaction of cupferron with 
dibromobutane. A mass of 496.2141 m/z, which did not correspond to any before isolated compound, 
was discovered. After contemplating different structures that would fit the newly found mass peak, 
compound 184 (Fig. 59) was highlighted as a suitable structure, existing as a trimer type molecule. 
There is a possibility that if the alkylation reaction depicted in scheme 49 is left for long enough that 
a polymeric form of cupferron could be isolated, however this does appear to involve alkylation on 
both the O1 and O8 oxygen’s and therefore the isolation of this compound may be impossible due to 
the stability of O1 alkylated cupferron compounds.4 
 
 
Figure 59: Compound 184, isolated from the mass spectrum of compound 181. 
 
In summary, the O-alkylation of cupferron was both successful and interesting, producing 
compounds 98-101 and 103-105 in varying yields, 1.8-36%. This reaction appears to be quite low 
yielding and can possibly be attributed to the production of the mono-bromo alkylated by-products 
113-116.  The low yield may also be contributed to by the stability of the parent compound within 
the reaction; if decomposition of the starting material is occurring at the same time as the alkylation 
then the resulting yield of the desired compounds is going to be the lower than expected. 
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From this series of reactions, the positon of alkylation has been 
successfully determined; the X-ray crystal structure (Fig. 54) clearly 
indicates that the O8, terminal oxygen on the cupferron molecule is the 
preferred site of alkylation and not on the O1 oxygen. It can be assumed 
that the non-crystalline compounds 98-101 and 104-105 are also 
alkylated at the O8 oxygen due to the evidence seen for the crystalline 
compound 103. However, a small amount of evidence depicted in Fig. 56, 
57 and 58 suggests that the intramolecular reaction can occur, forming 
the 8, 10 and 12 membered dioxadiazocinium rings but not in a 
progressively yielding way and possibly only as a side reaction.2.1.2.2- 
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2.1.3- NOS inhibitors 
The synthesis of neuronal nitric oxide synthase (nNOS) inhibitors was planned as a three step 
synthetic pathway, consisting of a protection step, a deprotonation and alkylation step and then 
finally a de-protection step to yield a series of novel diaminopyridine based NOS inhibitors. These 
potential nNOS inhibitors consist of two amino-pyridine rings, which will bind strongly within the 
active site for nNOS due to their strong similarity to the natural substrate L-arginine.1,2  It has been 
found through docking studies that the 2-aminopyridine moiety can bind into separate binding sites 




Figure 60: Natural substrate of nNOS with part of its guanidine group highlighted and its 
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The pi system present in the pyridine rings can also have pi- (π-π) interactions with the pyrrole 
rings of the haem in the active site of neuronal NOS (nNOS) as shown in Fig.61. 
 
 
Figure 61: 3D representation of Silverman's most potent compound docked in the nNOS active site, 
showing the π-π interactions between the haem group, shown in green, of NOS and the aminopyridine 
ring, shown in magenta. 
 
The first step of the synthesis was to protect the free amine in the 6-postion on the pyridine ring 
(scheme 52). This was conducted using a Paal-Knorr pyrrole synthesis4-6 to generate a bulky 
pyrrole ring which would be stable to any future chemistry .To generate the pyrrole ring, 2,4-
dimethyl-6-aminopyridine was refluxed with hexane-2,5-dione in the presence of p-TsOH acid for 
24 hours under Dean-Stark conditions to generate the desired pyrrole ring 147 in 35% yield. Dean-
Stark conditions are utilised to collect and isolate the water formed from the cyclisation of the 
pyrrole ring and to prevent any consequential ring opening and reversal of the forward reaction. 
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Scheme 52: Mechanism of pyrrole ring formation from the reaction of a dicarbonyl species with the 
free amine group of the aminopyridine ring4  
 
The pyrrole ring 147 is formed through a condensation reaction between a dicarbonyl species and an 
amine. The lone pair of the amine attacks the carbonyl group to generate an enamine intermediate 
with the loss of one molecule of water. This enamine species then attacks the second carbonyl group 
to form a semi-pyrrolidine ring, which then rapidly loses water to yield the desired pyrrole ring, 
serving in this instance as a protecting group for the forward deprotonation step.4  
A small amount of acid is known to accelerate this reaction, and therefore hence the addition of    
 p-TsOH as a catalyst.  
The second step in this pathway is the deprotonation of the methyl group in the ortho position so that 
addition of an alkyl bromide can take place7. Although seemingly straightforward, the deprotonation 
step provided quite a few hurdles to overcome. Following Silverman’s procedures7, 8 from the 
literature; initial experiments were conducting with 2.5 equivalents of n-butyl lithium. Under 
anhydrous conditions the protected dimethyl pyridine compound 147 was dissolved in dry THF and 
cooled to -78°C before the addition of n-BuLi was added turning the solution into a characteristic 
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red colour, denoting the coordination of the lithium atom with the lone pairs of nitrogen and the 
stabilisation of the forming methylene anion (CH2-). Dibromo alkanes were then injected into the 
reaction to form the new carbon-carbon bond as depicted in scheme 53. 
 
Scheme 53: General mechanism of the formation of a new C-C bond, using butyl lithium and 
bromoalkanes. 
 
Initially dibromopropanol was attempted as the linker compound, injected in a 2:1 protected starting 
material 147 to linker 186 ratio (scheme 54). After completion of the work up procedure it was found 
that no reaction had occurred and the starting material was recovered in almost quantitative yield. It 
was thought that maybe the free hydroxyl group present in the linker could be interfering with the 
reaction by reacting with the n-BuLi or that the dibromopropanol 186 was perhaps too wet, as it is 
sold at 95% purity and therefore may contain a small amount of moisture that could be detrimental 
to the reaction. The failure of this reaction was confirmed through 1H NMR analysis, as the ratio of 
hydrogens in the methyl region had not changed and there was no additional peak representing the 
newly formed methylene group. The number of equivalents of n-BuLi were increased from 2.5 to 5 
but this still failed to return the desired product. 
 
Scheme 54: Reaction of the pyrrole protected starting material 147 with dibromopropanol 186. 
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To try and avoid any extra acidic protons and moisture in the reaction possibly being caused by a 
free hydroxyl group, a different linker (scheme 55) was utilised. 1,4-Dibromobut-2-ene 187 was 
injected in the same manner as the previous linker with 5 equivalents of n-BuLi but also came to no 
fruition.  
 
Scheme 55: Reaction of the pyrrole protected starting material with dibromobut-2-ene 187. 
 
 A closer inspection of the procedure used by Silverman7-9 highlighted that too much water was 
being used during the work up procedure and that this may have contributed to the lack of product. 
Instead of pouring the reaction onto ice, an molar equivalent (~110 μL) of water was added to 
minimise the amount of water present in the system in an attempt to isolate the desired product. 
This was conducted over several attempts, to which no product was obtained. The equivalents of n-
BuLi were also increased from 2.5 to 6 in an attempt to cause efficient deprotonation of the starting 
material 147. All the attempts to deprotonate and sequentially alkylate the pyrrole protected starting 
material 147 were unsuccessful. 
It was theorised that deprotonation just wasn’t occurring with n-BuLi. One explanation could be that 
there are four similar sites (4 methyl groups with the potential to become deprotonated as highlighted 
in Fig. 62) that the base could act on. 
This may suggest that more base is required than first thought as any excess base is being used to 
deprotonate in the wrong position. However this theory can be discounted with 1H and 13C NMR 
analysis of the reaction mixture and even post column chromatography, as unchanged starting 
material and the unreacted linker compound are being isolated in clean fractions. This therefore 
suggests that no deprotonation is occurring at all. 
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Figure 62: Pyrrole protected 2,4-dimethylaminopyridine starting material. The four methyl groups, 
or potential deprotonation sites, are highlighted by a blue circle. 
 
To test if any deprotonation was occurring with n-BuLi, deuterium oxide (D2O) was used instead of 
water in the work up procedure. Deuterium has a magnetic spin of 1, instead of spin ½ like that of 
hydrogen and therefore will not be seen in 1H NMR spectrum. This should indicate if deprotonation 
has occurred, as one of the hydrogens on the methyl group will be replaced with a deuterium and 
therefore not be visible in the 1H NMR spectrum. The 1H spectrum show in Fig. 63 is a computer 
simulated spectra of the deprotonated and deuterated starting material 188. The hydrogen that has 
been replaced with a deuterium atom has been shifted downfield towards 3 ppm from around 2 ppm. 
Its integration also changes from being equivalent to 3 hydrogens to being equivalent to 2 hydrogens. 
 
 
Figure 63: The computer simulated 1H spectra of deuterated 2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-
dimethylpyridine, 188, showing the shifting of the metheleyne hydrogens towards 3 ppm. 
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The reaction shown in scheme 54 and 55 was performed in the same method as before; protected 
starting material was dissolved in dry THF and cooled to -78°C before n-BuLi (5 equivalents) was 
added. Instead of introducing the dibromoalkane linker, the reaction was quenched with D2O and 
extracted with diethyl ether. Upon analysis of the reaction the 1H spectrum (Fig. 64) showed that 
deprotonation was unsuccessful. This can be seen through the integration of the methyl groups still 
representing three (3) hydrogens each, when compared with the other methyl group in the para 
positon on the pyridine ring and the two on the pyrrole ring. There should be a change in integration 
due to the loss of one proton and a change in chemical shift towards that of 3 ppm. This confirms 
that no deprotonation has occurred during the reaction.  
 
 
Figure 64:  1H spectrm of the attempted deuteration of 2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-
dimethylpyridine, 188, there is no shift of the methylene protons towards 3 ppm indicating that 
deuteration was unsuccsessful. 
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It was concluded that deprotonation was simply not occurring or not enough to cause the forward 
reaction to go to completion. The pKa of 2-methylpyridine, a compound closely related to our starting 
material, is approximately 34 and n-BuLi has a pKa of around 50. This difference in pKa value could 
explain why n-BuLi failed to deprotonate the methyl group as it may not be basic enough to remove 
the required proton. Butyl lithium exists as a hexamer when in solution; each lithium atom of the 
butylithium coordinates to 2 other carbons creating a cluster of 6 lithium atoms with a triangular 
face10,11. This cluster formation (Fig. 65) can sometimes hinder the reactivity of the base. Lewis bases 
such as diethyl ether and THF are often used as the solvent for the reaction as they tend to 
disaggregate the cluster10. Nitrogen ligands10,12, such as tetramethylethylenediamine (TMEDA) or 
sparteine (Fig. 66) can also induce deaggregation and increases the solubility of the butyl lithium 
reagent therefore make it more reactive.13 
 
 
Figure 65: Crystal structures showing butyl lithium existing in its hexamer form. The lithium 
atoms (shown in purple) form a triangular face and coordinate with 3 butyl chains each. Taken 
from reference 14. 
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TMEDA (Fig. 66) has a high affinity for lithium ions and acts as a metal ligand causing disruption 
to the hexamer that n-BuLi adopts when solvated in hexane, it instead forces it to exist as a solvated 
tetramer10,13,15 or a dimer. By decreasing the aggregation16 of the n-BuLi it increases the reactivity of 
the base and therefore may solve the problem in our reaction.  
 
 
Figure 66: Two nitrogen ligands, TMEDA 189 and Sparteine 190, known to decrease the 
aggregation of n-BuLi. 
 
To test if this increase in basicity would cause the reaction to go to completion a model reaction was 
created. Due to the expensive nature of the dimethyl aminopyridine starting material 185 and the 
laborious purification needed to obtain pure protected starting material 147, it was decided that 2,4,6-
trimethylpyridine 191 would be used in the deprotonation experiments. The reason for this is clear, 
as it still contains the methyl protons required for deprotonation in our own reaction (Fig. 67) but at 
a much cheaper price. The linker was also changed to bromoethane for the same reasons. An initial 
test reaction of n-BuLi and 2,4,6-trimethylpyridine 191 and bromoethane as a linker also failed to 
give the desired product, giving validation for their use as model reactants for hypothesis testing. 
 
Figure 67: 2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyridine has very similar deprotonation sites 
to 2,4,6-trimethylpyrdine and therefore can be used as a model reagent to test different reaction 
conditions. 
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1.1 equivalents of freshly distilled TMEDA, was added to n-BuLi and 2,4,6-trimethylpyridine at  
-78°C (scheme 56). The resulting orange solution was allowed to reach 0°C over the course of an 
hour before bromoethane was added causing the solution to turn pink. The reaction was allowed to 
progress for 30 minutes, before the resulting colourless solution was worked up by addition of a 
molar equivalent of ammonium chloride (NH4Cl), and an aqueous extraction. Analysis of the 
resulting 1H and 13C NMR data showed that the reaction had not worked and unreacted starting 
material was recovered once again. 
 
Scheme 56: Reaction of 2,4,6-trimethylpyridine 191 with bromoethane. TMEDA 189 was added in 
an attempt to increase the reactivity of n-BuLi. 
 
It was decided that perhaps n-BuLi was not a strong enough base, and the pKa was not high enough 
for sufficient removal of the methyl proton. Comparing n-BuLi to other alkyl bases (Fig. 68) it can 
be seen that there are plenty of other options to turn to. t-BuLi, is known to be a very good base but 
has various safety issues which makes it less appealing to work with compared to the other options. 
s-BuLi has enhanced basicity, with a greater pKa value when compared to n-BuLi and also has less 
severe handling issues compared with that of t-BuLi. Phenyl lithium is a slightly weaker base 
compared to n-BuLi but is a bulkier group than the butyl chain so should be less prone to nucleophilic 
reactions and more selective towards deprotonation. 
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Figure 68: Various alkyl lithium bases and their relative basicity quoted in terms of pka. 
 
  
While researching the most effective bases, an interesting publication17 was discovered performing 
very similar chemistry to our own. The authors alkylated 4 and 2-picoline using phenyl lithium in a 
1.1 ratio as shown in scheme 29. In contrast to many other reactions which are conducted at sub -
20°C temperatures, this reaction was refluxed for half an hour to give their desired alkylated products 
in 55-92% yields. 
 
Scheme 57: Reaction of 4-piccoline, 4-methylpyridine 192, with phenyl lithium under reflux 
conditions. 
 
The discovery of this work17 coincided with a personal communication18 from Professor Silverman. 
After consulting his research group, as to why the outcomes of our reactions were so different to 
those reported, Silverman stated that at temperatures closer to 0°C, the site of deprotonation favoured 
the ortho position. The solvent for the reaction also played a role in Silverman’s reported chemistry, 
with THF favouring the ortho position while diethyl ether moved the reaction towards the para 
position deprotonation, but n-BuLi should still be added at -78°C. 
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Applying the newly found experimental procedures17 and Silverman’s suggestions to our model 
reaction (scheme 58), resulted in 2,4,5-trimethylpyridine 191 being dissolved in dry diethyl ether and 
one equivalent of phenyl lithium being introduced at -78°C, causing the solution to turn a deep red 
colour. After an hour the reaction was brought to room temperature before one equivalent of 





Scheme 58: Reaction of 2,4,6-trimethylpyridine 191 with phenyl lithium under reflux conditions to 
successfully produce the alkylated product.17 
 
Upon work up, crude 1H NMR analysis was undertaken to assess the situation as TLC analysis proved 
to be inconclusive to whether a reaction had occurred or not. The crude NMR data spectra (Fig. 69) 
didn’t look very promising and just appeared to be a mixture of bromoethane and unreacted starting 
material. However when studied more closely (highlighted by the red arrows in Fig. 69), there was 
a small amount of evidence to suggest that a reaction had in fact occurred. This coupled with a faint 
spot on TLC, led to the crude mixture being purified by flash column chromatography in a 10:1 
petroleum ether:ethyl acetate solvent system to yield 4% of desired product 148. The post column 
1H NMR spectra, now clearly shows the desired product 148 with the highlighted portions being the 
small peaks from the crude spectrum (Fig.69). Trimethylpyridine is a symmetrical molecule and 
therefore with successful addition of an ethyl substituent, an unsymmetrical molecule has been 
formed resulting in more 1H signals in both the crude and pure 1H NMR spectra. The peaks 
highlighted can be attributed to the addition of the ethyl chain with peak at 2.6 ppm being the 
methylene hydrogens in the ortho position of the pyridine ring. Their shift downfield from 2.4 ppm 
in the starting material confirmed that successful deprotonation had occurred. 
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Figure 69: 1H spectra of the crude and purified reaction shown in scheme 58. The red arrows indicate 
the diagnostic product peaks and their isolation from the crude material. 1H NMR analysis conducted 
with at 300 MHz in CDCl3. 
 
 
Observations18 found by the Silverman group concluded that a temperature closer to 0°C favours 
deprotonation at the ortho position but the use of diethyl ether as a solvent pushes the reaction more 
towards deprotonation at the para position. The 1H NMR spectra shown in Fig. 69 indicates that 
deprotonation and alkylation has in fact occurred at the ortho position (labelled ‘a’ in Fig. 69), due 
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to the unsymmetrical nature of the peaks seen. The integration is 2:3:3:2:3, suggesting the presence 
of three separate methyl environments all integrating for 3 protons (peaks ‘c’, ‘d’ and ‘e’ in Fig.69) 
and two methylene protons integrating for 2 protons each, indicated by ‘a’ and ‘b’ in Fig. 69.  
 This evidence therefore slightly contradicts what Prof. Silverman saw during his experiments and 
perhaps the solvent has less of an effect in this procedure than first thought. The only other compound 
isolated from the column was unreacted 2,4,6-trimethylpyridine, 191. 
To test Silverman’s observations further the same reaction was repeated but this time using THF as 
the solvent, in the hope that if diethyl ether was interacting with the reaction this would be quashed 
by the use of THF.  Using the same experimental set up, and a 1.1 ratio of phenyl lithium to 2,4,6-
trimethylpyridine 191, the desired product 148 was isolated in a 2% yield. Comparing the two 
reactions, it appears that diethyl ether is a marginally better solvent for this type of alkylation, 
however, the poor isolated yield, 2 and 4% also suggests that deprotonation is still not a highly 
favoured process under these reaction conditions. With deprotonation and alkylation at the ortho 
proving successful, the new procedure17 involving phenyl lithium and refluxing for 4 hours was then 
applied to the problematic reaction with the pyrrole protected aminopyridine starting material 147. 
The protected starting material was dissolved in diethyl ether, as this gave us the best yield in the 
model reaction, and 1.1 equivalents of phenyl lithium were injected at -78°C to yield a bright red 
solution. The reaction (scheme 59) was allowed to come to room temperature over the course of 1 
hour before dibromoxylene 192 was injected in in a 1.1 equivalent ratio. Dibromoxylene 192 was 
used as the linker in this case to try and minimise any interactions between linker and the base. The 
resulting solution was heated at reflux for 4 hours before being worked-up and the crude mixture 
purified by column chromatography.  
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Scheme 59: Reaction of 2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyridine with dibromoxylene 
under the newly discovered conditons using phenyl lithium. This reaction was unsuccsessful at 
producing the desired product in an isolatable yield. 
 
Upon analysis of the reaction with both 1H and 13C NMR spectroscopy (Fig.70), the reaction showed 
a mixture of unreacted starting materials.  Column chromatography produced a set of clean fractions 
but separation of the two spots was not possible. A GC-MS was conducted on the sample in an 
attempt to discover what the inseparable compounds were. It was found that the majority of product 
was unreacted starting material 147. However an interesting peak was isolated from the GC column, 
albeit in a very small proportion compared to the starting material peak. This peak was found (Fig.71) 
to be for the desired product 151 with a mass peak of 502.23 m/z, and although this was proof that a 
successful reaction had taken place using phenyl lithium as a base, the material was inaccessible by 
column chromatography.  
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Figure 70: 1H NMR spectrum of reaction shown in scheme 8, which appears to show a mixture of 
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Figure 71: Low resolution mass spectrum of compound 151, confirming the successful synthesis of 
the desired product. 
 
Table 3 is a summary of the different bases, solvents and number of equivalents used in the attempt 
to make the protected nNOS inhibitors 149-151. Out of the reactions that were attempted, three were 
successful in producing the desired products, however in either a very low yield or an unattainable 
one post column chromatography. Changing the base used from n-BuLi to phenyl lithium appeared 
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n- BuLi 2.5 THF 147 NO 
n- BuLi 5 THF 147 NO 
n-BuLi 1.1 Diethyl Ether 191 NO 
n-BuLi and 
TMEDA 
1.1 Diethyl Ether 191 NO 
Phenyl Li** 1.1 Diethyl Ether 191 Yes, 4% 
Phenyl Li** 1.1 THF 191 Yes, 2% 
Phenyl Li 1.1 Diethyl Ether 147 Yes N/A 
 
Table 3: Summary table, showing the different bases and solvents used in the attempt to isolate 
desired products. ** Reactions were done at -78°C for 1.5 hours before reflux at 40°C for 4 hours. 
 
The objective for this section of research was to synthetically produce a series of nNOS inhibitors 
based on the amino-pyridine ring and to expand on the work by Silverman after key interactions were 
highlighted in his lead compounds structure that remained unexploited. The first stage of pyrrole 
protecting the free amine functional group on the starting material was successful producing 30% of 
the product. The next step of deprotonating the ortho position on the pyridine ring proved to be a 
bigger challenge than first thought. After several reactions and adjustment of conditions (table 3), 
successful deprotonation occurred, however only for the model reaction. The removal of a hydrogen 
atom from the methyl group appears to need a strong base and the addition of a stoichiometric amount 
of water to quench the reaction. Although phenyl lithium is a weaker base than n-BuLi, it successfully 
deprotonated 2,4,6-trimethylpyridine 191, where n-BuLi failed to do so. Comparing the pKa values 
of the two bases (43 and 50 respectively) the successful deprotonation with phenyl lithium appears 
to go against what is expected. This may be due to the degree of aggregation seen with organolithium 
reagents. As aforementioned, n-BuLi can form hexamers in solution whereas phenyl lithium is prone 
to form dimers11, 14. This may mean that the lithium counter ion is more available to coordinate with 
the nitrogen lone pair of the pyridine and initiate the deprotonation.  
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In contrast to Silverman’s observations, the use of diethyl ether as solvent saw deprotonation at the 
ortho position preferential to the para position. Although deprotonation was made possible with the 
use of phenyl lithium, a much stronger alternative may be needed to afford a higher yield of the 
desired compounds. A variant of a Schlosser’s base or another suitable ‘superbase’ may be required 
to produce a more workable yield for the deprotonation step in this synthesis. The rationale of 
optimising the hydrogen bond interaction with the propionic acid group within the haem group of 
nNOS is still a good one, and now that successful deprotonation has occurred, with optimisation 
compounds 149-151 can by synthesised and eventually tested for their inhibitory potential. 
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2.2- NO release methodology and results 
 
As nitric oxide has an extremely short half-life (approximately 5 seconds in solution1) measurement 
of any donated NO needs to occur either in situ or as direct reaction of NO with something that is 
more stable and therefore quantifiable.  Ozone based chemiluminescence (Fig. 73) was the method 
used to test if the synthesised compounds (described in section 2.1.1 and 2.1.2) were capable of 
releasing NO and in addition identify the experimental conditions by which release could be best 
supported. 
In the presence of ozone, nitric oxide produces nitrogen dioxide in an excited state, NO2*. Upon 
relaxation of this excited species back towards its ground state, a photon is emitted and amplified by 
a photo-multiplier tube (PMT) which produces a readable signal. Typically this signal is measured 
in millivolts and the relative information is obtained through manipulation of the area under the curve 
(AUC), although it has been quoted that 1mV is approximately equal to a 1nM concentration of NO.2 
 
Figure 72: Basic schematic showing how NO measurement is possible using ozone 
chemiluminescence. 
 
Due to the reactive nature of nitric oxide, side reactions can readily occur producing nitrite (NO2) or 
nitrate (NO3-) products which would alter the total reading of nitric oxide being produced as it is 
NO’s reaction with ozone which creates the readable signal. To account for any side reactions, and 
to make sure all NO produced by the compounds being tested was being recorded, we needed a way 
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to convert the nitrite and nitrate back into ‘free’ measureable NO. The oxidation of nitrite using 
acidified potassium tri-iodide solution was utilised to convert any nitrite formed in the chamber back 
into NO (as shown in scheme 60). 
 
 
Scheme 60: Reactions required for measurement of NO levels from nitrite (NO2-) ions.2 
 
Potassium tri-iodide disassociates in solution to form iodine and free iodide ions as shown by 
equation 1 (scheme 60). These iodide ions can then oxidise any nitrite (NO2-) ions present back into 
nitric oxide which can then go on to react with ozone and produce a measureable photon as already 
shown in Fig. 73. This redox reaction works best at 40°C and can be used to convert other NO 
metabolites produced, such as RSNOs.2  
Nitrate ions (NO3-) can also be converted back into NO following a redox reaction using acidic 
vanadium trichloride (VCl3 in 1M HCl) but a much higher temperature, 95°C, is needed for this 
oxidation to take place (scheme 61). Nitrate ions react with free V3+ ions in solution to form a 
stoichiometric amount of nitric oxide and vanadium oxide.  
 
 





Results and Discussion- NO Release 
141 | P a g e  
 
The main problem with measuring nitrate levels with this nitric oxide analyser (NOA) apparatus is 
the risk of contamination. When measuring low levels of nitrate, anything over a concentration of 
1µM can be considered a contamination and will affect the baseline and interpretation of results. The 
main source of contamination is the water used to produce standard samples. During the initial 
experiments it was found that the water source had a high concentration of nitrate present and 
therefore any measurement of nitrate from our samples was impossible. 
 
 
Figure 73: Schematic drawing2 of the reaction chamber alongside a photo of the actual apparatus. 
 
To determine the concentration of nitric oxide released from our compounds, a calibration curve was 
needed.2 This was created by injecting known quantities (100 μL) of varying concentrations of 
sodium nitrite into the reaction chamber (Fig. 73) which contained a reservoir of tri-iodide solution. 
This data was then plotted to generate a standard straight line graph as shown by graph 2. The area 
under each NO peak is typically measured as it provides the total NO release/detected rather than a 
time course for NO release which can be affected by other factors.3 Fig. 73 shows the experimental 
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set up for analysing nitric oxide levels, the reaction chamber is surrounded by a water jacket to 
maintain a constant temperature within the cell. Pure inert gas such as helium or nitrogen gas flows 
continuously throughout the apparatus to ensure any NO generated goes to the detector as well as 
providing an inert environment to limit the amount of oxidative reactions that can occur. Analytes, 
once produced are forced through a glass chamber containing sodium hydroxide solution, this 
ensures that none of the reaction medium travels through to the detector and etches the sensitive 
photo-multiplier tube (PMT).  
 
Graph 2: Calibration curve for NO release. Obtained by injecting known quantities (100 μL) of 
varying concentrations (six in total) of sodium nitrite solutions. 
 
Using the formula generated from the calibration curve, this indicates that if the NO release from a 
compound produces an area under the curve (AUC) of 3500 it would correspond to 5.73 μM of nitric 
oxide being released. The parameters generated from this calibration graph were used for all the 




































Calibration Curve for NO release derived from NaNO2
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2.2.1- NO release from a known NO-donor 
 
After successfully producing a calibration curve (graph 2) using sodium nitrite, it was decided that 
the capabilities of the NOA should first be tested using a compound know to release ‘pure NO’ rather 
than being converted from nitrite to NO. To do this, a known NO-donor was chosen so that any 
observations seen could be compared to what is found within the literature.  
SNAG 19, an S-nitrosothiol, is known to decompose to release nitric oxide under three main 
conditions as already mentioned in chapter one. Both light and temperature can bring about the 




Scheme 62: Reaction of Pre-SNAG 193 with nitrite fumes to produce SNAG 19. 
 
SNAG, 19, was synthesised5 by nitrosating 1-thio-2,3,4,6-tetra-O-acetyl-β-D-glucopyranose, 193, 
with a continuous stream of N2O4 fumes. These fumes were generated in situ from the action of 
concentrated hydrochloric acid on ground sodium nitrite of high purity. The volume of ethanol in the 
final solution was corrected back to 5ml to account for any evaporation during the reaction since the 
thiol containing vessel was flushed with nitrogen for 3 minutes once the nitrosation was complete. 
This was done to remove any excess fumes and any nitrosated ethanol produced in the reaction. 
SNAG, 19, was used directly from the EtOH solution, which was a bright orange solution, without 
any further purification. The crude experimental set up for this reaction is shown in Fig. 74. 
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Figure 74: The reaction set up for the nitrosation of SNAG 19. 
 
The NOA reaction chamber shown in Fig. 73 was incubated at 37°C before a 10µM solution of 
SNAG 19 was injected and monitored for NO release over 1 minute. Initial screening showed that 
all measureable NO was released within 1 minute and hence this time frame was used for the 
collection of data. The same initial set up was used for the photochemical test however, before and 
during addition of the 10 µM solution of SNAG, 19, the reaction chamber was irradiated with  
254 nm of light within a foil casing. 
The copper catalysed reaction was observed at 37°C but SNAG 19 was injected into the reaction 
chamber containing a reservoir of copper sulphate (CuSO4). A concentration of 2 µM of CuSO4 was 
used, to ensure that the copper was in an excess and that any results observed were due to the catalytic 
effects of copper and not any other effect. The results from each NO release study are shown in  
graph 3.  
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Graph 3: NO release from SNAG 19 under different conditions analysed for 60 seconds. 
 
In a consistent fashion with what is reported in the literature4-6 the copper catalysed reaction does 
produce the fastest release of NO with the majority being produced in the first 10 seconds. With the 
chamber incubated at 37°C SNAG 19, also produced the majority of NO before 10 seconds but failed 
to produce as much in terms of arbitrary units (AUC). Under photochemical conditions, after 
irradiation with 254 nm light, SNAG 19 produced the most NO but taking a slightly longer time to 
do so, around 12 seconds. This is perhaps due to the induction of radicals upon decomposition with 
light.9 Under photolysis conditions, homolytic cleavage occurs producing the NO radical and a 
sulphide radical which then rapidly forms the corresponding disulphide, although this should be a 
rapid process it may explain why more NO is measured under photochemical conditions as formation 
of the disulphide is energetically favourable due to the strength of the S-S bond.10 With the NOA 
able to detect the levels of ‘pure’ NO released from SNAG 19, attention was turned to monitoring 
the NO release of the novel NO-donors  
The combretafuroxan compounds (86-95, 126/128) and the cupferron compounds (96-105) have very 
different mechanisms of release and therefore required different approaches to experimentally obtain 









































NO release from SNAG ,19, at 37°C under different conditons
37 Degrees + Copper + light (254nm)
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results will be outlined in this section. However within each compound set the conditions of the 
experiments were kept absolutely constant to allow for direct comparisons in NO release behaviour 
to be observed. 
2.2.2- NO release from cupferron compounds  
 
Cupferron compounds 98-105 in addition to the furoxan compounds mentioned earlier were analysed 
for their NO releasing capabilities using photochemical decomposition, to test the claims for NO 
release as described in the literature1. The reaction chamber was irradiated with UV light 
(experimental setup is shown in Fig. 75) at a wave length of 254 nm, to this chamber 3 mL of 7 mM 
cupferron compound (dissolved in diethyl ether) were injected and a NO signal was seen almost 
instantly. 
The parent compound, cupferron 56, when tested under these conditions rapidly produced NO to a 
scale the instrument could not interpret suggesting just how unstable cupferron is as a NO-donor. 
Because of this unquantifiable result the photochemical release of compounds 98-105 could not be 
compared directly to the parent compound. 
 
 
Figure 75: Picture of the experimental set-up for photochemical release studies using the nitric oxide 
analyser (NOA) on the cupferron series of compounds. 
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Cupferron derivatives were monitored for their NO releasing capabilities over 15 minutes. Mono 
alkylated cupferron compounds 98-101 varied in their ability to release NO when exposed to a 
wavelength of 254nm. Each compound tested had heightened stability in comparison to cupferron 
with all compounds releasing the majority of NO in the first three minutes and gradually reducing 
the amount of NO production over the next 12 minutes. The most stable compound was found to be 
the mono butyl derivative 99 producing 16 times less nitric oxide than the mono hexyl derivative 
100. Mono hexyl cupferron 100 also managed to produce 11 times more NO than the mono ethyl 
derivative 98. This can be seen in graph 4. Similarly to cupferron, compound 101 alkylated with an 
octyl chain, produced unquantifiably high levels of NO and were unmeasurable under the 
experimental conditions used. It may be said that alkylation with an eight carbon chain length on the 
terminal oxygen of cupferron decreases its stability, however this may have also decreased its 
solubility and therefore measurement of NO release. Comparatively two, four and six carbon 
alkylations greatly increase the stability of cupferron and its release of NO under photochemical 
conditions. 
 
Graph 4: Analysis of NO release from compounds 98-100 over 15 minutes. Measurements were 




























Time intervals (in 3 minute blocks)
NO release of mono alkylated cupferron compounds at 254 nm 
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Under the same experimental conditions compounds 103-105, with two cupferrons linked by a four, 
six or an eight carbon chain were also tested for their NO releasing capabilities in the presence of 
254 nm light (graph 5). In comparison to cupferron all dicupferron compounds 103-105 were more 
stable than the parent compound, with the butyl linked cupferron 103 being the most stable over 15 
minutes producing around eight times less NO than the hexyl linked compound 104. Unlike its mono-
substituted counterpart 101, compound 105 with an octyl linker was successfully measurable under 
the reaction conditions producing slightly more NO (1.7 times more) than the butyl linked compound 
103. In comparison to the hexyl linker 104, the eight carbon chain 105 produced 4.8 times less NO 
making the di hexyl 104 the least stable compound of the di-cupferron series. 
 
Graph 5: Analysis of NO release from compounds 103-105 over 15 minutes. Measurements were 
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NO release from allklylated di-cupferron derivatives at 254 nm
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As the mono octyl compound 101 produced unquantifiable results we cannot compare mono and di 
alkylations for that chain length. However the hexyl and butyl compounds 99/100 and 103/104 all 
produced NO at a level that was readable on the equipment. Comparing the compounds that contain 
a butyl chain (99 and 103) length, under the same experimental conditions (graph 6) shows that the 
mono butyl 99 is more stable than its di cupferron counterpart 103 producing less NO over 15 
minutes. The di cupferron 103 compound produces 1.4 times more nitric oxide upon exposure to UV 
light at 254 nm. 
 
Graph 6: Comparing the NO release from compounds 99 and 103, mono and di cupferron 
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Interestingly comparing the hexyl derivatives 100 and 104, (graph 7) the opposite trend to graph 6 is 
seen. In this case compound 104 was more stable than its mono cupferron counterpart 100 and 
therefore released less NO over 15 minutes. 
 
 
Graph 7: Comparison of compounds 100 and 104, mono and di cupferron compounds in the 
presence of UV light (254 nm). 
 
The di cupferron series 103-105 appears to have a unique mechanism of NO release, by first expelling 
the alkyl linker through a homolytic bond cleavage. This creates a di-radical alkyl chain, which then 
quickly cyclises to form a cycloalkane (scheme 63) due to it being more energetically favourable to 
exist as a ring structure than as the di-radical. This leaves the cupferron molecule with an O-radical 
in the terminal position. Movement of electrons causes the expulsion of NO and the formation of a 
nitrosobenzene molecule 195 and the nitric oxide is detected by the NOA. High resolution mass 
spectroscopy (HRMS) confirmed the formation of cyclohexane and cyclooctane from the di 
cupferron compounds 104 and 105 (full HRMS for each cycloalkane can be found in appendices 
AP02 and AP03 respectively). Compound 103 with the butyl linker showed no evidence of any 
cyclobutane product; this is possibly due to cyclobutane being a strained ring and not the most 
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Scheme 63: Proposed mechanism of photochemical induced NO release from cupferron compounds. 
 
Literature indicates that when cupferrons decompose under thermal or photochemical conditions that 
along with nitric oxide being produced, an azoxy compound (scheme 64) is also generated.12, 13 No 
evidence of the azoxy compound 196 was isolated from our experiments, however this indicates a 
possible mechanism for NO release for the mono alkylated compounds 98-101. 
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Scheme 64: Cupferron’s decompostion in the presence of light can yield nitric oxide along with an 
azoxy compound, 201. 
 
The cupferron compounds were also tested for their thermal stability at 25°C and 37°C and compared 
to the parent compound cupferron (graph 8). Cupferron’s NO release over 15 minutes was set as 
100% release and each derivative was then related back to the parent compound. 
 
Graph 8: Comparison of cupferron derivatives 98-105 with the parent compound 54. Compound 































%NO release compared to Cupferron
25°C 37°C
Results and Discussion- NO Release 
153 | P a g e  
 
When compared directly to cupferron both the di-cupferron and the mono-cupferron derivatives were 
more stable at both 25°C and 37°C with the exception of the mono-octyl compound (101). Mono-
octyl cupferron (101) produced 40% more NO than cupferron at 25°C and 44% more NO at 37°C. 
This suggests that the mon-ooctyl compound 101 is inherently less stable than cupferron under both 
thermal and photochemical conditions. As you increase the chain length of the cupferron derivatives 
from two carbons to eight carbons the solubility will obviously change. Mono-octyl cupferron, 
having the longest chain and only two electrostatic atoms present (the N+ and O- from the 
diazeniundiolate) is likely to be the least soluble in an aqueous solution and as a result is not solvated 
to the same degree as the other compounds in the series and can therefore release more NO as shown 
in graph 8.  
The general trend with the cupferron derivatives appears to be that as you increase the temperature 
from 25°C to 37°C, the compounds release less nitric oxide. The exception to the trend is compound 
99, cupferron alkylated with a butane chain, this produces an almost directly comparable amount of 
nitric oxide to that of cupferron. 
In terms of the stability of the cupferron derivatives 98-105 shown in graph 8 a stability factor was 
generated by directly comparing the compounds with cupferron once cupferron was set at 100% 
release.  This allowed the direct comparison of each compound with its un-alkylated parent 
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Compound Number Linker chain Stability factor in 
reference to cupferron 
at 25°C 
Stability factor in 
reference to cupferron 
37°C 
98 Ethyl 4 7 
99 n-Butyl 5 1 
100 n-Hexyl 3 3 
101 n-Octyl 0 0 




105 n-Octyl (Dicupferron) 4 7 
 
Table 4: Stability of cupferron derivatives compared to cupferron at both 25°C and 37°C. Stability 
factors were calculated by comparing % NO release per compound to cupferron, where cupferron 
was set at 100% release. . 98-101 are mono alkylated cupferron and 103-105 are dicupferron 
derivatives. 
 
The most stable compound at 25°C was compound 103, with a stability factor of 6. This means that 
in comparison to cupferron, compound 103 (dicupferron bridged by a butyl chain) is 6 times more 
stable releasing 84% less NO over 15 minutes compared to cupferron. The least stable compound at 
25°C was found to be compound 104 which had a stability of 1, meaning that it is as stable as the 
parent compound producing just 12% less NO than cupferron. At 37°C, representative of body 
temperature, compound 103 was again the most stable compound with a stability factor of 8. This 
means that 103 is 8 times more stable than the parent compound at 37°C, releasing 87% less NO over 
15 minutes. Interestingly at 37°C the mono ethyl cupferron 98 and the di-octyl compound 105 had a 
comparable stability to that of 103 with a stability factor of 7 each releasing 86% and 85% less NO  
respectively over 15 minutes than the parent compound 54. A general trend that can be obtained from 
this NO release work is that as the alkyl chain increases by 2 carbons both mono alkylated and 
dicupferron compounds become more thermally stable with increasing temperature from 25°C to 
37°C. The exception to this rule appears to be the monobutyl cupferron 99 which released 
comparable levels of NO to the parent compound cupferron at 37°C. 
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Cupferron derivatives 98-105 are capable of releasing NO in the presence of both light and heat 
(37°C) with varying levels of stability. SNAG 19, the known NO-donor mentioned previously in 
chapter 2.2.1 was also capable of releasing nitric oxide under these conditions and therefore can be 
compared to the cupferron compounds 98-105. In terms of NO released per millimole (mM) of 
compound, cupferron derivatives produce significantly more NO under both photochemical (254 nm 
light) and thermal (37°C) conditions. This suggests that in terms of NO donor capabilities that 
cupferron derivatives 98-105 are considerably better at releasing NO compared to SNAG 19 with 
compounds 99 and 101 producing 36 and 85 times more NO per mM of compound respectively. This 
data can found in appendix AP04. 
2.2.3-NO release from combretafuroxan compounds 
 
As aforementioned (chapter 1.1.3) furoxan compounds can release nitric oxide in a variety of ways 
including thermally, photochemically or by oxidation. Initial tests on compounds 86-128 found they 
were all thermally stable at 37°C. This led to oxidative and photochemical release being explored. 
Furoxan compounds 86-128 were analysed for their NO release under photochemical conditions, 
irradiating the reaction chamber (shown in Fig. 73 and 75) with light at a wavelength of 254 nm. To 
this chamber, 1 mM solutions of furoxan were injected and their relative NO release analysed using 
the nitric oxide analyser (NOA). Each furoxan compound successfully released NO in the presence 
of ultra-violet light confirming reports in the literature that describe this type of release.14, 15 Graph 9 
shows the relative release of NO per furoxan compound in terms of the area under the curve (AUC) 
for the NO spike that was obtained following the injection of the furoxan derivative into the reaction 
chamber. 
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Graph 9: Photochemical release of NO from furoxan compounds 86, 88, 90, 92, 94, 95, 126 and 
128 at 254 nm. 
 
Graph 9 shows that each furoxan compound tested, released nitric oxide at 254 nm to some degree. 
Compound 128 produced by far the most nitric oxide with around 5 times more NO released than 
compound 92 which was the para substituted methoxy derivative. A general trend appears to be that 
an electron donating substituent provides a stabilising effect towards NO release compared to those 
compounds 94 and 95 with an electron withdrawing functionality such as the trifluromethyl (CF3) or 

































Photochemical release of furoxan compounds at 254 nm
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Mechanistically it has been stated16 that aryl substituted furoxan compounds decompose in the 
presence of light to yield nitric oxide and a corresponding alkyne compound, however these alkynes 
are rarely isolated due to their rapid decomposition under the reaction conditions. Auricchio16 and 
researchers managed to ‘trap’ the forming alkyne 197 compound using a 2+2 cycloaddition with 
various alkenes to generate the phenanthrene type structure 198, as shown in scheme 65.  
 
Scheme 65: Photochemical release of NO from furoxan compounds can yield an alkyne. Auricchio16 
isolated these by trapping the alkyne with a [2+2] cycloaddition. 
 
The authors found that furoxans substituted with two phenyl rings produced the largest proportion 
of corresponding alkyne, this correlates with the results from graph 9 as compound 128 released the 
most NO and therefore would have produced the corresponding alkyne.  Interestingly evidence of 
the alkyne formation, and production of 1,2-diphenylethyne was found in the sample of 128 that 
HRMS was performed on (shown in Fig.76). This suggests that ambient light conditions (such as 
those seen during sample preparation for HRMS) are enough to induce the release of nitric oxide for 
the furoxan compounds. 
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Figure 76: HRMS data for compound 128, showing the isolation of 1,2-diphenylethyne and thus 
confirming the mechanism of NO release. 
 
As seen by Auricchio,16 no other alkyne compounds (such as that of 199 shown in scheme 66) were 




Scheme 66: Acetophenone produced furoxan compounds, when exposed to light would release NO 
to yield a diketo-alkyne type compound 195. These compounds could not be isolated from the 
reaction chamber of the NOA. 
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With confirmation that the combretafuroxan series of compounds (86-128) were capable of releasing 
nitric oxide under photochemical conditions, it was sought to see if they were also capable of 
releasing nitric oxide under oxidative conditions as often seen in the literature. 15,17-21 Initial 
experiments involved the oxidative release of NO in the presence of different concentrations of 
thiolate in the form of potassium thioacetate. Ratios ranging from 0.5- 4 and an excess of thiol with 
respect to furoxan compound were tested with varying results. It was found that it took an excess, 
10:1 ratio of thiolate:furoxan, to promote release of NO from the furoxan compounds. As 
aforementioned (scheme 60) an acidified tri-iodide solution was used to obtain nitric oxide from 
nitrite, however it also appeared to cause NO to be released from the furoxan compounds directly. 
Due to the oxidative nature of triiodide, it was theorised that I3- was decomposing the furoxan 
compounds and producing a NO signal, without providing information on the relative NO release 
from that compound in the presence of thiolate. The initial injection of furoxan compounds into the 
reaction chamber containing an acidic tri-iodide solution at 40°C gave an intense peak, however the 
volume of NO released using the tri-iodide method cannot be quantified as this is due to the 
decomposition of the entire furoxan ring and is not indicative of their relative NO release. To produce 
accurate results that would provide information on each compounds relative NO release potential, 
experimental procedures were altered to account for this observation. Furoxans were instead injected 
(shown schematically in Fig.77) into a solution of excess potassium thioacetate which produced an 
initial signal, then acidified triiodide solution was introduced into the reaction chamber to convert 
any nitrite by-product that formed back into NO for detection. A combination of these two peaks 
would then equate to the total NO release for that compound. 
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Figure 77: Schematic diagram of reaction vessel used to obtain NO release data from furoxan 
compounds using oxidative conditions. Taken and adapted from reference 2. 
 
The reaction chamber (Fig. 77) was filled with excess potassium thioacetate solution. To this 100uL 
of 1mM furoxan was added into the chamber resulting in an initial peak on the analysis window. 
This was determined to be ‘free’ NO released by the thiolate attacking the ring and being detected 
before it is converted to nitrite (NO2). Excess (1ml) of acidic tri-iodide solution was then injected 
into the chamber, oxidising any nitrite that had formed back into NO for detection. The results of this 
experiment are shown in graph 10. Each combretafuroxan compound (86-128) was tested for their 
NO release under these oxidative conditions. 
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Graph 10: Oxidative release of NO from furoxan compounds, showing the amount of NO obtained 
as the 'free' form, nitrite and a combination of the two. Relative NO release is measured as the area 
under the curve (AUC) of each spike produced from the release of NO. 
 
Splitting the data into three distinct sets helps show the complete story. In terms of ‘free NO’ (shown 
as the blue bars in graph 10) compounds 86 and 95 produced around 6 times more NO than the next 
compound, 88. This appears to follow the trend as seen with the photochemical release (graph 9) as 
95 has an electron withdrawing group, CF3, in the para position and 86 has 6 electron donating 
methoxy groups decorating its structure, indicating that an electron withdrawing substituents release 
more NO in comparison to electron donating substituents. However this is not a consistent trend as 
86 releases more NO than 94 which is substituted with the electron withdrawing group, OCF3. This 
paradigm suggests that electronics have little effect on the release of nitric oxide under oxidative 
conditions and photochemical conditions (graph 9) and supports the idea that as the compounds 
tested do not behave exactly the same, the substituents themselves, must play a role in the release of 
nitric oxide other than in terms of electronics. 
In terms of the total NO (green bars in graph 10) released at 40°C, a trend can be identified. It can 
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their O-alkyated counterparts. This suggests that O-alkylated compounds (92 and 94) are less stable 
producing 3 and 1.5 times more NO than their respective alkyl compounds 88 and 95. This trend is 
confirmed by the trimethoxy substituted furoxan 86, which also produces more NO than the methyl 
substituted furoxan 88 and suggests that the introduction of an electronegative atom such as oxygen 
destabilises the furoxan in terms of its NO release. 
To convert the data produced in graph 10, into a more useable form such as the actual concentration 
of NO released, the calibration curve depicted in graph 2 needs to be used. The concentration of nitric 
oxide release per furoxan compound can be calculated using the parameters from the calibration 
graph. The data presented in table 5 correlates to the total NO release produced for each compound 
under oxidative conditions. 
Compound number Total NO  
(AUC) 
Concentration of NO 
x10-6 (mol/dm-3) 
88 1342.5 2.14 
92 4102.7 6.74  
95 1615.0 2.59 
94 2453.9 3.99 
90 3761.7 6.17 
86 3129.8 5.11 
128 3271.0 5.24 
126 3741.4 6.13 
 
 
Table 5: The actual concentration of NO released from furoxan compounds under oxidative 
conditions. Results were obtained using the calibration curve in graph 2. 
 
In the presence of thiolate, compound 92 produced the highest concentration of NO at 6.74 µM. 
Following the trend mentioned earlier, as the substituents positioned around the aryl ring become 
more electron withdrawing, the combretafuroxan compound becomes more stable with respect to the 
release of nitric oxide. This is consistent with what is presented in the literature, as Nirode observed 
that electron-withdrawing substituents present on the aryl rings resulted in a lower NO yield.17 
Compound 95 produced around 2.6 times less NO with a concentration of 2.59 µM. From the data 
generated, the most stable combretafuroxan appears to be compound 88 which contains a methyl 
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group in the para position of each aryl ring producing only 2.14 µM of nitric oxide under the 
conditions studied. 
Although each furoxan compound successfully produced nitric oxide upon exposure to thiolate, the 
concentration produced per furoxan compound does not correlate to the initial concentration injected 
into the reaction vessel. As outlined in Fig. 77, 1 mM of each furoxan (86, 88, 90, 92, 94, 95, 126, 
and 128) was injected into the chamber containing and excess of thiolate. This in turn released 
micromolar (µM) levels of NO. This equates to a 1000 fold difference in concentration unaccounted 
for from each furoxan compound. There are two possible explanations as to where the missing NO 
has gone. It is thought that during the decomposition of the furoxan to produce nitrite that a 
significant proportion of nitrate may have also formed. Due to experimental limitations with the nitric 
oxide analyser (NOA), nitrate levels could not be measured and therefore the remaining 
concentration may be existing as unquantifiable nitrate. Another explanation for the missing 
concentration could be that the furoxan compounds are photosensitive. As seen in graph 9 in the 
presence of light, furoxan compounds (86, 88, 90, 92, 94, 95, 126, 128) can release substantially 
more nitric oxide, around a 10x enhancement in release profile for 128 compound, than they do under 
oxidative conditions. The experimental preparation for oxidative release is quite laborious in 
preparing the conditions required for analysis and it is therefore possible that photochemical induced 
NO release occurred before the furoxan compounds were exposed to thiolate producing the observed 
lower concentrations. The furoxan compounds appear to release less nitric oxide than anticipated 
under oxidative conditions, this paradigm was confirmed by our collaborators who found that 
compounds 86, 88, 90, 92, 94, 95, 126, and 128 released less than 5% nitric oxide in total when 
analysed using the Greiss test, a classic method for the analysis of nitric oxide. 
Despite a lower concentration of nitric oxide being recovered than expected, the production of NO 
from the oxidation of nitrite does confirm findings from the literature in terms of the mechanism of 
release. Upon release of NO from the furoxan compounds, literature14,17 indicates that a new 
heterocycle is formed known as an isoxazole 200 along with a molecule of nitrite as before depicted 
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in scheme 12 (chapter 1.1.3,  page 35). Evidence of this formation was found using compound 94 as 
a test sample (scheme 67).  
 
Scheme 67: Thiol induced release of NO leads to the formation of a new heterocycle, the isoxazole 
ring 200. Its partially decomposed form 201 was found for compound 94 using HRMS. 
 
HRMS data confirmed the presence of the isoxazole ring with a mass of 448.9783 ppm, however this 
corresponds to the free thiolate having lost the acetyl group from the original potassium thioacetate 
starting material shown in scheme 64. The presence of the isoxazole ring 201 in the reaction vessel 
confirms the mechanism of NO release as aforementioned in chapter 1.1.3 (scheme 12, page 35) and 
reinforces the mechanism of which nitrite (NO2-) is produced.14,17 Interestingly the isoxazole ring has 
recently been published22 as a combretastatin analogue, for increasing rigidity of the cis double bond 
and showed promising anti-tubulin functions. This could suggest that there may be a limited loss of 
anti-tubulin activity in the combretafuroxan compounds upon initial decomposition as the isoxazole-
combretastatin is also active towards tumour reduction. There is also potential that the 
combretafuroxan could act as a novel prodrug formulation, and convert to the active isoxazole-
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combretastatin in situ with release of nitric oxide and have synergistic effects as the release of NO 
can relieve the cardiotonic side effects often seen with anti-tubulin compounds. 
Ozone-based chemiluminescence was a useful technique for measuring NO-release and allowed the 
successful measurement of the nitric oxide releasing capabilities of synthetically novel NO-donors 
spanning two classes. However, the sensitivity issues, such as the background atmosphere affecting 
baseline readings, meant that certain experiments and conditions were not viable. Problems with the 
levels of nitrate in standard samples meant that the levels of nitrate produced from our compounds 
could not be measured and therefore the full picture and profile for the furoxan compounds could not 
be established. Although there were experimental constraints, the NO-release methodology used, 
successfully showed that all furoxan based NO-donors were able to release NO under both 
photochemical and oxidative conditions. It appears that the substituents decorating the aryl rings in 
compounds 86, 88, 90, 92, 94, 95, 126, 128 have little effect on the relative NO release under these 
conditions other than that electron withdrawing groups appear to produce a lower amount of NO 
compared to those compounds with a more electron donating group attached to the aryl ring. This 
may be due to the positon that the thiolate attacks the furoxan being affected by the electronics of the 
compound, electron withdrawing groups are known to increase the electrophilicity of the benzoyl 
carbon16 may cause the thiol to attack the carbonyl carbon preferentially to the imino carbon of the 
furoxan and thus affect the level of NO release. However photochemical decomposition produces a 
higher amount of NO per compound compared to oxidative induced release suggesting that 86-128 
have a high degree of photosensitivity to both natural light and 254 nm light.  
The cupferron derivatives 98-105 tested were all capable of releasing nitric oxide in the presence of 
light (254 nm). The alkylation chemistry performed on the terminal oxygen appears to have a 
stabilising effect on the parent compound for the majority of the NO-donors. All compounds except 
101 evolved less nitric oxide than non-alkylated cupferron, 56. The most stable compound appears 
to be 103, where a butyl chain links two molecules of cupferron, this stability may be due to the 
mechanism of release and that the formation of a butyl di-radical and the subsequent ring closure to 
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form the cyclobutane ring is energetically unfavourable compared to the cyclohexane and 
cyclooctane rings formed from decomposition of compounds 104 and 105 respectively.  
Analysis of the known NO-donor, SNAG 19 confirmed what has been observed in the literature that 
in the presence of copper ions (Cu+) the release of nitric oxide is accelerated compared with its 
relative release under thermal conditions. Under our experimental conditions it was found that 
photochemical release produced a greater quantity of NO compared to thermal and copper catalysed 
release, however it took slightly longer to do so. Comparatively in terms of NO-donor capabilities 
the cupferron derivatives 98-105 produce more NO per mM of compound than SNAG 19 did.  
2.2.4- References 
1. A. Butler, and R. Nicholson, “Life, Death and Nitric Oxide”, RSC paperbacks, The Royal 
Society of Chemistry, 2003. 
2. P. H. MacArthur, S. Shiva and M. T. Gladwin, J. Chromatogr. B, 2007, 851, 93-105 
3. A. G. Pinder, S. C. Rogers, A. Khalatbari, T. E. Ingram and P. E. James, Redox-Mediated 
Signal Transduction- Chapter 2, 2009, Humana Press 
4. J. McAinly, D. L. Williams, S. C. Askew, A. R. Butler and C. Russell, J. Chem. Soc. Chem. 
Commun, 1993, 1758-1759 
5. R. J. Pearson, PhD thesis, University of St Andrews, 2001 
6. D. L. Williams, Acc. Chem. Res. 1999, 32, 869-876 
7. J. S. Stamler, O. Jaraki, J. Osborne, D. I. Simon, J. Keaney, J. Vita, D. Singel, C. R. Valeri 
and J. Loscalzo, Proc. Nat. Acad. Sci. 1992, 89, 7674-7677 
8. H. M. S. Patel and D. L. H. Williams, J. Chem. Soc. Perkin Trans 2, 1990, 37-42 
9. S. C. Askew, D. J. Barnett, J. McAninly and D. L. H. Williams, J. Chem. Soc. Perkin Trans 
2, 1995, 4, 741-745 
10. M. M. Veleeparampil, U. K. Aravind and C. T. Aravidakumar, Adv. Phys. Chem., 2009. 
1-5 
11. J. A. Hrabie and L. K. Keefer, Chem. Rev., 2002, 102, 1135-1154 
12. J. R. Hu, C. S. Yau, S. C. Tsay and T. I. Ho. Tetrahedron. Lett. 1997, 38, 52, 9001-9004 
Results and Discussion- NO Release 
167 | P a g e  
 
13. Y. Hou, W. Xie, A. J. Janczuk and P. G. Wang, J. Chem. Org., 2000, 65, 4333-4337 
14. R. Fruttero, M. Crosetti, K. Chegaev, S. Guglielmo, A. Gasco, F. Berardi, M. Niso, 
 R. Perrone, M. A. Panaro and N. A. Colabufo, J. Med. Chem, 2010, 53, 5467-5475. 
15. R. M. Paton, Comprehensive Heterocyclic Chemistry I, 1984, 393-426 
16. S. Auricchio, A. Selva and A. M. Truscello, Tetrahedron, 1997, 53, 51, 17407-17416 
17. W. F. Nirode, J. M. Luis, J. F. Wicker and N. M. Wachter, Bioorg. Med. Chem. Lett., 2006, 
16, 2299-2301 
18. P. G. Wang, T. B. Cai and N. Taniguchi, Nitric oxide donors: For Pharmaceutical and 
Biological Applications, Science, John Wiley and Sons, 2005 
19. R. M Paton, Comprehensive Heterocyclic Chemistry II, 1995, 229-265 
20. G. N. Nikonov, and S. Bobrov, Comprehensive Heterocyclic Chemistry III, 2008, Vol.5, 
315-394 
21. M. Feelisch, K. Schonafinger and E. Noack, Biochem. Pharmocol., 1992, 44, 5, 1149-1157 
22. J. Kaffy, R. Pontikis, D. Carrez, A. Croisy, C. Monneret and J. C. Florent, Bioorg. Med. 














Results and Discussion- Vasodilatory work 
168 | P a g e  
 
2.3- Biological results 
 
The furoxan ring was introduced into the combretastatin structure to increase the stability of the anti-
tubulin agent and prevent its original alkene bond from isomerising in vivo. Furoxans capability to 
release nitric oxide, and therefore induce vasodilation, is an advantageous property for the 
combretafuroxans due to the cardiotonic side effects associated with combretastatin and can therefore 
work as a dual purpose compound. To assess the effectiveness as NO-donor compounds, 
collaborators at Kingston University were sent samples of compounds from the combretafuroxan 
series to test their effectiveness as vasodilators. Using rings of rat aorta submerged in organ baths 
the success of each compound was determined by the percentage relaxation that occurred on pre-
contracted aortic rings. Contraction of aortic rings was induced before experimentation using 




Figure 78: Methoxamine 202, a chemical agent used to induce vasoconstriction. 
 
 The following compounds were tested for their effectiveness as vasodilators and produced varying 
results which are presented and discussed in the following section. 
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Figure 79: Combretafuroxans, GSNO, a nitroalkane and a combretafuarzan used in the vasodilatory 
study using contracted rat aorta. 
 
Each compound was tested for its ability to induce relaxation on the aortic smooth muscle, which 
was pre-contracted with methoxamine (Fig.78). Dimethyl sulphoxide (DMSO) was used a reference 
compound due to all samples being dissolved in this organic solvent. DMSO produces minimal to 
no relaxation of the aorta and therefore any response seen can be attributed to the testing compound 
and not that of the solvent.  
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Graph 11: Initial vasodilatory investigations of furoxans on rat thoracic aorta, graphically grouped 
according to compound potency and comparing effect to compound vehicle, dimethyl sulfoxide 
(DMSO). (n= 4-6 animals). 
 
Graph 11 shows the initial relaxation results for compound 86, 203 and 206 on rat aortic rings.  In 
this initial study the furoxan compounds tested were all substituted with a tri-methoxy unit decorating 
the aryl ring in various positions. All compounds were able to reverse contraction by 100%, with 
compound 206 only requiring 0.3 µM to induce half of the maximal response. Comparatively 
speaking, 206 is 3 and 8 times more potent than 86 and 203 respectively. This suggests that the tri-
methoxy subunit and specifically methoxy (OMe) groups in the 2, 4 and 5 positions are important in 
NO-release and the induction of vasorelaxation. 
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Graph 12: Initial vasodilatory investigations of furoxans on rat thoracic aorta, graphically grouped 
according to compound potency and comparing effect to compound vehicle, dimethyl sulfoxide 
(DMSO). The compound 205 causes the unexpected effect of contracting the aorta further than the 
maximum obtained from use of methoxamine.  (n= 4-6 animals). 
 
Graph 12 shows the initial relaxation test for compounds 88, 94 and 205, with DMSO used as a 
control. Compound 205 displays an interesting profile in that it increases the percentage contraction 
of the aortic rings compared to the other furoxan compounds tested in this study (88 and 94). This 
phenomenon suggests that 205 in fact acts more as a vasoconstrictor rather than a vasodilator possibly 
giving scope for its use as a lead compound based upon combretastatin, which depletes tumour cells 
by disrupting the vascular structure supplying the tumour with blood.1 Out of the compounds tested 
in this relaxation study, compound 205 is the only one with a substituent in the 2 and 6-position on 
the aryl rings. This observation suggests that having substituents in both the 2 and the 6 positions of 
the aryl rings flanking the furoxan disrupts NO-release in some manner and instead increases their 
potential for vasoconstriction by hindering NO release. 
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Graph 13: Initial vasodilatory investigations of furoxans on rat thoracic aorta, graphically grouped 
according to compound potency and comparing effect to compound vehicle, dimethyl sulfoxide 
(DMSO) – without compound 205. (n= 4-6 animals). 
 
Graph 13 shows the percentage relaxation for compounds 88 and 94, this time without the outlier 
compound 205. This graph shows more clearly that compound 94 is a potent vasodilator inducing 
100% reversal in contraction at a remarkably low concentration (IC50: 0.25 µM) compared with the 
furoxan compounds seen already (86, 88, 203, 205 and 206). Compound 88 has a methyl group in 
the para position of the aryl rings flanking the furoxan, whereas compound 94 is substituted with a 
trifluromethoxy (OCF3) in the para positon (as shown in Fig. 79). This observation suggests that an 
electron withdrawing group present in the furoxan structure increases its ability to release nitric oxide 
and induce vasodilation. 
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Graph 14: Initial vasodilatory investigations of furoxans on rat thoracic aorta, graphically grouped 
according to compound potency and comparing effect to compound vehicle, dimethyl sulfoxide 
(DMSO). (n= 4-6 animals). 
 
Graph 14 shows another comparative study for the relaxation potential of compounds 92, 95 and 207 
(their structures can be seen in Fig. 79). Compound 95 is substituted with a trifluromethyl (CF3) 
group and appears to produce relaxation in a more sigmoidal profile compared to that of 92 and 207. 
Compound 207 is a nitro alkene (Fig. 79) and successfully produces 100% relaxation however in a 
much more concentration dependent way. There is no relaxation in concentrations lower than 1 µM 
but there is almost an instant relaxation at 1 µM. Compound 92 also produces a sigmoidal curve but 
is a lot less potent than either 95 or 208. Compound 92 contains a methoxy (OMe) substituent and 
its lack in potency compared to 95 which has the more electron withdrawing group, CF3, suggests 
that electronegativity again plays a key role in the relaxation potential of the furoxan compounds, as 
already seen in graph 13 with compound 94. 
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From the graphs shown above (11-14), it can be seen that there is a range of relaxation activity 
produced from the compounds tested. This can also be seen in Table 6, which displays the relative 
IC50 for each compound. An IC50 is defined as the effective concentration of a drug or compound that 
produces half of the maximal response2.  













Table 6: IC50 values for the panel of furoxan compounds tested on rat thoracic aorta. All 
concentrations are reported in µM. 
 
The relative IC50 data indicate that compound 94 (OCF3) is the most potent compound, reversing 
contraction by 100% and producing a IC50 of 0.25 µM. Converting the OCF3 group to CF3 invokes a 
3 fold loss in potency suggesting that the oxygen is somehow key to the mechanism of relaxation 
seen for compound 94. It appears as you increase the electron donating potential of the substituent, 
the potency with respect to vasodilation, decreases. This is especially the case within the mono-
substituted compounds. Which can be seen clearly by compound 88 (p-Me) and 92 (p-OMe), having 
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an IC50 of 0.98 µM and 3.15 µM respectively. For the tri-MeO substituted compounds, the most 
potent vasodilator was the 2,4,5-trimethoxy furoxan 207, closely followed by the 3,4,5-trimethoxy 
86 and then the 2,3,4-trimethoxy 203 all with IC50’s below 5 µM. The 2,4,5-trimethoxy 206 
compound producing an IC50 of 0.34 µM. This shows that the trimethoxy substituent is a beneficial 
functionality in terms of vasodilation with the majority (86 and 206) producing sub 2.0 μM potency. 
It appears that the relative position of the methoxy group does however affect the IC50 value. 
Comparing 203 and 206, one methoxy group has been moved from the 5-position (206) to the 3-
position (203) of the benzene ring. This change in position causes a significant drop in potency from 
0.34 μM to 2.99 μM. Removing the ortho methoxy group completely and changing the substitution 
pattern to the three, four and five positions (86) changes the IC50 to 1.13 μM. This suggests that a 
methoxy group in the five position induces more relaxation as both 86 and 206 both contain this 
substituent and have sub 3 μM IC50’s. However, having a methoxy group in both ortho positions (2 
and 6) alters the relaxation profile totally. Compound 205 was the only compound not to induce 
relaxation and instead induced an increase in the contraction of the rat aorta. Comparing 205 with 
the other trimethoxy substituted compounds 86, 203 and 206, it is the only compound tested that has 
a methoxy substituted in the 6 position of the aromatic ring. This suggests that having a substituent 
in both the two and six position of these symmetrical combretafuroxan compounds impedes the 
release of NO in some manner. The lack of relaxation from compound 205 correlates with findings 
from the ovarian cancer cell line studies. Previous work3 on symmetrical combretafuroxans found 
that compound 205 was a potent anti-tubulin agent producing an IC50 of 3.64 μM against the A2780 
ovarian cancer cell line as well as sub 100 μM activity against several others. Anti-tubulin agents 
work by restricting the blood flow to the tubulin cells, causing oxygen deprivation and eventually 
cell death, so it is no surprise that compound 205 did not cause any relaxation. Instead it acts as an 
effective vasoconstricting agent. 
An interesting observation from the initial biological testing is that there is a stark difference between 
the relaxation ability of compound 95 and compound 96. Both of these compounds are substituted in 
the para position with a trifluromethyl group; however compound 96 lacks the two carbonyl groups 
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bridging the furoxan ring and the aryl groups. It appears that without the carbon spacer present, there 
is around a 30 fold loss in potency with 96 producing an IC50 of 23.5 μM compared to 95’s IC50 of 
0.84 μM. This can potentially be explained by the mechanism that each compound uses to release 
nitric oxide. Both furoxan compounds will release NO in the presence of thiols, however due to the 
presence of the carbonyl groups, compound 95 can undergo rearrangement upon release of NO to 
produce the isoxazole ring as already seen in scheme 67 (page 163). Without the carbonyl group 
present adjacent to the furoxan, this new ring formation cannot occur and therefore the resulting 
compound post NO release for compound 96, may not be as stable and therefore the process may not 
be as energetically favourable as the decomposition of 95. Depending on the exact mechanism of 
NO release within the aortic rings, compound 95 may also interact differently with endogenous thiol 
groups as it can form additional non-covalent interactions with amino acid residues along the aortic 
wall. These interactions may also stimulate nitric oxide to be produced by NOS enzymes and 
stimulate the relaxation mechanism from the aortic cells therefore creating a summative relaxation 
and hence the much lower IC50. 
Compounds 90 and 96 were the least effective in these relaxation studies with IC50’s of 15.5 and  
23.5 µM respectively. Compound 204 is similar to the combretafuroxan compounds 86, 203, and 
205 and 207 but instead contains a furazan ring. A furazan ring is chemically similar to the furoxan 
ring but lacks the ability to release nitric oxide, as it lacks the N-oxide functionality and therefore 
should not be able to induce relaxation. Compound 204 produced an IC50 of 20.5 μM, which was 
much lower than initially expected due to the inability to release nitric oxide. The observation that 
204 still produces relaxation may suggest that relaxation is not entirely induced by the release of 





Results and Discussion- Vasodilatory work 
177 | P a g e  
 
2.3.1- Lead compound isolation and further analysis 
 
From the derived IC50’s, compound 94 was determined to be the most potent compound, resulting in 
the collaborators choosing it as their lead compound for further biological analysis. It has been 
established from both NO release data using the NOA apparatus and initial biological experiments 
that compound 94 is capable of producing nitric oxide and to a high enough concentration to promote 
100% relaxation. Although the most potent furoxan compound in the initial studies (graph 11-14) 
the question arose, how does this compare to other NO-donors. Sodium nitrosoprusside (SNP) as, 
aforementioned in chapter 1, is a known NO-donor, commercially available in the BNF4, and is 
considered as the ‘gold standard’ in NO release despite its unfavourable metabolites such as cyanide 
and cyanoheamaglobin.5 
Samples of compound 94 and SNP 9 were studied alongside each other to test their relative relaxation 
effects. Aortic rings were pre-contracted with methoxamine 202 (Fig.78) before the appropriate 
testing compound was introduced. 
 
Graph 15: A direct comparison between the vasodilatory effects of compound 94 against SNP, 9.  It 
can be seen that SNP is the more potent compound; however, compound 94 appears to be able to 
reverse a methoxamine induced α-1 contraction the greatest. (n=4-6). 
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Sodium nitrosprusside (SNP) is clearly a more potent vasodilator than compound 94 inducing 
relaxation with an IC50 of 0.05 µM compared to 0.25 µM for compound 94. However although less 
potent in terms of IC50 value, compound 94 appears to be able to fully reverse methoxamine induced 





Graph 16:  A representative trace showing the effects of cumulative concentrations of both sodium 
nitroprusside (SNP, black trace) and compound 94 (blue trace).  The concentration additions are 
from the left: 1 nM, 3 nM, 10 nM, 30 nM, 100 nM, 300 nM, 1 µM.  
 
A vascular pressure gauge (graph 16) was constructed to analyse compound 94 and SNP’s 9 
relaxation profile in terms of reducing the pressure observed upon contraction. Aortic rings were pre-
contracted with 10 µM methoxamine (Fig. 78) as shown by point ‘A’ on graph 16. The contraction 
of the aortic ring increased the pressure measured on the gauge and hence the rise in peak line. 
Increasing concentrations of both SNP 9 and 94 were then injected and their effect on contracted 
aorta was observed over 45 minutes. As the concentration of SNP 9 increased from 1 nM towards  
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1 µM, the aorta relaxed at a greater rate. Compound 94 was shown to be the less potent of the two 
compounds but it elicits a more sustained relaxation with no fluctuations in vascular tone when 
compared to SNP, once the vessel became fully relaxed.  
 
 
Graph 17: Comparison of effect between SNP and 94 in vasodilation of pulmonary arteries.  SNP 
is a more potent vasodilator in pulmonary artery, however, it appears from the data available that 
compound 94 has a greater Vmax (SNP – 83.6 ± 0.98% and 94= 94.86 ± 3.42 %. Data are means ± 
SEM. (n= 6-8). 
 
SNP’s 9 potency when compared against compound 94 is not just isolated to the aortic vessel. Graph 
17 shows the action of SNP and compound 94 upon pre-contracted pulmonary arteries. SNP 9 
produces a lower IC50 value of 0.1 µM where compound 94 has an IC50 of 2.0 µM (a slight reduction 
in relaxation potential). Despite SNP 9 producing relaxation at a faster rate, it only ever induces up 
to 80% relaxation; this is where compound 94 performs better. Although a higher concentration of 
94 is needed, almost 100% relaxation of the pulmonary artery is possible; this is consistent with the 
results seen within the aortic vessel.  
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Mechanistically, vasodilation in vivo is said to occur through activation of soluble guanylate 
cyclase’s (sGC) heam centre by nitric oxide.6,7 It is this activation that induces the cascade of 
biochemical reactions that result in vasodilation and the increase of blood flow. In an attempt to 
establish the mechanism by which compound 94 was acting, and if in fact it works by binding and 
activating sGC, an inhibitory experiment was set-up. ODQ or [1H-[1,2,4]oxadiazolo-[4,3-
a]quinoxalin-1-one] 208 (Fig. 80) is a known inhibitor of guanylate cyclase8 and was introduced to 
the rat aorta rings 10 minutes prior to contraction with methoxamine. 
 
 
Figure 80: The industry used sGC inhibitor, [1H-[1,2,4]oxadiazolo-[4, 3-a]quinoxalin-1-one] or 
ODQ 208. Which can help assess the mechanism of action of lead compound 94. 
 
Both SNP 9 and compound 94 were then injected into the aorta and analysed for their ability to 
reverse relaxation under identical conditions. The results from this study are depicted in graph 18. 
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Graph 18: Comparison of dose-effect of sodium nitroprusside (SNP) and 94 in pre-contracted rat 
thoracic aorta, both with and without incubation with ODQ (20 µM) for ten minutes before 
contracting the vessel. Aorta rings were pre-contracted with 10-5 M methoxamine. Data are means ± 
SEM. Statistical analysis was conducted and significance is shown by P <0.05 = *; P <0.01 = **; P 
<0.001. (n=6-7). 
 
Graph 18 shows the profile of SNP with and without the ODQ inhibitor. Without ODQ inhibition, 
SNP reproduces its profile from graph 16, however upon inhibition of sGC its effectiveness as a 
vasodilator is greatly reduced causing only 5% relaxation and essentially very little vasodilation 
occurs. In contrast compound 94 in the presence of the ODQ inhibitor still induces around 80% 
relaxation of aortic muscle suggesting activation of sGC is not its primary route to vasodilation and 
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Graph 19: Comparison of 20 µM ODQ and 100 µM of ODQ 209 on inhibition of vasodilation in rat 
thoracic aorta. ODQ was allowed to incubate in the vessels for ten minutes before contraction. Aorta 
rings were pre-contracted with 10-5 M methoxamine. Data are means ± SEM. Statistical analysis was 
conducted using two-way ANOVA and significance when compared to compound 94 is shown by P 
<0.05 = *; P <0.01 = **; P <0.001 = ***. A student’s t-test indicates that the effects of the two ODQ 
concentrations are not significantly different. (P = 0.7845). (N=7). 
 
Increasing the concentration of sGC inhibitor fivefold to 100µM still has minimal effect on the action 
of compound 94 on aortic relaxation, increasing the IC50 from 0.2 µM to 10 µM. Compound 94 still 
produces around 80% relaxation suggesting that an alternative relaxation mechanism is being utilised 
to reverse the contraction of aortic smooth muscle and therefore an alternative experiment is needed 
to assess compound 94’s mechanism of action. 
 
Comparison  of  different  concentrations  of  ODQ  
inhibitor  on  lead  compound 94 
94  and  ODQ  (100  M) 94 and  ODQ  (20  M) 
94 alone 
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Haemoglobin is a known scavenger of nitric oxide6, 9, 10, with the ferric centre of haemoglobin readily 
able to bind to nitric oxide in vivo. Introducing a NO scavenger into the experiment (graph 20) could 
assess what overall action NO release from 94 has on the vessel if it is not acting via the sGC 
activation pathway. 
 
Graph 20: Effect of 10 µM haemoglobin on nitrovasodilator effect. Haemoglobin was added prior 
to addition of methoxamine. All vessels were pre-contracted with 10-5 M methoxamine before 
addition of compound 94 or SNP (9). Data are means  SEM. Statistical analysis was conducted and 
significance is shown by P <0.05 = *; P <0.01 = **; P <0.001.  A student’s t-test shows that the effect 
of haemoglobin on SNP and compound 94 is significant (P=0.0042 and 0.0078 respectively). (n= 5-
7). 
 
Graph 20 shows the effect of haemoglobin (Hb) on SNP 9 and compound 94. It appears that SNP 9 
is not greatly affected by the scavenging properties of haemoglobin as almost 100% relaxation still 
occurs; the effect of vasodilation in the presence of haemoglobin is probably due to the NO release 
saturating haemoglobin and then surplus NO being free to bind to sGC and promote relaxation.  
When compound 94 is exposed to haemoglobin the effect is much more drastic. The relaxation profile 
of compound 94 is completely reversed upon NO scavenging with only 20% relaxation being brought 
about, even at concentrations close to 100 µM, a 200 fold increase in concentration from the IC50 of 
compound 94 with Hb. The fact that very little relaxation occurs in the presence of Hb confirms that 
compound 94 works by the release of nitric oxide, consistent with what was observed using the nitric 
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oxide analyser. This observation suggests that NO release from compound 94 is more of a causative 
agent that induces a vasodilation cascade rather than directly causing relaxation. 
One explanation of why compound 94 is able to observe an effect upon relaxation when sGC has 
been inhibited with ODQ, is that compound 94 is interacting with eNOS enzymes present in the 
aortic ring and perhaps stimulating them to produce more NO and therefore combat the inhibition of 
sGC. To test this theory, L-NAME and Indomethacin, two known NOS inhibitors aforementioned in 
chapter 1 were introduced to the pre-inhibited aortic rings, to see if compound 94’s relaxation profile 
changed from Graph 18. 
 
Graph 21: A group comparison of molecular inhibitors used on the effect of compound 94. Inhibitors 
were added ten minutes prior to the addition of methoxamine to allow time to act. Aorta rings were 
pre-contracted with 10-5 M methoxamine Data are means  SEM. Statistical analysis was conducted 
comparing inhibitors with control compound 94 and significance is shown by P <0.05 = *; P <0.01 
= **; P <0.001= ***. (n = 5-7 animals). 
 
Graph 21 shows that inhibition of the NOS enzymes present in the aortic vessel has no effect on the 
relaxation profile of compound 94 and therefore indicates that there is no interaction between the 
furoxan compound and the NOS enzymes. This therefore suggests that relaxation of the aortic smooth 
muscle occurs by an alternative mechanism to that of SNP. In the presence of L-NAME there is only 
Results and Discussion- Vasodilatory work 
185 | P a g e  
 
a small loss of potency of compound 94, shifting the sigmoidal profile slightly to the right, but still 
producing 100% relaxation. This suggests that the presence of the NOS inhibitor does not affect the 
relaxation potential of compound 94 and that in fact the NOS inhibitor is more likely disrupting any 
NO being produced by the aortic endothelium itself. To further account for any endogenous NO 
interfering with the relaxation profiles, and to attempt to explain the mechanism of action, the 
endothelium was removed from the aortic ring entirely. The removal of this layer of cells should 
remove any endogenous NO affecting the results as eNOS will no longer be present in the 
experiment. This was also compared to eNOS inhibited with L-NAME aortic muscle.  
 
Graph 22: A group comparison of molecular inhibitors used on the effect of compound 94. Inhibitors 
were added ten minutes prior to the addition of methoxamine to allow time to act. Aorta rings were 
pre-contracted with 10-5 M methoxamine Data are means ± SEM. Statistical analysis was conducted 
comparing inhibitors with control compound 94 and significance is shown by P <0.05 = *; P <0.01 
= **; P <0.001= ***. (n = 5-7 animals). 
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Graph 22 shows that with the endothelium layer removed and no endogenous nitric oxide being 
produced, there is still 100% relaxation when the aortic rings are treated with compound 94. Almost 
identical profiles can be seen with the inclusion of a NOS inhibitor, confirming that compound 94 
works independently to that of endogenous NO production and the relaxation seen from compound 
94 is solely from the furoxan rings decomposition of this ring. The difference in the two profiles can 
be used to calculate how much NO endogenous contributes to the relaxation of aortic smooth muscle 
when compound 94 is applied. It can be concluded that compound 94 does produce relaxation of 
aortic smooth muscle in an independent process to that of SNP and with a larger Vmax.  
2.3.2- Is relaxation induced through potassium channels? 
 
The data for compound 94, upon inhibition of sGC (graph 18) and scavenging with Hb (graph 20), 
indicates that an alternative pathway to relaxation via a direct NO route is in operation here. 
Potassium channels have been shown to be involved in NO-mediated vasodilation.11-13 Potassium 
channels are found in most cell types and are involved in a number of other physiological processes 
such as neurotransmission and endocrine function, to which NO is also known to contribute. In these 
processes involving potassium channels there are four main classes14: Voltage-gated potassium 
channel (Kv), ATP-sensitive potassium channel (KATP), large conductance calcium-activated K 
channels (BK) and inward rectifier K channel (KIR). Voltage-gated potassium channels are by far 
the largest class, and are frequently used by biologists for experimentation and were hence used in 
this analysis.  
 
 
Figure 81: 4-Amino pyridine 209 and tetraethylammonium 210, two common potassium channel 
blockers that were used to assess the potential mechanism that compound 94 operates through in 
order to bring about the vasodilatory profiles seen previously. 
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To test the hypothesis that compound 94 was inducing relaxation by synergistically working with 
potassium channels, two different channel blockers (Fig. 81) were utilised. If no or less relaxation 
occurs when the potassium channels are blocked then it suggests that compound 94 induces dilation 
through the use of these channels. 4-Amimpyridine (4-AP) 209 and tetraethylammonium (TEA) 210 
are two commonly used potassium channel blockers, and were utilised in this experiment. 4-AP 209 
is known to block voltage-gated K+ channels and TEA is a known inhibitor of calcium dependent K+ 
channels. 
 
Graph 23: Comparison of different concentrations of the Kv channel blocker 4-aminopyridine 210. 
The channel blocker was allowed to incubate in the vessels for ten minutes before contraction. Aorta 
rings were pre-contracted with 10-5 M methoxamine. Data are means  SEM. Statistical analysis was 
conducted and significance is shown by P <0.05 = *; P <0.01 = **; P <0.001. According to a paired 
student’s t-test, the difference between the effect of the two concentrations is significant (P=0.0114). 
(n= 6-8 animals). 
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In the presence of 1 mM of 4-AP 209, there appears to be no effect on the relaxation profile of 
compound 94. It takes a 10 fold increase in K+ channel inhibitor to cause a difference in the relaxation 
profile. With a 10 mM concentration of 4-AP 209 inhibiting all potassium channels, it requires 10µM 
of compound 94 to induce vasodilation. This suggests that there is a correlation between furoxan-
mediated vasodilation and the voltage-gated potassium channel (Kv). This paradigm was confirmed 
by introduction of the second potassium channel blocker, TEA (graph 24).  
At a concentration of 10 mM TEA 211 produced a similar effect on relaxation to that of 4-AP 209. 
Compound 94’s IC50 in the presence of TEA is 10 µM compared to an IC50 of 0.2 µM without the 
presence of a K+ blocker. Combining both K+ channel blockers, prompted a dramatic effect on 
compound 94 induced relaxation increasing the IC50 to upwards of 50 µM. The action of two different 
potassium channel blockers indicates that compound 94 causes vasodilation from interaction with 
both voltage-gated and calcium dependent potassium channels. 
 
Graph 24: Comparison of each of the potassium channel blockers used in this investigation to 
elucidate which, if any potassium channels are implicated in compound 94-mediated vasodilation. 
Channel blockers were allowed to incubate in the vessels for ten minutes before contraction. Aorta 
rings were pre-contracted with 10-5 M methoxamine. Data are means  SEM. Statistical analysis was 
conducted and significance is shown by P <0.05 = *; P <0.01 = **; P <0.001  (N=6-8 animals). 
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Rat aorta rings were pre-contracted with methoxamine and left to incubate with the appropriate 
potassium channel inhibitor for 10 minutes before introduction of compound 94. Graph 24 shows 
that compound 94 is capable of reversing the inhibition of potassium channels and producing around 
80% relaxation of the aortic vessel, however this requires a large increase in concentration of the 
furoxan compound, upwards of 10 μM and 100% relaxation is still not observed. As vasodilation 
occurs in all blood vessels and not just the aorta, compound 94’s relaxation potential was tested 
against two other vessels and compared to the previous finding within the rat aorta. 
.  
Graph 25: A comparison of the regional effect of compound 94 in different vessels. All vessels were 
pre-contracted with 10-5 M methoxamine before addition of 94. These data were not obtained 
concurrently; renal and pulmonary artery results were obtained simultaneously on a myograph and 
the aorta data were obtained using organ baths.  Data are means  SEM (n= 5-7). 
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Graph 25 shows that compound 94 does produce effective relaxation in all three blood vessels. 
However, only 100% relaxation is seen for the aortic smooth muscle with the renal and pulmonary 
only being relaxed by 18 and 15% respectively. This effect may be due to the size of the respective 
blood vessels; the renal and pulmonary are considerably smaller in diameter than the aortic muscle 
and therefore have a slightly different vasculature. Smaller vessels contain other endothelium-
derived vasodilators such as prostacyclin and endothelium derived hyperpolarising factor (EDHF).15-
17 It can therefore be said that compound 94 is a more potent vasodilator for larger diameter vessels, 
which suggests potential applications linked to cardiac arrest for example. 
To be an effective pharmaceutical compound, the effects of compound 94-mediated vasodilation on 
blood vessels, needs to be assessed in even greater detail. Ideally its mode of action will be reversible 
and allow for repeated use once the initial effects have worn off. A common comparison compound 
is the effect of carbon monoxide (CO) on haemoglobin, an irreversible reaction which renders the 
protein out of action. To assess this potential, a two-curve protocol was used. Aortic vessels were 
contracted with methoxamine and re-dilated using 1 µM of compound 94 until its maxima was 
reached. The organ bath was then washed out and re-contracted at different time intervals. The results 
for this experiment are shown in graph 26. 
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Graph 26: Comparison between first and second response curves; initially contracting the aorta with 
methoxamine and relaxing with 1 µM of 94, and then allowing the vessel to rest for set periods of 
time before attempting to re-contract using methoxamine again. 
 
Graph 26 indicates that the process of vasodilation caused by compound 94 is a reversible one. Thirty 
minutes after the initial contraction and subsequent relaxation with compound 94 only 20% 
contraction was observed upon re-contraction with methoxamine 202. As more time passes towards 
that of 180 minutes, the ability of the smooth muscle to re-contact increases to that of 60%, 
suggesting that there is a lag time of at least 180 minutes before the aortic smooth muscle can be 
fully contracted again by methoxamine 202. 
 Biological tests conducted on compounds shown in Fig. 79 found that the majority of compounds 
induced vasodilation to some degree. Out of the compounds tested, all except compounds 90, 96 and 
204, managed to produce 100% reversal on the aortic rings that were pre-contracted with 
methoxamine. Compound 205 was found to be an effective vasoconstricting agent instead of 
inducing relaxation but is supported by the data found in the anti-cancer studies3. There is good 
evidence, in combination with the results from the NO release studies (chapter 2.2), that the 
Results and Discussion- Vasodilatory work 
192 | P a g e  
 
synthetically produced NO-donors are capable of releasing nitric oxide and in concentrations high 
enough to induce a biological effect. 
Isolation of the lead compound 94 enabled further insight into the potential mechanism of action of 
these furoxan based NO-donors. Results shown in graphs 18-20 indicate that relaxation does not 
occur by the sGC pathway as inhibition of this route still produced 100% relaxation by compound 
94. In the presence of a nitric oxide scavenger such as haemoglobin (Hb), 94’s activity was greatly 
diminished, only producing 20% relaxation. This observation confirms that 94 does induce 
vasodilation through the release of nitric oxide, but through an alternative mechanism to that of SNP 
9 and the sGC pathway. Further experiments alluded to the idea that relaxation is stimulated through 
the use of K+ channels. Graphs 23 and 24 indicate that with inhibition of these potassium channels, 
the effects of compound 94 are far less potent, needing 50x more furoxan to bring about full 
relaxation. Evidence was also found to suggest that the potency of compound 94 is vessel dependent, 
as 94 performed 10x better in the aortic vessel than it did in the renal and pulmonary arteries. 
However, this may be due to the relative size of the vessel but is nevertheless and interesting 
observation.  
When compared to an existing NO-donor, such as SNP 9, the results are interesting. Graphs 15-17 
show that SNP 9 is a better vasodilator under the conditions used, but compound 94 produces 100% 
relaxation at much lower concentrations than SNP (graph 15) in the aortic vessel. In the pulmonary 
artery (graph 17) SNP 9 fails to bring about 100% relaxation, whereas 10 μM of compound 94 
completely reverses methoxamine induced contraction.  
As SNP is the ‘gold standard’ NO donor used by our collaborators, compound 94’s relaxation profile 
is impressive. Although (as seen in graph 16) it is less potent than SNP, compound 94 produces a 
more sustained relaxation over time, suggesting that although a slightly higher concentration is 
needed initially, sequential doses may be needed less frequently. Compound 94’s relaxation profile 
was also found to be highly reproducible and reversible as shown in graph 26. After initial relaxation 
of the aortic vessel with compound 94, aortic cells were washed out and left for allotted time periods 
before being successfully re-contracted with methoxamine 202. This showed that over time 
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relaxation could be achieved again as the induction of vasorelaxation by compound 94 does not occur 
through a damaging process, and is in fact reversible and reproducible giving further scope to its use 
as a lead compound for any future biological work. 
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Chapter 3.0- Conclusions 
Conclusions drawn on results presented in chapter 2.0 
 
The aim of this project was to discover a method to successfully moderate the levels of nitric oxide 
in attempt to provide suitable compounds for the application of a variety of medical conditions known 
to be affected by the concentration of nitric oxide, such as angina, ischemia and Alzheimer’s disease. 
The synthesis of compounds that release nitric oxide under a variety of conditions was largely 
successfully. Furoxan compounds substituted in a logical and systematic way were synthesised using 
a combination of acetic acid and dilute nitric acid along with a catalytic amount of sodium nitrite 
(NaNO2). Furoxan compounds 86-128 were analysed for their ability to release NO using a Siever’s 
nitric oxide analyser (NOA); all compounds were found to release NO under both photochemical 
and oxidative conditions. The furoxan compounds appear to be photosensitive, releasing the majority 
of NO in the presence of light (254 nm) and as well as under conditions of ambient light.  
Collaborators at Kingston University tested the furoxan compounds for their ability to reverse 
methoxamine induced constriction of aortic, pulmonary and renal arteries. It was observed that all 
compounds bar 205 induced vasodilation of the vascular structure and produced IC50’s ranging from 
0.25-20.5 μM. Compound 205 in fact increased the constriction of the blood vessel passed that of 
methoxamine, and can therefore be considered of a vasoconstriction agent similar to that of 
combretastatin. Compound 94 substituted with an OCF3 group in the para position, produced an IC50 
of 0.25 μM. This led to its use as a lead compound in further biological tests and was found to induce 
100% relaxation of aortic smooth muscle and produced a more sustained relaxation compared to that 
of the BNP listed SNP. Analysis also showed that compound 94’s action on aortic smooth muscle is 
a reversible one, as with a suitable lag time (180 minutes) and introduction of methoxamine, re-
contraction could be brought about. This is obviously an advantageous attribute of compound 94 as 
it means that the vascular tone is not permanently changed in the presence of 94. 
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The stabilisation of the industry chelator cupferron 56 was also successful using simple alkylation 
chemistry. Serendipitous crystallisation also afforded the isolation of a single crystal structure of 
compound 103. This led to the confirmation that the site of alkylation was in fact on the terminal 
oxygen (shown in Fig. 54 in section 2.1.2.1, page 116) of cupferron as predicted. NO release work 
established that the alkylation chemistry had stabilised cupferron, with all compounds releasing less 
NO under the experimental conditions than the parent compound. Compound 103 was the most stable 
at both 25 and 37°C when compared to cupferron. All cupferron derivatives 99-101 and 103-105 
were capable of releasing nitric oxide under both photochemical and thermal conditions. The classic 
alkylation chemistry used, not only provided the desired cupferron derivatives but also produced 
evidence of some very interesting by-products. The intramolecular ring closure reaction produced 
the 8, 10 and 12 membered heterocycles (shown in Fig. 57 and 58 in section 2.1.2.1, page 118). The 
isolation of these ring systems had not been reported previously but was confirmed through the use 
of HRMS. In terms of increasing the levels of nitric oxide, a variety of novel NO-donors that are 
capable of producing nitric oxide under thermal, oxidative and photochemical conditions and 
therefore are a set of tailorable NO-donors, have been successfully synthesised. Biologically the NO-
donors tested were efficient in producing vasodilation in pre-contracted blood vessels. The cupferron 
series are yet to be tested as anti-cancer or vasodilatory agents but their comparison to the furoxan 
series will be very interesting.  
Reducing the levels of nitric oxide using NOS inhibitors remains a viable and relevant avenue to 
further explore. The rationale developed from the three-dimensional work in the KAVE (Keele 
Active Virtual Environment) is certainly very robust and compelling, especially with regard to the 
potential for hydrogen bonding interactions between nNOS inhibitors and the propionic acid 
functionality of the enzyme’s heam centre. An interesting literature precedent, using phenyl lithium 
to deprotonate the ortho position of trimethylpyridine has been successfully found and tested 
producing a successful alkylation albeit in low yield. With further optimisation of this reaction the 
nNOS inhibitors shown in section 1.3 can by synthesised. With the successful synthesis and 
purification of these inhibitors, further docking studies and testing can be conducted which may 
 Conclusions 
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allude to the key structural features being uncovered and ultimately allow an improvement in the 
potency and selectivity of nNOS inhibitors of this type. 
Experimental 
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Chapter 4.0- Experimental 
Synthesis, purification and characterisation of compounds 
All commercial solvents were purchased from either Sigma Aldrich or Ficher Scientific and unless 
otherwise stated were used without further purification. THF was distilled using sodium 
benzophenone under anhydrous conditions. Diethyl ether was stirred for 24 hours over calcium 
hydride under anhydrous conditions and used directly. N,N-Dimethylformamide was purchased in 
anhydrous form.  TLC plates used were silica gel 60 F254 (Merck) and detection was conducted using 
UV light or vanillin stain. Melting point determination was completed using a Bibby Stuart Scientific 
Melting point apparatus (uncorrected). 
IR spectra were recorded using Thermo Nicolet FT-IR Nexus with an Avatar Smart Omni Sampler 
and diamond crystal. Scan rate was set at a minimum of 32 scans. 1H NMR and 13C NMR spectra 
were obtained using Bruker Avance 300 operating at frequencies 300.13 and 75.47MHz respectively 
and referenced using the following internal standards. δH CDCl3: 7.24 ppm, DMSO: 2.50 ppm, δC 
CDCl3: 77.36 ppm, DMSO: 40.45 ppm.19F NMR spectra were obtained using a Bruker Avance 400 
operating at 376. 41 MHz and using the internal standard, δF CF3Cl: -28.6 ppm 
Accurate mass spectrometry data was obtained from NMSF (EPSRC National Mass Spectrometry 
Facility). The instrument used to obtain accurate mass data is noted after the mass data. LTQ Orbitrap 
refers to Thermofisher LTQ Orbitrap XL (High resolution instrument giving accurate mass 
measurement over the full mass range in electrospray), MAT 95 refers to Finnigan MAT 95 XP (EI, 
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3-(4-Iodophenyl)-4-(2,4,6-trimethoxyphenyl)-1,2,5-oxadiazole 2-oxide1, 80 
 
To a stirred solution of (1E,2E)-1-(4-iodophenyl)-2-(2,4,5-trimethoxyphenyl)ethane-1,2-dione 
dioxime (0.119g, 0.26mmol) in acetonitrile (10ml) copper (II) chloride (0.1g, 0.78mmol) and sodium 
perchlorate (0.19g, 1.56mmol) were added turning the solution green and then gradually turned a 
pale brown over the course of 12 hours. The resulting brown solution was poured into a separating 
funnel and upon standing revealed a green oil, which was then separated. This oil was dissolved in 
distilled water (5ml) before aqueous ammonia (30ml) was added, causing the solution to immediately 
turn a deep blue colour. The blue solution was left to stir vigorously for 3 hours before being extracted 
with chloroform (4 x 20ml). The combined organic layers were dried over MgSO4 and concentrated 
to give the title compound as a pale yellow solid, 0.2 g, 16%. δH (300 MHz, CDCl3) 4.19-4.10 (m, 
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3,4-Bis(3,4,5-trimethoxybenzoyl)-1,2,5-oxadiazole-2-oxide2, 3, 4, 86 
 
To a solution of 3,4,5-trimethoxyacetophenone, (5.0 g, 23.7 mmol) in glacial acetic acid (30ml.) 
dilute nitric acid (8 mL in 15ml H2O) was added drop-wise over the course of 30 minutes. A catalytic 
amount of NaNO2 was then added to the solution which was then heated to 60°C for 2 hours. TLC 
showed an incomplete conversion so the reaction was maintained at 60°C for a further 2 hours. The 
reaction was then cooled to room temperature and a small amount of ice was added to quench the 
reaction and to encourage precipitation. No precipitate formed, so the solution was extracted with 
DCM (3 x 30 mL). The combined extracts were washed with water (25 mL), brine (25 mL), and 
dried over MgSO4. The combined extracts were combined and reduced to give a red solid (3.23g), 
this was then purified by column chromatography (hexane:ethyl acetate 10:1 to 1:1, followed by 
100% ethyl acetate) to yield the title compound as red/orange solid 1.01 g, 9.0%, Rf: 0.86 (petroleum 
ether :ethyl acetate, 1:1)  Mp: 117.3-119.8°C (Lit Mp: 116-118°C4), IR (cm-1), 3099 C-H (Ar), 2943 
C-H (Ar), 2839 C-H (Methyl), 2659 C-H (Methyl), 1675 (C=O), 1606 (C=N), 1455 (C=N+-O-), 1331 
(Methyl), 1120 (C-O-Me), δH NMR (300 MHz, CDCl3)  3.75-3.94 (m, 18H), 7.01 (s, 1H), 7.36 (s, 
1H), 7.41 (s, 2H), δC NMR (75 MHz, CDCl3) 56.2 (2 x OCH3), 56.3 (2 x OCH3), 60.9 (2 x OCH3), 
101.1 (2 x Ar-C), 111.9 (C=N+-O-), 128.5 (2 x Ar-C), 128.7 (Ar-C), 144.5 (Ar-C), 144.5 (C=N), 
152.7 (2 x Ar-COCH3), 153.1 (2 x Ar-COCH3), 153.2 (2 x Ar-COCH3), 179.0 (C=O), 180.3 (C=O). 
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3,4-Bis(4-ethylbenzoyl)-1,2,5-oxadiazole 2-oxide2,3,4, 87 
 
To a solution of 4-ethylacetophenone (2.9g, 20.0mmol) in acetic acid (30ml), dilute nitric acid (12.5 
ml in 18ml H2O) was added drop-wise over the course of 30 minutes. The reaction was slowly heated 
to 55°C and a catalytic amount of NaNO2 was added causing the evolution of brown fumes and 
turning the solution an orange colour. The reaction was left to stir at 55°C for 2 hours, at which time 
more NaNO2 was added and the reaction left for a further 2 hours. The reaction was then cooled to 
room temperature and then added drop-wise onto ice to produce a yellow precipitate of the title 
compound, 2.2g 29%. Mp: 78.8-79.6°C, IR (cm-1): 2964, 2930, 2872, 1677, 1600 (C=N), 1457 
(C=N+-O-), 1245, 895. δH (300 MHz, CDCl3) 1.26 (dd, J = 6.8, 6.8 Hz, 6H), 2.73 ( q, J = 7.62, 7.62, 
7.62, 7.62 Hz, 4H), 7.51-7.02 (m, 4H), 7.84-7.73 (m, 2H), 8.12 (m, 2H) δC (75 MHz, CDCl3) 14.9, 
15.0, 29.2 (2C), 111.9 (C=N+-O-) 128.5 (2C), 128.8 (2C), 129.9 (2C), 130.8 (2C), 131.5, 131.6, 
152.8, 153.0, 154.5 (C=N), 180.0 (C=O), 181.3 (C=O). MS: theoretical (m/z): 357.1159. Actual: 
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3,4-Bis(4-methylbenzoyl)-1,2,5-oxadiazole 2-oxide2 88 
 
 
4-Methylacetophenone (5.0g, 37.3mmol) was dissolved in acetic acid (30 ml) and heated to 60°C 
under reflux conditions.  Dilute HNO3 (8ml in 20ml H2O) was added drop-wise to the solution over 
the course of 30 minutes. A catalytic amount of NaNO2was added and the reaction was left to reflux 
for a further 2 hours.  The reaction was then left to cool, but no precipitate formed so the solution 
was extracted with DCM and dried over MgSO4, and concentrated in vacuo. The resulting solid was 
then purified further using flash column chromatography, 10:1 (petroleum ether:ethyl acetate) to give 
a yellow oil of the title compound, 0.26g, 2%. Rf: 0.93 (petroleum ether: ethyl acetate 1:1) Mp:110-
114°C (Lit value5: 123-125°C), IR (cm-1), 3271 C-H (Ar), 2923 C-H (Methyl), 2854 C-H (Methyl), 
1674 (C=O), 1661 (C=O), 1602 (C=N), 1471 (C=N+-O-), 775 (C-H bend), 753 (C-H), δH (300 MHz, 
CDCl3)  2.43 (s, 3H), 2.46 (s, 3H), 7.33 (dd, J= 8.04, 11.62 Hz, 4H), 7.78 (d, J= 8.25 Hz, 2H), 8.12 
(d, J= 8.25 Hz, 2H) δC (75 MHz, CDCl3)  21.9 (CH3), 22.0 (CH3), 111.9 (C=N+), 129.7 (2C Ar-C), 
129.8 (2C Ar-C), 129.9 (4C Ar-C), 130.7 (C-C=O), 131.4 (C-C=O), 146.8 (C-CH3), 147.0 (C-CH3), 
154.5 (C=N), 180.0 (C=O), 181.3 (C=O). MS: theoretical (m/z) 324.1060, Actual: 323.1020 
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3,4-bis(4-chlorobenzoyl)-1,2,5-oxadiazole 2-oxide2,3 89 
 
To a solution of 4-chloroacetophenone (3.0g, 19.5 mmol) in acetic acid (30ml), dilute nitric acid 
(12.5 ml in 18ml H2O) was added drop-wise over the course of 30 minutes. The reaction was slowly 
heated to 55°C and a catalytic amount of NaNO2 was added causing the evolution of brown fumes 
and turning the solution an orange colour. The reaction was left to stir at 55°C for 2 hours, cooled 
and poured drop-wise on to ice. A white solid was filtered off and recrystallized from DCM to give 
a fine white powder 1.37g 19.4%, Rf: 0.4 (1:1 petroleum ether:ethyl acetate),  Mp: 116.4-117.8°C 
(Lit value6: 124°C), IR (cm-1): 3093, 1680, 1661, 1584 (C=N), 1487 (C=N+-O-), 1239, 1088. δH (300 
MHz, CDCl3) 7.55-7.52 (m, 4H), 7.58-7.49 (m, 2H), 7.86-7.76 (m, 1H), 8.18 (m, 1H), δC (75 MHz, 
CDCl3) 111.3 (C=N+-O-), 129.5 (2C), 129.7 (2C), 131.0 (4C), 131.9 (2C), 142.4 (2C), 154.0 (C=N), 
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3,4-Bis(4-bromobenzoyl)-1,2,5-oxadiazole 2-oxide2,7 90 
 
4-Bromoacetophenone (10.0g, 50.5mmol) was dissolved in acetic acid (53 ml) and heated to 80°C 
under reflux conditions.  Dilute HNO3 (11.9ml in 35ml H2O) was added drop-wise to the solution 
over the course of 30 minutes. A catalytic amount of NaNO2 was added and the reaction was left to 
reflux for a further 2 hours. The reaction was then left to cool, forming a precipitate which was then 
filtered off. The filtrate was extracted with DCM and dried over MgSO4, and concentrated in vacuo. 
The resulting solid was then recrystallized from hot DCM, producing a white precipitate which 
corresponded to the by-product 4-bromobenzoic acid. The recrystallization was repeated a further 
four times but the TLC still showed two spots so the final filtrate was then reduced to yield a pale 
yellow solid and purified further using flash column chromatography, 8:1 (petroleum ether:ethyl 
acetate) to give white needles of the title compound 2.97g, 12%. Rf: 0.92 (petroleum ether:ethyl 
acetate, 1:1), Mp: 123.3-124.4°C (Lit value7: 128°C). IR (cm-1) 2923 C-H (Ar), 1675 (C=O), 1651 
(C=O) 1601 (C=N), 1470 (C=N+-O-), 1326 (N-O), 754 (C-Br). δH (300MHz, d6-DMSO) 7.81 (d, J = 
8.62 Hz, 2H), 7.88 (d, J = 8.66 Hz, 2H), 7.94 (d, J = 8.62 Hz, 2H), 8.08 (d, J = 8.67 Hz, 2H). δC 
(75MHz, d6-DMSO) 112.4 (C=N+-O-), 129.9 (C-Br), 130.0 (Ar C-C), 131.4 (Ar C-C), 132.0 (Ar C-
H, 2C), 132.34 (Ar C-H, 4C), 132.7 (Ar C-C, 2C), 132.8 (C-Br), 153.9 (C=N), 180.0 (C=O), 181.5 
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To a solution of 4-iodoacetophenone (3.3g, 12.2mmol) in acetic acid (30ml), dilute nitric acid (12.5 
ml in 18ml H2O) was added drop-wise over the course of 30 minutes. The reaction was slowly heated 
to 55°C and a catalytic amount of NaNO2 was added causing the evolution of brown fumes and 
turning the solution an orange colour. The reaction was left to stir at 55°C for 2 hours, cooled and 
poured drop-wise on to ice. A pink solid was filtered off and washed with water (5ml) to give a 
yellow solid of the title compound, 1.1g. 15%.  Rf: 0.94 (1:1 petroleum ether:ethyl acetate)  IR (cm-
1): 3091, 1685, 1659, 1576 (C=N), 1469 (C=N+O-), 1176, 794. δH (300MHz, CDCl3) 7.61-7.45 (m, 
4H), 7.92 (m, 4H) δC (75MHz, CDCl3) 105.1, 105.2, 112.3 (C=N+-O-), 130.8, 131.5, 132.9 (2C), 
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3,4-Bis(4-methoxybenzoyl)-1,2,5-oxadiazole 2-oxide2 92 
 
4-Methoxyacetophenone (5.0g, 30.0mmol) was dissolved in acetic acid (35 ml) and heated to 60°C 
under reflux conditions.  Dilute HNO3 (8ml in 20ml H2O) was added drop-wise to the solution over 
the course of 30 minutes. A catalytic amount of NaNO2 was added and the reaction was left to reflux 
for a further 2 hours.  The reaction was then left to cool, but no precipitate formed so the solution 
was extracted with DCM and dried over MgSO4, and concentrated in vacuo. The resulting crude 
yellow solid (4.54g) was then purified further using flash column chromatography, 10:1 (petroleum 
ether:ethyl acetate) to give a pale yellow solid of the title compound, 2.24g, 21%  Rf: 0.88 (petroleum 
ether:ethyl acetate, 1:1), Mp: 127.0-128.0°C (Lit value5: 138°C), IR (cm-1) 3298 (C-H Ar), 3045 (C-
H Ar), 2938 (C-H Methyl), 2843 (C-H Methyl), 1653 (C=O), 1594 (C=N), 1439 (C=N+-O-), 1327 
(NO), 1172 (C-O), 1163 (C-O). δH (300 MHz, CDCl3) 3.92 (s, 3H), 3.94 (s, 3H) 7.02 (m, 2H), 7.83-
7.91 (m, 4H), 8.24 (m, 2H). δC (300 MHz, CDCl3) 55.7 (2 x OCH3), 112.2 (C=N+-O-) 114.3, 114.6, 
126.7 (2C Ar-C), 126.9 (2C Ar-C), 132.4(2C Ar-C), 133.2 (2C Ar-C),  154.8 (C=N), 165.4 (C-
OCH3), 165.5 (C-OCH3), 178.8 (C=O), 179.9 (C=O), MS: theoretical (m/z) 354.0852, Actual: 
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3,4-Bis(4-ethoxybenzoyl)-1,2,5-oxadiazole 2-oxide 93 
 
To a solution of 4-ethoxyacetophenone (3.3g, 20.0mmol) in acetic acid (30ml), dilute nitric acid 
(12.5 ml in 18ml H2O) was added drop-wise over the course of 30 minutes. The reaction was slowly 
heated to 55°C and a catalytic amount of NaNO2 was added causing the evolution of brown fumes 
and turning the solution an orange colour. The reaction was left to stir at 55°C for 2 hours, cooled 
and poured dropwise on to ice. No filterable solid was recovered so the aqueous solution was 
extracted with ethyl acetate (3 x 50ml), washed with brine (50ml) and dried over MgSO4 and the 
solvent removed to give a crude orange gum (1.35g). This was then purified by silica-gel 
chromatography (petroleum ether : ethyl acetate, 10:1) to give a white solid of the titled compound 
0.21g, 2.1%, Rf: (petroleum ether:ethyl acetate, 10:1), Mp: 132.0-133.0°C (Lit value8: 131-134°C), 
IR (cm-1): 3062, 2976, 2890, 1674, 1648, 1615 (C=N), 1471 (C=N+-O-), 1258, 1227, 1127.  
 δH (300MHz, CDCl3) 1.37 - 1.49 (m, 6 H), 4.05 - 4.17 (m, 4 H) 6.88 - 7.04 (m, 4 H), 7.82 (d, J=9.04 
Hz, 2 H) 8.18 (d, J=9.04 Hz, 2 H),  δC (75MHz, CDCl3) 14.5 (2C), 64.1 (2C), 112.4 (C=N+-O-), 114.7 
(2C), 114.9 (2C), 126.5 (2C), 126.6 (2C), 132.4 (2C), 154.8 (C=N), 164.8 (C-OCH2), 164.9 (C-
OCH2), 178.6 (C=O), 179.8 (C=O). MS: theoretical mass (m/z) 382.1238 Actual: 383.1236 ± 0.4 
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3,4-Bis(4-(trifluoromethoxy)benzoyl)-1,2,5-oxadiazole 2-oxide3 94 
 
To a solution of 4-trifluoromethoxyacetophenone, (5.0g, 24.5 mmol) in glacial acetic acid (30ml.) 
dilute HNO3 (8 mL in 12ml H2O) was added drop-wise over the course of 30 minutes. A catalytic 
amount of NaNO2was then added to the solution which was then heated to 60°C for 2 hours. TLC 
showed an incomplete conversion so the reaction was maintained at 60°C for a further 2 hours. The 
reaction was then cooled to room temperature and a small amount of ice was added to quench the 
reaction and to encourage precipitation. No precipitate formed, so the solution was extracted with 
DCM (3 x 30 mL). The combined extracts were washed with water (25 mL), brine (25 mL) and dried 
over MgSO4. The combined extracts were concentrated to give a yellow oil (5.3g). The yellow oil 
was purified by column chromatography (hexane: ethyl acetate 10:1 to 1:1, followed by 100% ethyl 
acetate) to yield the title compound as a yellow oil 2.55g, 23%. Rf: 0.6 (hexane:ethyl acetate 1:1), 
Mp: 58°C, IR (cm-1) 3116 (Ar-H), 2988, 2900, 1694 (C=O), 1693 (C=O), 1600 (C=N), 1475 (C=N+-
O-), 1309, 1246, 1202 1155. δH (300 MHz, d6-DMSO) 7.58 (dd, J = 19.71, 8.34 Hz, 4H), 8.16 (d, J 
= 7.42 Hz, 2H), 8.29 (d, J = 7.42 Hz, 2H). δC (d6-DMSO, 75 MHz) 112.5 (C=N+-O-),  118.1(2C), 
120.6 (2C), 120.9 (2C), 120.9 , 121.5, 131.6, 132.2 (2C), 132.8 (2C), 152.9, 153.9 (C=N), 179.5, 
181.5, δF {1H} (CDCl3, 376 MHz) -57.5 (6F). MS (m/z) theoretical: 462.0286. MS (m/z) actual: 
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3,4-Bis(4-(trifluoromethyl)benzoyl)-1,2,5-oxadiazole 2-oxide3 95 
 
To a solution of 4-trifluoromethylacetophenone, (5.0g, 27.7 mmol) in glacial acetic acid (30ml), 
dilute nitric acid (8 mL in 15ml H2O) was added drop-wise over the course of 30 minutes. A catalytic 
amount of NaNO2was then added to the solution which was then heated to 60°C for 2 hours. TLC 
showed an incomplete conversion so the reaction was maintained at 60°C for a further 2 hours. The 
reaction was then cooled to room temperature and a small amount of ice was added to quench the 
reaction and to encourage precipitation. No precipitate formed, so the solution was extracted with 
DCM (3 x 30 mL). The combined extracts were washed with water (25 mL), brine (25 mL), and 
dried over MgSO4. The combined extracts were purified by column chromatography (hexane: ethyl 
acetate 10:1 to 1:1, followed by 100% ethyl acetate) to yield the titled compound 2.3g, 20%. Rf: 0.8 
(hexane:ether, 3:1), Mp: 76.0-77.9°C, IR (cm-1) 1690 (C=O), 1677 (C=O), 1623 (C=N), 1515, 1470 
(C=N+-O-), 1411, 1315. δH (300MHz, d6-DMSO) 7.97 (dd, J = 8.38 Hz, J = 18.40 Hz, 4H), 8.21 (d, 
J = 8.10 Hz, 2H), 8.34 (d, J = 8.10 Hz, 2H) ). δC (75MHz, d6-DMSO) 112.45 (C=N+-O-), 126.0 (CF3), 
126.0 (CF3), 130.2 (2x C=OC-CH), 130.9 (2 xC=OCCH), 133.9 (2x C-CF3), 134.3 (4x Ar-C), 136.9 
(C=O-C), 137 (C=O-C), 153.8 (C=N), 180.3 (C=O), 181.7 (C=O), δF {1H} (CDCl3, 376 MHz) –63.4 
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3,4-Bis(4-(trifluoromethyl)phenyl)-1,2,5-oxadiazole 2-oxide9, 10 96 
 
To a stirred solution of (E)-N-hydroxy-4-(trifluoromethyl)benzimidoyl chloride (0.93g, 4.17mmol) 
in dry diethyl ether (5ml), dry pyridine (0.34ml, 4.17mmol) was added. The reaction was monitored 
by TLC (7:3 petroleum ether:ethyl acetate) and left to stir overnight. The precipitate was filtered off 
and dried in air to give the title compound 0.09g, 5.8%, Mp: 96°C, IR (cm-1): 1694 (C=O) 1599 
(C=O), 1600 (C=N), 1470 (C=N+-O-), 1155 (C-O), δH (300 MHz, d6-DMSO)  7.40-7.65 (m, 4H), 8.1 
(d, J = 8.0 Hz, 2H), 8.3(d, J = 8.0 Hz, 2H). δC (75MHz, d6-DMSO) 121.23 (C=N+-O-), 123.30 (2C, 
CF3), 125.74 (4C), 129.97 (2C, C-CF3), 130.59 (4C), 130.95 (2C, Ar-C), 160.46 (C=N). MS 
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(Z)-2-Ethoxy-1-phenyldiazene oxide11 98 
 
Cupferron (5.0g, 32.2 mmol) was dissolved in dry DMF (40ml) under nitrogen conditions and cooled 
to 0°C before 1-bromoethane (7.21ml, 96mmol) was injected. The resulting yellow solution was left 
to stir at room temperature in the dark for 3 days. The DMF was then removed via a cold finger 
apparatus resulting in a dark brown/black sludge which was purified using flash column 
chromatography in petroleum ether:ethyl acetate (1:1) to give a brown oil of the title compound 1.47g 
27%, Rf: 0.57 (petroleum ether:ethyl acetate 1:1), δH NMR (300 MHz, CDCl3) 0.76 (t, J = 7.12 Hz, 
3H), 3.80 (q, J = 7.12 Hz, 2H), 6.96-6.59 (m, 3H), 7.31 (dd, J = 5.93, 1.57 Hz, 2H) δC (75MHz, 
CDCl3), 13.9, 69.9, 120.3(2C), 128.4, 130.6 (2C), 142.6. MS: theoretical 166.1057 m/z. Actual: 
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(Z)-2-Butoxy-1-phenyldiazene oxide11 99 
 
Cupferron (2.0g, 12.8 mmol) was dissolved in dry DMF (40ml) under nitrogen conditions and cooled 
to 0°C before 1-bromoebutane (4.08ml, 38mmol) was injected. The resulting yellow solution was 
left to stir at room temperature in the dark for 3 days. The DMF was then removed via a cold finger 
apparatus resulting in a dark brown/black sludge which was purified using flash column 
chromatography in petroleum ether:ethyl acetate (1:1) to give a brown oil of the titled compound 
0.25g 10% Rf: 0.6 (petroleum ether:ethyl acetate 1:1). IR(cm-1): 3095, 2983, 2900, 1471, 1436, 1033, 
1021, 817, δH NMR (300 MHz, CDCl3) 0.95 (t, J = 7.37 Hz, 3H) 1.82 (td, J = 14.68, 6.92, Hz, 2H), 
1.54-1.35 (m, 2H), 4.44 (t, J = 6.78, 6.78 Hz, 2H), 7.56-7.34 (m, 3H), 7.96 (m, 2H) δC (75 MHz, 
CDCl3) 13.7, 18.8, 30.9, 74.7, 121.0, 128.0 (2C), 131.1 (2C,) 143.1. MS: theoretical 195.1128, actual 
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(Z)-2-(hexyloxy)-1-phenyldiazene oxide11 100 
 
Cupferron (5g, 32 mmol) was dissolved in dry DMF (40ml) under nitrogen conditions and cooled to 
0°C before 1-bromohexane (13.5ml, 96mmol) was injected. The resulting yellow solution was left 
to stir at room temperature in the dark for 3 days. The DMF was then removed leaving a dark 
brown/black sludge (4.56g) which was purified using flash column chromatography in petroleum 
ether:ethyl acetate (4:1) to give a yellow/brown oil of the title compound 2.57g, 36%, Rf: 0.35 (1:1 
petroleum ether:ethyl acetate), IR(cm-1): 3421 (Ar-H), 2937 (CH2), 1681 (N=N), 1477 (N+-O-), 1033, 
913, 744,  δH (300 MHz, CDCl3) 0.95-0.76 (m, 3H), 1.27-1.35 (m, 6H), 1.68-1.91 (m, 2H), 4.43 (t, J 
= 6.87 Hz, 2H), 7.67-7.14 (m, 3H), 7.97 (m, 2H), δC (75 MHz, CDCl3) 13.9, 22.5, 25.2, 28.9, 31.4, 
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(Z)-2-(Octyloxy)-1-phenyldiazene oxide11 101 
 
Cupferron (10.0g, 64.5mmol) was dissolved in dry DMF (40ml) under nitrogen and cooled to 0°C. 
To this suspension, 1-bromooctane (3.68ml, 21.3mmol) was injected forming a dark yellow/brown 
solution. The reaction was left to stir at room temperature for 3 days. The DMF was then removed 
using a cold finger apparatus resulting in a dark brown tar (6.81g). This was then purified using silica 
gel chromatography, petroleum ether:ethyl acetate (4:1), to give a dark brown oil of the title 
compound, 1.45g, 9.06%, Rf: 0.78 (1:1 petroleum ether: ethyl acetate), IR(cm-1): 2925 (Ar-H), 2855 
(CH2), 1582, 1503 (N=N), 1476 (N+-O-), 1030, 1015, 764, δH (300 MHz, CDCl3) 0.86 (d, J = 1.76 
Hz, 3H), 1.33 (d, J = 46.24 Hz, 10H), 1.83 (s, 2H), 3.97-4.74 (m, 2H), 7.79-6.99 (m, 3H), 7.92 (m, 
2H), δC (75 MHz, CDCl3) 14.1, 22.6, 25.5, 29.0, 29.1, 29.2, 31.7, 75.0, 121.0, 128.9 (2C), 131.1 (2C), 
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(1Z,1'Z)-2,2'-(Butane-1,4-diylbis(oxy))bis(1-phenyldiazene oxide)11 103 
 
Cupferron (10.03g, 64.51mmol) was dissolved in dry DMF (85ml) under nitrogen and cooled to 0°C. 
To this suspension 1,6-dibromobutane (2.55ml, 20mmol) was injected forming a yellow solution. 
The reaction was left to stir at room temperature for 1 week resulting in a dark brown/red solution. 
The DMF was removed using a cold finger apparatus giving a dark brown sludge. This sludge was 
re-dissolved in DCM (30ml) and extracted with water (3 x 50ml). The organic layers were combined, 
dried over MgSO4 and the solvent removed in vacuo. The product was then purified using flash 
column chromatography in 8:1 petroleum ether: ethyl acetate followed by 4:1 and 1:1 petroleum 
ether:ethyl acetate. This produced a brown oil, which was recrystallized from ethyl acetate yielding 
a light brown crystalline compound. 1.5g 7%, Rf: 0.67 (1:1 petroleum ether: ethyl acetate), Mp: 
100.0-100.9°C, IR(cm-1): 2952 (Ar-H), 2887 (Ar-H), 2358 (C-H), 1474 (N=N), 1436 (N+-O-), 1051, 
1040, 768, δH (300 MHz, CDCl3) 2.06 (t, J = 2.7, 4H), 4.33-4.43 (m, 4H), 7.65-7.33 (m, 6H), 7.98 
(m, 4H). δC (75 MHz. CDCl3) 25.4(2C), 74.2 (2C), 121.15 (4C), 129.0 (4C), 131.2 (2C), 143.2 (2C), 
1H-15N HSQC (40MHz, CDCl3) -22.5, 312.7, MS theoretical: 331.1401 m/z, Accurate: 331.1402 ± 
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(1Z,1'Z)-2,2'-(Hexane-1,6-diylbis(oxy)bis(1-phenyldiazene oxide)11 104 
 
Cupferron (10.06g, 64.8mmol) was dissolved in dry DMF (85ml) under nitrogen and cooled to 0°C. 
To this suspension 1,6-dibromohexane (3.06ml, 20mmol) was injected forming a yellow solution. 
The reaction was left to stir at room temperature for 1 week resulting in a dark brown/red solution. 
The DMF was removed using a cold finger apparatus giving a dark brown sludge. This sludge was 
re-dissolved in DCM (30ml) and extracted with water (3 x 50ml). The organic layers were combined, 
dried over MgSO4 and the solvent removed in vacuo. The product was then purified using flash 
column chromatography in 8:1 petroleum ether: ethyl acetate followed by 4:1 and 1:1 petroleum 
ether:ethyl acetate to give a dark brown oil 1.27g, 6.6%, IR(cm-1): 2960 (Ar-H), 2920 (C-H) 1470 
(N=N), 1424 (N+-O-), 1386, 1036, 1020, 769, δH (300 MHz, CDCl3) 1.3 -1.50 (m, 4H), 1.94-1.77 (m, 
4H), 3.63 (t, J = 6.45Hz, 2H), 4.44 (t, J = 6.73Hz, 2H), 7.40-7.56 (m, 6H), 7.97 (m, 4H), δC (75 MHz, 
CDCl3) 25.4 (2C), 28.9 (2C), 74.8 (2C), 121.1 (2C), 128.9 (4C), 131.2 (4C), 143.1 (2C), MS (m/z) 
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(1Z,1'E)-2,2'-(Octane-1,8-diylbis(oxy)bis(1-phenyldiazene oxide)11 104 
 
Cupferron (10g, 64mmol) was dissolved in DMF (40ml) under nitrogen and cooled to 0°C. To this 
suspension 1,8-Dibromooctane (3.9ml, 21.3mmol) was injected giving a dark brown solution. This 
solution was left to stir for 3 days before the DMF was removed using a cold finger apparatus to 
yield a dark brown gum (3.8g). This was then purified using silica-gel chromatography 9:1 petroleum 
ether:ethyl acetate to give a brown oil of the titled compound 0.45g, 1.8%. Rf: 0.73 petroleum 
ether:ethyl acetate (9:1), δH (300 MHz, CDCl3) 1.30-1.57 (m, 8H), 1.78-1.97 (m, 4H), 4.45 (t, J = 
6.81Hz, 4H), 7.38-7.62 (m, 6H), 8.00 (m, 4H), δC (75 MHz, CDCl3) 25.4 (2C), 28.8 (2C), 29.0 (2C), 
74.9 (2C), 120.9 (2C), 128.9 (4), 131.1 (4C), 143.0 (2C). MS: theoretical 387.2027, Actual: 387.2027 
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(Z)-2-(8-Bromoethoxy)-1-phenyldiazene oxide11 113 
 
Cupferron (5.0g, 32.3 mmol) was dissolved in dry DMF (40ml) under nitrogen conditions and cooled 
to 0°C before dibromoethane (7.21ml, 96mmol) was injected. The resulting yellow solution was left 
to stir at room temperature in the dark for 3 days. The DMF was then removed via a cold finger 
apparatus resulting in a dark brown/black sludge which was purified using flash column 
chromatography in petroleum ether:ethyl acetate (1:1) to yield the title compound as a brown oil, 
0.35g, 2.05%, δH (300 MHz, CDCl3) 3.66 (t, J = 6.78Hz, 2H), 4.70 (t, J = 6.78, 6.78 Hz, 2H), 7.54-
7.45 (m, 3H), 7.97 (m, 2H), δC (75 MHz, CDCl3) 27.8, 73.4, 121.1, 129.0 (2C), 131.5 (2C), 143.0. 
















Cupferron (10.03g, 64.8mmol) was dissolved in dry DMF (85ml) under nitrogen and cooled to 0°C. 
To this suspension 1,6-dibromobutane (2.55ml, 20mmol) was injected forming a yellow solution. 
The reaction was left to stir at room temperature for 1 week resulting in a dark brown/red solution. 
The DMF was removed using a cold finger apparatus giving a dark brown sludge. This sludge was 
re-dissolved in DCM (30ml) and extracted with water (3 x 50ml). The organic layers were combined, 
dried over MgSO4 and the solvent removed in vacuo. The product was then purified using flash 
column chromatography in 8:1 petroleum ether:ethyl acetate followed by 4:1 and 1:1 petroleum 
ether:ethyl acetate to yield the title compound as a brown/yellow gum 0.7g, 20%. δH (300 MHz, 
CDCl3) 1.77-1.86 (m, 4H), 3.28 (t, J = 6.25Hz, 2H), 4.28 (t, J = 6.02 Hz, 2H), 7.11-7.40 (m, 3H), 
7.79 (m, 2H), δC NMR (75 MHz, CDCl3) 27.5, 28.7, 33.2, 73.6, 120.9, 128.9 (2C), 131.2 (2C), 142.9, 














Cupferron (10.0g, 64.8mmol) was dissolved in dry DMF (85ml) under nitrogen and cooled to 0°C. 
To this suspension 1,6-dibromohexane (3.06ml, 20mmol) was injected forming a yellow solution. 
The reaction was left to stir at room temperature for 1 week resulting in a dark brown/red solution. 
The DMF was removed using a cold finger apparatus giving a dark brown sludge. This sludge was 
re-dissolved in DCM (30ml) and extracted with water (3 x 50ml). The organic layers were combined, 
dried over MgSO4 and the solvent removed in vacuo. The product was then purified using flash 
column chromatography in 8:1 petroleum ether: ethyl acetate followed by 4:1 and 1:1 petroleum 
ether:ethyl acetate to give a dark brown oil of the title compound, 0.7g 3.6%, δH (300 MHz, CDCl3) 
1.12-1.41 (m, 4H), 1.58-1.77 (m, 4H), 3.26 (t, J = 6.69 Hz, 2H), 4.30 (t, J = 6.60 Hz, 2H), 7.17-7.46 
(m, 1H), 7.91 (m, 2H) δC (75 MHz, CDCl3) 24.8, 27.7, 28.7, 32.5, 33.9, 74.9, 121.0, 129.0 (2C), 














Cupferron (10.0g, 64.8mmol) was dissolved in DMF (40ml) under nitrogen and cooled to 0°C. To 
this suspension 1,8-dibromooctane (3.9ml, 21.3mmol) was injected giving a dark brown solution. 
This solution was left to stir for 3 days before the DMF was removed using a cold finger apparatus 
to yield a dark brown gum (3.8g). This was then purified using silica-gel chromatography 9:1 
petroleum ether:ethyl acetate to give a brown oil of the title compound 0.91g, 4.3%, δH  (300 MHz, 
CDCl3) 0.90-1.22 (m, 6H), 1.27 (d, J = 5.79 Hz, 2H),  1.54 (m, 2H), 1.73 (d, J = 2.33 Hz, 2H), 3.33 
(t, J = 6.19 Hz, 2H), 4.15 (t, J = 6.34 Hz, 2H), 7.00-7.26 (m, 3H), 7.69 (d, J = 7.52 Hz, 2H), δC 

















3-Iodobenzyl bromide (5.0g, 16.0mmol) was dissolved in dry THF (25ml) under an atmosphere of 
nitrogen before, triphenylphosphine (5.74g, 21.0mmol) in dry THF (15ml) was added. The resulting 
milky solution was allowed to reflux at 55°C for 24 hours. A white precipitate formed, which was 
filtered off and washed with ice cold hexane (5ml) and diethyl ether (5ml), and dried under vacuum 
to give a white powder 10.1g 86%, Mp: 286.5°C, IR(cm-1):3052 (Ar-H), 2852 (Ar-H), 2775 (Ar-H), 
1483 (P-Ph), 1434 (P-Ph), 1108 (P-Ph), 723, 694  δH (300 MHz, CDCl3) 5.53 (d, J = 14.63 Hz, 2H), 
6.90 (t, J = 7.82, Hz, 1H), 7.07 (s, 1H), 7.44 (d, J = 7.76 Hz, 1H), 7.52 (d, J = 7.87 Hz, 1H), 7.65 (m, 
8H), 7.80 (m, 7H) δC (75 MHz, CDCl3) 29.7, 30.3, 94.4, 117.0, 118.2, 130.0 (7C), 130.2 (7C), 134.4 
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(4-Iodobenzyl)triphenylphosphonium bromide12  
 
4-Iodobenzyl bromide (5.0g, 16.0mmol) was dissolved in dry THF (25ml) under an atmosphere of 
nitrogen, triphenylphosphine (5.74g, 21.0mmol) in dry THF (15ml) was then added. The resulting 
milky solution was allowed to reflux at 55°C for 24 hours. A white precipitate formed, which was 
filtered off and washed with ice cold hexane (5ml) and ether (5ml), and dried under vacuum to give 
a white powder, 10.3g, 88%, Mp: 270.9-271.1°C, IR(cm-1): 3319 (Ar-H), 3008 (Ar-H), 2900 (Ar-H), 
2790 (Ar-H), 1487 (P-Ph), 1436 (P-Ph), 1109 (P-Ph), 1074 (P-Ph), 761, 529.  δH (300 MHz, CDCl3)  
5.55 (d, J = 14.78 Hz, 2H), 6.93 (dd, J = 8.39, 8.40 Hz, 2H), 7.42 (d, J = 8.30 Hz, 2H), 7.64 (m, 6H), 
7.84-7.73 (m, 9H) δC (75 MHz, CDCl3) 29.7, 30.4, 94.4 (C-I), 117.1, 118.2, 130.0 (7C), 130.2 (7C), 
















4-Bromobenzyl bromide (10.0g, 54.0mmol) was dissolved in dry THF (60ml) under an atmosphere 
of nitrogen, triphenylphosphine (23.3g, 54.0mmol) in dry THF (15ml) was then added. The resulting 
milky solution was allowed to reflux at 55°C for 24 hours. A white precipitate formed, which was 
filtered off and washed with ice cold hexane (5ml) and ether (5ml), and dried under vacuum to give 
a white powder, 10.3g, 88%, Mp: 265.4-266.1°C, IR (cm-1) 3061 (Ar-H), 3008 (Ar-H), 2901 (Ar-H), 
2791 (C-H), 1488 (P-Ph), 1437 (P-Ph), 1109 (P-Ph), 692 (C-Br),  δH (300 MHz, CDCl3) 5.53 (d, 
J=14.88 Hz, 2 H) 6.99 - 7.09 (m, 2 H) 7.13 - 7.22 (m, 2 H) 7.53 - 7.65 (m, 7 H) 7.68 - 7.83 (m, 8 H), 
δC (75 MHz, CDCl3) 29.5, 116.9, 117.8, 122.5 (C-Br), 122.5 (C-P, 3C), 130.0 (6C), 130.1, 131.6, 















To a stirred solution of 3-iodobenzyl triphenylphosphonium bromide (1.99, 6.49mmol) in dry THF 
(15ml), n-BuLi (0.73ml, 7.78mmol) was added at -15°C and left to stir for 20 minutes. 2,4,5-
Trimethoxybenzaldehyde, (1.27g, 6.49mmol) in dry THF (5ml) was injected and the resulting 
solution was left to stir at room temperature for 1 hour and then treated with water (10ml). The 
reaction was allowed to cool and extracted with diethyl ether (3 x 20ml). The organic layers were 
washed with water (2x 10ml) and brine (2x 10ml) and concentrated in vacuo to give a yellow oil. 
This was purified through flash column chromatography with a 3:1 (petroleum ether:ethyl acetate) 
system to give a mixture of cis:trans (4:1 ratio) 0.04g. Rf: 0.52 and 0.36 (3:1 petroleum ether:ethyl 
acetate). IR (cm-1) 3517 (Ar-H), 2994 (Ar-H), 2937 (Methyl), 2830 (Methyl), 1516, 508 (C-I), δH 
(300 MHz, CDCl3) 3.43 (s, 3H), 3.71 (s, 3H), 3.81 (s, 3H), 6.36 (d, J = 12.13 Hz, 2H, cis isomer), 
6.60 (d, J = 15.00 Hz 2H, trans isomer), 6.93 (d, J = 8.33 Hz, 2H), 7.20 (m, 2H), 7.44 (d, J = 8.34 
Hz, 2H). δC (75 MHz, CDCl3) 55.7, 55.8, 56.2, 91.8, 96.8, 97.2, 109.0, 112.8, 116.5, 125.8, 127.4, 












To a stirred solution of 4-iodobenzyl triphenylphosphonium bromide (2.03g, 3.39mmol) in dry THF 
(15ml), n-BuLi (0.38ml, 4.06mmol) was added at -15°C and left to stir for 20 minutes. 2,4,5-
Trimethoxybenzaldehyde, (0.66, 3.39mmol) in dry THF (5ml) was injected and then left to stir at 
room temperature for 1 hour before being treated with water (10ml). The resulting solution was 
allowed to cool and extracted with diethyl ether (3 x 20ml). The organic layers were combined and 
washed with water (2x 10ml) and brine (2x 10ml) and concentrated in vacuo to give a yellow oil. 
This was purified through flash column chromatography with a 3:1 petroleum ether:ethyl acetate 
system to give a mixture of the cis and trans isomers as a pale white gum. (0.3g, 22%) (3:1 ratio, 
cis:trans) Rf: 0.70 and 0.53 (3:1 petroleum ether:ethyl acetate, 54mm). IR (cm-1) 2993 (Ar-H), 1509 
(C=C), 1479 (C-O), 534 (C-I), δH (300 MHz, CDCl3) 3.70 (s, 3H), 3.77 (s, 3H), 2.79-3.83 (m, 3H), 
6.35 (d, J=12.24 Hz, 1H, cis isomer), 6.41 (s, 1H), 6.57 (s, 1H), 6.60 (d, J=12.24 Hz, 1H, cis isomer) 
6.78 ( d, J=16.39 Hz, 1H, trans isomer), 6.92, (d, J=8.29 Hz, 2H), 7.12-7.19 (m, 2H), 7.34 (d, J=16.39 
Hz, 1H, trans isomer) δC (75 MHz, CDCl3) 56.0, 56.5, 56.6, 91.9, 97.3, 109.1 (2C), 117.6, 123.7, 
125.5, 128.0, 137.6, 137.6, 143.3, 149.8, 151.7, 151.8. MS: theoretical 397.0295, Actual 397.0284 ± 
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(Z/E)-2-(4-Iodostyryl)-2, 4, 6-trimethoxybenzene13 
 
To a stirred solution of 4-iodobenzyl triphenylphosphonium bromide (2.03g, 3.39mmol) in dry THF 
(15ml), n-BuLi (0.76ml, 4.06mmol) was added at -15°C and left to stir for 20 minutes. 2,4,6-
trimethoxybenzaldeyhde (0.66g, 3.39mmol) in dry THF (5ml) and left to stir at room temperature 
for 1 hour and then treated with water (10ml). The resulting solution was allowed to cool and 
extracted with diethyl ether (3 x 20ml). The organic layers were combined and washed with water 
(2x 10ml) and brine (2x 10ml) then concentrated in vacuo to give a yellow oil. This was purified 
through flash column chromatography with a 3:1 petroleum ether:ethyl acetate system to give a 
mixture 0.5g. (3:1 ratio, trans:cis) Rf: 0.5 and 0.4 δH (300 MHz, CDCl3) 3.49 (s, 3 H) 3.71 (s, 3 H) 
3.74 - 3.78 (m, 3 H) 6.01 (d, J=15.82 Hz, 2 H, trans), 6.06 (s, 2H), 6.34 (d, J=12.43 Hz, 1H, cis) 6.45 
(d, J=12.06 Hz, 1H, cis) 7.14 (d, J=8.29 Hz, 2 H) 7.51 (d, J=8.29 Hz, 2 H), δC (75 MHz, CDCl3) 
55.3, 55.4, 55.7, 119.9, 120.7 (2C), 122.0, 126.2, 126.6, 128.0, 128.4, 128.5, 129.8, 129.8, 136.7, 












To a stirred solution of 3-iodobenzyl)triphenylphosphonium bromide, (2g, 3.5mmol) in dry THF 
(15ml), n-BuLi (0.8ml) was added at -15°C and left to stir for 20 minutes. 3,5-Dibromobenzaldehyde, 
(0.9 g, 3.5mmol) in dry THF (5ml) was injected and the reaction was left to stir at room temperature 
for 1 hour and then treated with water (10ml). The resulting solution was allowed to cool and 
extracted with diethyl ether (3 x 20ml). The organic layers were washed with water (2x 10ml) and 
brine (2x 10ml) and concentrated in vacuo to give a yellow oil. This was purified through flash 
column chromatography with 100:1 petroleum ether:ethyl acetate system to give a pale yellow oil 
0.69g. Rf: 0.53 and 0.46 (100:1 petroleum ether:ethyl acetate), IR (cm-1) 3059 (Ar-H), 2917 (Ar-H), 
1577 (C=C), 1541 (C=C), 1466 (C=C-H), 741 (C-I), 681 (C-Br), 663 (C-Br), δH (300 MHz, CDCl3) 
6.86 (d, J=16.20 Hz, 1 H, trans isomer) 6.89 (d, J=16.58 Hz, 1 H, trans isomer) 7.04 (t, J=7.91 Hz, 
1 H) 7.19 (s, 1 H) 7.34 - 7.39 (m, 1 H) 7.48 (s, 2 H) 7.53 - 7.58 (m, 1 H) 7.78 (t, J=1.70 Hz, 1 H), δC 
(75 MHz, CDCl3) 94.4, 122.8, 126.8, 128.3 (2C), 130.4 (2C), 131.0, 132.8 (2C), 136.8 (2C), 137.7, 
140.1 











To a stirred solution of 4-iodobenzyltriphenylphosphonium bromide, (2.50g, 4.40mmol) in dry THF 
(15ml), n-BuLi (0.5ml) was added at -15°C and left to stir for 20 minutes. 3,5dibromobenzaldeyhde,  
(1.17g, 4.4mmol) in dry THF (5ml) was then injected and the reaction was left to stir at room 
temperature for 1 hour before then being treated with water (10ml). The resulting solution was 
allowed to cool and extracted with diethyl ether (3 x 20ml). The organic layers were washed with 
water (2x 10ml) and brine (2x 10ml) and concentrated in vacuo to give a yellow oil. This was purified 
through flash column chromatography with 100:1 petroleum ether: ethyl acetate system to give a 
mixture of inseparable isomers 0.86g. (13:1 ratio, trans:cis) Rf 0.59, 0.50 (100:1 petroleum 
ether:ethyl acetate). δH (300 MHz, CDCl3) 6.44 (d, J=12.43 Hz, 1 H, cis isomer) 6.71 (d, J=12.43 
Hz, 1 H, cis isomer) 6.95 (d, J=18.84 Hz, 2 H, trans isomer) 7.21 (d, J=8.29 Hz, 2 H) 7.32 (s, 1 H) 
7.61 (d, J=8.29 Hz, 2 H) 7.71 (d, J=8.29 Hz, 2 H), δC (75 MHz, CDCl3) 93.6, 122.4, 122.9, 125.9, 














(4-Bromobenzyl)triphenylphosphonium bromide (11.1g, 25.8mmol) was dissolved in dry THF 
(40ml) under anhydrous conditions, to which n-Buli (7.16ml, 77.4mmol) was injected at -20°C. The 
resulting red solution was left to stir for half an hour at -20°C and then brought to room temperature 
before 4-bromobenzaldehyde (4.73g, 25.8mmol) was added. The solution was then left to stir for 2 
hours before being quenched by addition of water (10ml) and then extracted with diethyl ether (3 x 
20ml). The organic layers were washed with water (2x 10ml) and brine (2x 10ml) and concentrated 
in vacuo to give a brown oil (2.71g). This was purified through flash column chromatography with 
20:1 petroleum ether:ethyl acetate system to give the title compound as a yellow oil, 0.2g, 2.3%, Rf: 
0.71 (20:1 petroleum ether:ether acetate), δH (300 MHz, CDCl3) 6.47 (s, 2 H) 6.98 - 7.04 (m, 4 H) 
7.25 - 7.32 (m, 4 H), δC (75 MHz, CDCl3) 121.2 (2C), 129.7 (2C), 130.4 (4C), 131.5 (4C), 135.6 
(2C). 
Synthesis of 3-acetyl-1,2,5-oxadiazole-2-oxide8 
 
Aqueous NaNO2 (34.0g, 0.449mol, 3.5eq) was added drop-wise to a stirred solution of 
crotonaldehyde (10.0g, 0.142mol) in acetic acid. During the addition the temperature of the reaction 
was kept at 14°C. The resulting yellow solution was left to stir for one hour, diluted with water 
(200ml) and then extracted with DCM (250ml) to yield a crude orange solid (5.45g). This was 
purified with flash column chromatography using DCM:petroleum ether (10:1) as an eluent to yield 
 Experimental 
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a viscous, pale yellow oil, 4.19g, 23%, Rf: 0.74 (petroleum ether:ethyl acetate, 1:1) IR (cm-1): 3362, 
2980, 1660, 1578 (C=N), 1470 (C=N+-O-)m 1244, 1006,  δH (300 MHz, CDCl3) 2.13 (s, 3H), 9.84 
(s, 1H). δC (75 MHz, CDCl3 18.83 (methyl), 110.35 (C=N+-O-), 154.35 (C=N), 198.73 (C=O). MS: 
theoretical (m/z): 129.0295. Actual: 129.0291± 2.9+ ppm for C4H5N2O3. 
3,4-Diphenyl-1,2,5-oxadiazole-2-oxide14 
 
To a warm solution (50-60°C) of acetic acid (6ml) and 1,4-dioxane (15ml), trans stilbene  (10.0g, 
0.05mol) was added and left to stir for 10 minutes to ensure a homogenous mixture before solid 
NaNO2 (26.0g, 0.38mol) was also added. The reaction was then allowed to proceed with stirring at 
55°C for 6.5 hours and then quenched by the addition of ice water (100ml). The mixture was 
extracted with ethyl acetate (2 x 60ml) and dried over MgSO4, to yield a brown oil. Purification was 
attempted by column chromatography (3:1 hexane: petroleum ether) to no effect. The oil was then 
recrystallized from hot hexane to yield orange crystals 0.12g, 1% in the first crop. The 
recrystallization process was repeated 6 times and all crystals were combined (0.8g, 6%) and the 
final remaining red oil was columned for a second time (10:1 hexane: petroleum ether). Further 
purification of the two spots from the TLC was not possible. Orange crystals were shown to be a 
mixture of furoxan and a nitrated starting material. Diagnostic signals consistent with furoxan 
formation were identified, and are as follows: Mp: 89.5-97.5°C, IR (cm-1), 3316 C-H (Ar), 3064 C-
H (Ar), 1657 (C=N), 1449 (C=N+-O-), 1246, C-H (Ar), 1209 C-H (Ar), δC (75 MHz,CDCl3) 114.3 
(C=N+-O-), 122.8, 126.6, 128.32, 128.7, 128.9, 129.0, 129.2 (2C), 129.9, 130.5, 131.0, 131.1, 156.2 
(C=N), MS: theoretical (m/z): 239.0815 Actual: 239.0814 ± 0.4 ppm for C14H11N2O2. Signals 
corresponding to nitrated material are MS: 226.0862 (low res) corresponding to C14H12NO2. 
 
 Experimental 




To a stirred solution of 2,4,5-trimethoxybenzaldehyde (10.0g 0.05mol) and 4-bromoacetophenone, 
(10.0g 0.05mol) in methanol (100ml) 5% NaOH (25ml) solution was added and the resulting yellow 
solution was left to stir at room temperature for 24 hours. This was worked up with the addition of 
water (100ml) which led to a bright yellow precipitate (7.14g). This was then recrystallized from hot 
ethanol to give a bright yellow powder 4.47g, 23%, M.p. 156.5°C, IR (cm-1) 536 (C-Br), 1201 (C-
OMe), 1274 (C-OMe), 1290 (C-OMe), 1610 (C=C), 1651 (C=O), 2833 (C-H), 2952 (C-H). δH (300 
MHz, CDCl3) 3.92 (d, J= 1.24 Hz, 6H), 3.97 (s, 3H), 6.54 (s, 1H), 7.13 (s, 1H), 7.41 (d, J= 15.74 Hz, 
1H), 7.64 (d, J= 8.61 Hz, 2H), 7.89 (d, J= 8.61 Hz, 2H), 8.10 (d, J= 15.76 Hz, 1H) δC (75 MHz, 
CDCl3)  56.1, 56.3 , 56.5 , 96.6, 111.41 , 115.2 , 119.7 , 127.3 (C-Br) , 130.0 (2C), 131.7 (2C), 137.5, 
140.8, 143.3, 152.7, 154.8, 190.1 (C=O), MS (m/z) theoretical: 377.0386 MS (m/z) actual: 377.0386 














To a solution of (E)-1-(3-iodostyryl)-2,4,6-trimethoxybenzene (0.5g, 1.26mmol) in acetic anhydride 
(15ml), potassium permanganate (0.79g, 5mmol) was added that turned the solution a deep purple 
colour. This was left to stir for 1 hour, then reaction was cooled to 0°C before sodium sulphite (2g) 
was added resulting in a dark brown solution. The precipitate was filtered off and the filtrate was 
extracted with ethyl acetate (2x 25ml) then washed with NaHCO3 (25ml) followed by brine (25ml) 
and then dried over MgSO4. The solvent was removed resulting in a pale yellow solid of the title 
compound, 0.2g, 37%,  IR(cm-1)  2944 (Ar-H), 1812 (C=O), 1733 (C=O), 1220, 1209 (C-O), 1120 
(C-H methyl), 1032 (C-H, methyl), 991, 588 (C-I), δH (300 MHz, CDCl3) 3.70 (s, 3H) 3.88-3.89 (m, 
6H), 6.02 (s, 2H), 7.29- 7.34 (m, 1H), 8.00-8.06 (m, 1H), 8.09-8.14 (m, 1H), 8.47 (t, J= 1.7, 1H), δC 
(75 MHz, CDCl3) 56.0 (3C), 90.1 (2C), 99.9 (C-I), 130.9, 132.7,134.9, 138.6 (2C), 144.1, 164.1 (2C, 


















To a solution of 1-(3-iodophenyl)-2-(2,4,6-trimethoxyphenyl)ethane-1,2-dione (0.2g, 47mmol) in 
dry pyridine (10ml) and ethanol (20ml), an excess of hydroxylamine hydrochloride was added. The 
resulting solution was heated 90°C for 3 days and then diluted with ethyl acetate and washed with 
2N sulphuric acid, water and brine. Removal of the solvent gave the title compound as a pale yellow 
oil 0.119g, 5.5%, IR (cm-1) 3234 (OH), 2922 (Ar-H), 2852, 1678 (C=N), 1561 (C=N), 1260 1229, 
1209, 528 (C-I), δH (400 MHz, CDCl3)  3.81 - 3.92 (m, 9 H) 6.07 (s, 2 H) 7.05 - 7.15 (m, 1 H) 7.92 
(d, J=7.09 Hz, 1 H) 7.99 - 8.11 (m, 1 H) 8.43 (s, 1 H), δH (75 MHz, CDCl3) 56.1 (3C), 90.3 (2C), 
93.8 (C-I), 129.3, 129.7, 130.0, 130.1, 139.0, 142.2, 151.4 (C=N), 154.3, 163.8 (3C). 
(E)-N-hydroxy-4-(trifluoromethyl)benzimidoyl chloride9 
 
To a stirred solution of 3-trifluromethyl-benzamidoxime (5.0g, 24.5mmol) in hydrochloric acid 
(12.5ml), NaNO2 (2.02g, 29mmol) was added portion-wise to the solution causing it to turn orange. 
The reaction was left to stir for 30 minutes causing an orange precipitate to form, which was then 
filtered off and purified by flash column chromatography with petroleum ether:ethyl acetate 7:3  to 
yield the title compound as a colourless oil. 1.34g 24%. (300 MHz, CDCl3) 7.66 (d, J = 7.77 Hz, 
2H), 7.81 (d, J = 7.78 Hz, 2H), δC (75 MHz, CDCl3) 121.6, 121.7, 125.3, 125.8, 129.1, 129.2, 134.2, 
149.6, MS theoretical (m/z): 223 MS actual: 221.3 and 223.3 for C8H5F3NOCl35+ and C8H5F3NOCl37+ 
respectively. 
 Experimental 




4-Chlorobenzaldehyde, (2.0g, 14.2mmol), hydroxylamine. HCl (1.16g, 16.8mmol) and sodium 
hydroxide (0.67, 16.8mmol) were ground together using a pestle and mortar. To this silica (2.0g) was 
added and the four solids ground for 10 minutes at room temperature. The fine powder was then 
ground every 15 minutes for 2 hours and then washed with water and allowed to dry in air to yield a 
pale white solid. 2.9g, 83% δH (300 MHz, CDCl3) 7.39 (d, J = 8.54 Hz, 2H), 7.53 (d, J = 8.51 Hz, 




4-Chlorobenzaldehyde (2.0g, 14.2mmol), hydroxylamine. HCl (1.16g, 16.8mmol) and sodium 
hydroxide (0.64g) was added at the same time to a pestle and mortar and ground continuously for 10 
minutes forming a ‘wet dough’ consistency. This mixture was then ground intermittently over the 
course of 2 hours and then washed with water and dried in air to give a cream solid of the titled 
compound 1.3g, 59% δH (300 MHz, CDCl3) 7.39 (d, J = 8.54 Hz, 2H), 7.54 (d, J = 8.50 Hz, 2H), 








To a stirring solution of 4-Chlorobenzaldehyde (2.0g, 14.2mmol) in diethyl ether (30ml), aqueous 
hydroxylamine. HCl (1.16g (16.8mmol) and sodium hydroxide (0.55g, 13,7mmol) was added at 
room temperature. This was then stirred vigorously for 2 hours. The reaction was then diluted with 
water (50ml) and extracted with diethyl ether (100ml) to produce a white solid of the titled compound 
1.9g, 87% δH (300 MHz, CDCl3) 7.39 (d, J = 8.56 Hz, 2H), 7.55 (d, J = 8.56 Hz, 2H), 8.13 (s, 1H), 
δC (75 MHz, CDCl3) 128.2, 129.1, 130. 3 (2C), 133.6, 136.0 (C-Cl), 149.3 (C=N).  
(Z)-4-Chloro-N-hydroxybenzimidoyl chloride19 
 
To a solution of (Z)-4-chlorobenzaldehyde oxime  (1.8g, 11.6mmol) in THF (30ml) at room 
temperature, N-chlorosuccinamide (1.54g, 11.6mmol) was added and the resulting yellow solution 
allowed to stir for 2 hours before water (25ml) and diethyl ether (25ml) were added. The organic 
layer was extracted and washed with brine (20ml) to yield pale yellow flakes, of the titled compound 
2.0g, 88.6% Rf: 0.83 (1:1 petroleum ether:ethyl acetate), Mp: 102.9-103.8°C δH (300 MHz, CDCl3) 









To a solution of (Z)-4-chlorobenzaldehyde oxime, (1.2g, 7.7mmol) in THF (30ml), N-
chlorosuccinamide (1.03g, 7.7mmol) was added at room temperature. The resulting yellow solution 
was left to stir for 2 hours.  After stirring water (25ml) and ether (25ml) were added and the organic 
layer was washed with brine (25ml) and dried over MgSO4 to yield a pale yellow solid, 1.4 g, 96% 
Rf: 0.83 (1:1 petroleum ether:ethyl acetate), Mp: 102.9-103.8°C, δH (300 MHz, CDCl3) 7.39 (d, J = 
8.75 Hz, 2H), 7.78 (d, J = 8.78 Hz, 2H), δC (75 MHz, CDCl3) 68.06, 128.2, 128.3, 128.7, 129.1, 
129.4, 149.18 (C=N). 
4-Bromobenzoic acid 
 
4-Bromoacetophenone (10.0g, 50.5mmol) was dissolved in acetic acid (53 ml) and heated to 80°C 
under reflux conditions.  Dilute HNO3 (11.9ml in 35ml H2O) was added drop-wise to the solution 
over the course of 30 minutes. A catalytic amount of NaNO2 was added and the reaction was left to 
reflux for a further 2 hours. The reaction was then left to cool, forming a precipitate which was then 
filtered off. The filtrate was extracted with DCM (3 x50ml) and dried over MgSO4, and concentrated 
in vacuo. The resulting solid was then recrystallized from hot DCM, producing a white precipitate 
which corresponded to the by-product 4-bromobenzoic acid, 0.99g, 9.8%, Mp: 245-247°C (Lit: 247-
250°C20), δH (300 MHz, d6-DMSO) 7.67 (d, J = 8.47 Hz, 2H), 7.85 (d, J = 8.51 Hz, 2H), 13.21 (s, 
1H), δC (75 MHz, d6-DMSO) 126.8, 129.9, 131.2 (2C), 131.6 (2C), 166.5 (C=O). 
 
 Experimental 




To a solution of 4-trifluoromethoxyacetophenone, (5.0g, 24.5 mmol) in glacial acetic acid (30ml.) 
dilute HNO3 (8 mL in 12ml H2O) was added drop-wise over the course of 30 minutes. A catalytic 
amount of NaNO2was then added to the solution which was then heated to 60°C for 2 hours. TLC 
showed an incomplete conversion so the reaction was maintained at 60°C for a further 2 hours. The 
reaction was then cooled to room temperature and a small amount of ice was added to quench the 
reaction and to encourage precipitation. No precipitate formed, so the solution was extracted with 
DCM (3 x 30 mL). The combined extracts were washed with water (25 mL), brine (25 mL) and dried 
over MgSO4. The combined extracts were concentrated to give a yellow oil (5.3g). The yellow oil 
was purified by column chromatography (hexane: ethyl acetate 10:1 to 1:1, followed by 100% ethyl 
acetate) to yield the title compound as a fine white powder, 0.19g, 3.6%, Rf: 0.46 (10:1 petroleum 
ether:ethyl acetate) Mp: 138.9-139.7°C (Lit: 150-152°C, hexane21) δH (300 MHz, d6-DMSO) 7.48 
(d, J=7.91 Hz, 2 H) 8.06 (t, J=8.85 Hz, 2 H), 13.19 (s, 1H), δH (75 MHz, d6-DMSO) 120.7, 129.7 















4-Methylacetophenone (5.0g, 37.3mmol) was dissolved in acetic acid (30 ml) and heated to 60°C 
under reflux conditions.  Dilute HNO3 (8ml in 20ml H2O) was added drop-wise to the solution over 
the course of 30 minutes. A catalytic amount of NaNO2was added and the reaction was left to reflux 
for a further 2 hours.  The reaction was then left to cool, but no precipitate formed so the solution 
was extracted with DCM and dried over MgSO4, and concentrated in vacuo. The resulting solid was 
then purified further using flash column chromatography, 10:1 (petroleum ether:ethyl acetate) to give 
a yellow oil of the title compound, 1.44g, 25.3%, Mp: 175.2-175.6°C , δH (300 MHz, CDCl3)  3.89 
(s, 3 H) 6.89 - 7.09 (m, 2 H) 8.00 - 8.14 (m, 2 H) δC (75 MHz, CDCl3) 55.7, 113.7, 114.3, 121.6, 
132.3, 133.2, 164.0 (C-OMe), 171.6 (C=O). 
4-Iodobenzoic acid23 
 
To a solution of 4-iodoacetophenone (3.3g, 12.2mmol) in acetic acid (30ml), dilute nitric acid (12.5 
ml in 18ml H2O) was added drop-wise over the course of 30 minutes. The reaction was slowly heated 
to 55°C and a catalytic amount of NaNO2 was added causing the evolution of brown fumes and 
turning the solution an orange colour. The reaction was left to stir at 55°C for 2 hours, cooled and 
poured drop-wise on to ice forming a white precipitate, and was isolated to yield the title compound 
as a colourless oil, 0.62g, 20.5%, δH (300 MHz, d6-DMSO), 7.68 (d, J=8.67 Hz, 2 H) 7.87 (d, J=8.48 








To a solution of 4-ethylacetophenone (2.9g, 20.0mmol) in acetic acid (30ml), dilute nitric acid (12.5 
ml in 18ml H2O) was added drop-wise over the course of 30 minutes. The reaction was slowly heated 
to 55°C and a catalytic amount of NaNO2 was added causing the evolution of brown fumes and 
turning the solution an orange colour. The reaction was left to stir at 55°C for 2 hours, at which time 
more NaNO2 was added and the reaction left for a further 2 hours. The reaction was then cooled to 
room temperature and then added drop-wise onto ice to produce a yellow precipitate. The filtrate was 
then extracted with DCM (2 x50ml), dried over MgSO4 and reduced to give a colourless oil of the 
title compound, 0.64g, 21%, δH (300 MHz, CDCl3) 1.06 - 1.18 (m, 3 H) 2.52 - 2.64 (m, 2 H) 7.16 (d, 
J=8.10 Hz, 2 H) 7.90 (d, J=8.10 Hz, 2 H) 12.25 (br. s., 1 H), δC (75 MHz, CDCl3) 15.1, 29.0, 126.6, 
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 2, 4, 5-Trimethoxy-5-nitrobenzene 
 
To a solution of 2,4,5-trimethoxyacetophenone, (5.0g, 24.0 mmol) in glacial acetic acid (30ml.) 
dilute nitric acid (8 mL of conc. nitric acid in 15ml H2O) was added drop-wise over the course of 30 
minutes. A catalytic amount of sodium nitrite was then added to the solution which was then heated 
to 60°C for 2 hours. TLC showed an incomplete conversion so the reaction was maintained at 60°C 
for a further 2 hours. The reaction was then cooled to room temperature and a small amount of ice 
was added to quench the reaction and to encourage precipitation. No precipitate formed, so the 
solution was extracted with DCM (3 x 30 mL). The combined extracts were washed with water (25 
mL), brine (25 mL), and dried over MgSO4. The combined extracts were combined and reduced to 
give a red solid (3.23g), this was then purified by column chromatography (hexane:ethyl acetate 10:1 
to 1:1) to give the titled compound as a bright orange solid, 0.42g, 8%, Rf: 0.56 (1:1 petroleum 
ether:ethyl acetate), Mp:112.9-113.7°C (Lit: 123-124°C25, acetone), δH (300 MHz, CDCl3) 3.91 (s, 
3H), 3.99 (s,3H), 4.00, (s, 3H), 6.57 (s, 1H), 7.60 (s, 1H)  δC (75 MHz, CDCl3)  56.4, 56.5, 57.1, 97.3, 
108.8, 130.7, 142.3, 150.4, 154.7 MS theoretical: 214.0708 m/z Actual: 2.14.0710 ±0.9 












To a solution of 2,4-dimethylaminopyridine (25.7g, 21.08mmol) and acetonlyacetone (25.0g, 
21.9mmol) in toluene (200ml) was added p-TsOH (0.40g, 2.10mmol). The resulting solution was 
refluxed under dean-stark conditions for 8 hour. The solvent was then removed and the crude product 
was purified via silica gel chromatography in 10:1 petroleum ether: ethyl acetate to give a pale yellow 
oil, 12.95g, 30.5% which upon standing crystallised to a yellow solid. Rf: 0.51 (petroleum ether: 
ethyl acetate, 10:1) Mp: 38.5°C (lit value 59°C17) IR (cm-1): 2959 (Ar-H), 2925, 1607 (C=N), 1570, 
839.  δH (300 MHz, CDCl3) 2.15 (s, 6H), 2.41 (s, 3H), 2.58 (s, 3H), 5.90 (s, 2H), 6.88 (s, 1H), 7.03 
















A solution of 2,4-dimethylaminopyridine (1.0g, 8mmol) in THF (25ml) was cooled to -78°C and n-
BuLi (0.85ml, 9mmol) was added and stirred for 20 minutes. TMEDA* (1.3ml, 9mmol) was added 
drop-wise and the solution was left to stir for a further 10 minutes before warming the solution to 
0°C for 1 hour. To the orange solution bromoethane (0.59ml, 8mmol) was added and left to stir for 
30 minutes. The reaction was quenched with a molar equivalent of NH4Cl. The solution was then 
extracted with DCM, (50ml) dried over MgSO4 and the solvent removed. No product was obtained 
for this reaction. *TMEDA was distilled over calcium hydride prior to use. 
2,4-Dimethyl-6-propylpyridine27 
 
Phenyl lithium (3.4g 41mmol) was added at -78°C to a solution 2,4,6-trimethylpyridine (5g, 
41mmol) in dry diethyl ether (40ml) under anhydrous conditions. The resulting red solution was 
stirred at -78°C for half an hour then at room temperature for 30 minutes. To this red solution, 
bromoethane (4.42, 41mmol) was injected and the resulting mixture was then refluxed at 40°C for 4 
hours and then poured onto ice (25g). The organic layer was extracted with diethyl ether (100ml) and 
reduced to give a brown/dark yellow oil which was then purified by flash column chromatography 
(10:1, petroleum ether:ethyl acetate) to give the title compound as a pale yellow oil, 0.3g, 4%. H 
(300 MHz, CDCl3) 0.89 (t, J = 7.35 Hz, 3H), 1.65 (qd, J = 14.92, 7.42, 7.42, 7.42 Hz, 2H), 2.21 (s, 
3H), 2.43 (s, 3H), 2.63 (m, 2H), 6.73 (s, 2H), δC (75 MHz, CDCl3) 13.9, 20.8, 23.4, 24.2, 40.3, 120.5, 
121.4, 147.3, 157.3, 161.4. 
 Experimental 




Phenyl lithium (3.4g 41mmol) was added at -78°C to a solution 2,4,6-trimethylpyridine (5g, 
41mmol) in dry THF (40ml) under anhydrous conditions. The resulting red solution was stirred at -
78°C for half an hour then at room temperature for 30 minutes. To this red solution, bromoethane 
(4.42, 41mmol) was injected and the resulting mixture was then refluxed at 40°C for 4 hours and 
then poured onto ice (25g). The organic layer was extracted with diethyl ether (100ml) and reduced 
to give a brown/dark yellow oil which was then purified by flash column chromatography (10:1, 
petroleum ether:ethyl acetate) to give the title compound as a pale yellow oil, 0.1g, 2%. H (300 
MHz, CDCl3) 0.97 (t, J=7.35 Hz, 3 H) 1.72 (m, 2 H) 2.28 (s, 3 H) 2.50 (s, 3 H) 2.63 - 2.76 (m, 2 H) 




2-(2,5-Dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyridine (0.5g, 2.5mmol) was dissolved in dry THFl 
ether (40ml) and cooled to -78°C, where n-butyl lithium (1.17ml, 12.5mmol) was injected dropwise. 
. The resulting orange solution was left to stir for 1 hour at -78°C and then brought to 0°C for 30 
minutes when 1,3-dibromo-2-propanol (0.26g, 1.25mmol) was added and the reaction left to stir for 
1 hour. The reaction was quenched with addition of water (10ml). The THF was then removed under 
reduced pressure to give a brown/yellow oil. Only starting material was recovered, this was 
confirmed by GCMS and 1H NMR spectroscopy. 
 Experimental 




2-(2,5-Dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyridine (7.0g, 35mmol) was dissolved in dry diethyl 
ether (40ml) and cooled to -78°C, where phenyl lithium (3.87ml, 38mmol) was injected dropwise. 
The resulting bright red solution was left to stir for 1 hour at -78°C and then brought to room 
temperature. The solution was slowly warmed to 45°C, where 1,4-dibromo-2,3-butandione (9.38g, 
38mmol) was injected and the solution left to reflux for a further 4 hours. The resulting solution was 
poured onto ice (25g) and the phases extracted with diethyl ether (3x 100ml), dried over MgSO4 and 
the solvent removed to give a brown oil. No product was obtained from this reaction this was 
confirmed by GCMS and 1H NMR spectroscopy. 
1,2-Bis((6-(2,5-dimethyl-1H-pyrrol-1-yl)-4-methylpyridin-2-yl)methyl)benzene26 
 
2-(2,5-Dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyridine (7.0g, 35mmol) was dissolved in dry diethyl 
ether (55ml) and cooled to -78°C, where phenyl lithium (3.87ml, 38mmol) was injected drop-wise. 
The resulting bright red solution was left to stir for 1 hour at -78°C and then brought to room 
temperature. The solution was slowly warmed to 45°C, where α,α’-dibromo-o-xylene (4.7ml, 
35mmol) was injected and the solution left to reflux for a further 4 hours. The resulting solution was 
 Experimental 
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poured onto ice (25g) and the phases extracted with diethyl ether (3x 100ml), dried over MgSO4 and 
the solvent removed to give a brown oil. No product was obtained from this reaction; this was 




2-(2,5-dimethyl-1H-pyrrol-1-yl)-4,6-dimethylpyridine (0.5g, 2.5mmol) was dissolved in dry THF 
(20ml) and cooled to -78°C, where n-BuLi (0.58ml, 6.2mmol) was injected dropwise. The resulting 
orange solution was left to stir for 1 hour at -78°C and then brought to 0°C for 30 minutes when 1,4-
dibromobut-2-ene (0.26g, 1.25mmol) was added and the reaction left to stir for 1 hour. The reaction 
was quenched with addition of water (110µl). The THF was then removed under reduced pressure to 




To an ice cold solution of glutathione (5.0g, 16.2mmol) in water (40ml) containing 2N HCl (10ml), 
sodium nitrite (1.0g, 14.4mmol) was added in one portion. The resulting solution was stirred for 40 
minutes at 5°C until the solution turned red. At this point acetone (10ml) was added and the reaction 
was stirred for a further 10 minutes. The resulting light pink solid was filtered off and washed with 
 Experimental 
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ice cold water (5ml), acetone (10ml), and diethyl ether (10ml) to afford the title compound (4.5g, 
82%). Compound was used directly upon isolation. 
S-Nitroso-1-thio-2,3,4,6-tetra-O-acetyl-β-D-glucopyranose (SNAG)29 
 
1-Thio-2,3,4,6-tetra-O-acetyl-β-D-glucopyranose (75mg, 0.25mmol) was dissolved in ethanol (5ml). 
The solution was then kept in the dark, while nitrous fumes were bubbled through the solution. These 
were generated by reacting concentrated HCl with solid NaNO2 in an attached, adjacent flask. The 
orange solution was then filtered off and the ethanol volume corrected back to 5ml to account for 
evaporation. Compound was used directly upon isolation. 
Acidic triiodide solution for conversion of nitrite and use in the NOA30 
Potassium iodide (2.0g, 12.0mmol) and iodine (1.3g, 10.3mmol) was dissolved in a combination of 
distilled water (40ml) and glacial acetic acid (140ml). The dark brown solution was sonicated to 
insure all particulates were dissolved. Aliquots of this solution was then used to measure nitrite 
formation in the nitric oxide analyser (NOA) apparatus. 
Acidified vanadium (III) chloride solution for conversion of nitrate and use in the NOA31 
Vanadium (III) chloride (0.5g, 5.0mmol) was weighed into a pre-dried conical flask. To this 1M HCl 
(100ml) was added very carefully, turning the solution a vibrant blue colour. Inversion of the flask 
was completed several times before the solution was ready to use. Aliquots of this solution were used 
to measure nitrate levels in the nitric oxide analyser (NOA) apparatus. NB: Before use in an NOA 
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Appendices 
AP01-Single crystal raw data for compound 103 
 




Empirical Formula C16H18N4O4 
 
Formula Weight 330.34 
 
Crystal Colour, Habit colourless, prism 
 
Crystal Dimensions 0.200 X 0.200 X 0.200 mm 
 
Crystal System triclinic 
 
Lattice Type Primitive 
 
Lattice Parameters a =   7.2312(8) Å 
 b =   7.8356(9) Å 
 c =   8.4677(9) Å 
 α =  64.604(9) o 
 β =  66.847(10) o 
 γ =  73.147(12) o 
 V = 394.24(9) Å3 
 
Space Group P-1 (#2) 
 
Z value 1 
 




 1.023 cm-1 
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Diffractometer XtaLAB P200 
 
Radiation MoKα (λ = 0.71075 Å) 
 multi-layer mirror monochromated 
 




Detector Aperture 83.8 x 70.0 mm 
 
Data Images 1441 exposures 
 
 -75.0 - 105.0o 
 
 




No. of Reflections Measured Total: 5339 
 Unique: 1422 (Rint = 0.0693) 
 
Corrections Lorentz-polarization 
  Absorption 
  (trans. factors: 0.501 - 0.980) 
  Secondary Extinction 
  (coefficient: 3.23000e-002) 
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Structure Solution Direct Methods (SIR2011) 
 
Refinement Full-matrix least-squares on F2 
 
Function Minimized Σ w (Fo2 - Fc2)2  
 
Least Squares Weights w = 1/ [ σ2(Fo2) + (0.0629 . P)2  
  + 0.0824 .  P ] 
  where P = (Max(Fo2,0) + 2Fc2)/3 
 
max cutoff 50.7o 
 
Anomalous Dispersion All non-hydrogen atoms 
 
No. Observations (All reflections) 1422 
 
No. Variables 110 
 




Residuals: R (All reflections) 0.0554 
 
Residuals: wR2 (All reflections) 0.1494 
 
Goodness of Fit Indicator 1.181 
 
Max Shift/Error in Final Cycle 0.000 
 
Maximum peak in Final Diff. Map 0.27 e-/Å3 
 
Minimum peak in Final Diff. Map -0.30 e-/Å3 
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Table 1. Atomic coordinates and Biso/Beq 
 
 




2 + 2U12(aa*bb*)cos  + 2U13(aa*cc*)cos  + 2U23(bb*cc*)cos α) 
 
Table 2. Atomic coordinates and Biso involving hydrogen atoms 
 
Atom    x    y    z  Biso 
H2      0.38661  0.23273  0.40133  1.844 
H3      0.50778 -0.01072  0.27770  2.033 
H4      0.78563  0.02063  0.01068  2.036 
H5      0.94840  0.29087 -0.13176  1.980 
H6      0.82113  0.53987 -0.01419  1.786 
H9A     0.06006  0.61482  0.65655  1.915 
H9B    -0.01828  0.72375  0.47967  1.915 
H10A    0.10651  0.91775  0.63316  1.778 











Atom X Y Z Beq 
O1      0.6342(2)  0.6840(2)  0.2209(2)  1.82(4) 
O8      0.2796(2)  0.72819(19)  0.4219(2)  1.47(3) 
N1      0.5174(3)  0.5659(2)  0.2687(3)  1.26(4) 
N7      0.3315(3)  0.5715(2)  0.3702(2)  1.37(4) 
C1      0.5930(3)  0.4072(3)  0.2005(3)  1.27(4) 
C2      0.4985(3)  0.2449(3)  0.2918(3)  1.54(4) 
C3      0.5715(4)  0.1007(3)  0.2189(3)  1.69(4) 
C4      0.7372(4)  0.1191(3)  0.0606(3)  1.70(4) 
C5      0.8327(4)  0.2806(3) -0.0254(3)  1.65(4) 
C6      0.7585(3)  0.4278(3)  0.0447(3)  1.49(4) 
C9      0.0707(3)  0.7279(3)  0.5415(3)  1.60(4) 
C10     0.0071(3)  0.9099(3)  0.5837(3)  1.48(4) 
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Table 3. Anisotropic displacement parameters 
 
Atom   U11   U22   U33   U12   U13   U23 
O1     0.0194(10) 0.0161(8) 0.0338(10) -0.0050(7) -0.0035(7) -0.0118(7) 
O8     0.0164(9) 0.0142(8) 0.0259(9)  0.0016(6) -0.0047(7) -0.0120(7) 
N1     0.0139(11) 0.0120(9) 0.0215(10)  0.0014(7) -0.0063(8) -0.0070(7) 
N7     0.0174(11) 0.0130(9) 0.0230(10)  0.0019(7) -0.0076(9) -0.0093(8) 
C1     0.0154(12) 0.0132(10) 0.0218(12)  0.0031(8) -0.0093(10) -0.0084(9) 
C2     0.0153(13) 0.0176(10) 0.0240(12)  -0.0005(9) -0.0051(10) -0.0082(9) 
C3     0.0195(13) 0.0149(10) 0.0321(13)  -0.0006(9) -0.0103(11) -0.0094(9) 
C4     0.0230(13) 0.0183(11) 0.0275(13)  0.0038(9) -0.0118(11) -0.0129(9) 
C5     0.0208(13) 0.0204(11) 0.0201(12)  0.0022(9) -0.0068(10) -0.0090(9) 
C6     0.0197(13) 0.0149(10) 0.0208(12) -0.0010(9) -0.0078(10) -0.0050(9) 
C9     0.0147(13) 0.0179(11) 0.0252(12)  -0.0003(9) -0.0029(10) -0.0095(9) 
C10    0.0157(12) 0.0175(11) 0.0227(12)  0.0026(9) -0.0064(10) -0.0097(10) 
 
 
The general temperature factor expression: exp(-22(a*2U11h2 + b*2U22k2 + c*2U33l2 + 
2a*b*U12hk + 2a*c*U13hl + 2b*c*U23kl)) 
Table 4. Bond lengths (Å) 
Atom Atom Distance Atom Atom  Distance 
O1 N1 1.263(3) O8 N7 1.380(3) 
O8 C9 1.451(2) N1 N7 1.280(2) 
N1 C1 1.467(3) C1 C2 1.388(3) 
C1 C6 1.374(3) C2 C3 1.390(4) 
C3 C4 1.388(3) C4 C5 1.389(3) 
C5 C6 1.395(4) C9 C10 1.517(4) 
C10 C101 1.526(3)    
 
Symmetry Operators: 
(1)  -X,-Y+2,-Z+1 
Table 5. Bond lengths involving hydrogens (Å) 
Atom Atom Distance Atom Atom Distance 
C2 H2 0.95 C3 H3 0.95 
C4 H4 0.95 C5 H5 0.95 
C6 H6 0.95 C9 H9A 0.99 
C9 H9B 0.99 C10 H10A 0.99 
C10 H10B 0.99    
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Table 6. Bond angles (o) 
Atom Atom Atom Angle Atom Atom Atom Angle 
N7 O8 C9 107.22(18) O1 N1 N7 126.4(2) 
O1 N1 C1 119.25(16) N7 N1 C1 114.3(2) 
O8 N7 N1 108.25(19) N1 C1 C2 120.41(18) 
N1 C1 C6 117.08(19) C2 C1 C6 122.5(2) 
C1 C2 C3 118.35(19) C2 C3 C4 120.2(2) 
C3 C4 C5 120.3(2) C4 C5 C6 119.98(19) 
C1 C6 C5 118.6(2) O8 C9 C10 107.2(2) 
C9 C10 C101 113.3(2)     
 
Symmetry Operators: 
(1)  -X,-Y+2,-Z+1 
Table 7. Bond angles involving hydrogens (o) 
Atom Atom Atom Angle Atom Atom Atom Angle 
C1 C2 H2 120.8 C3 C2 H2 120.8 
C2 C3 H3 119.9 C4 C3 H3 119.9 
C3 C4 H4 119.8 C5 C4 H4 119.8 
C4 C5 H5 120 C6 C5 H5 120 
C1 C6 H6 120.7 C5 C6 H6 120.7 
O8 C9 H9A 110.3 O8 C9 H9B 110.3 
C10 C9 H9A 110.3 C10 C9 H9B 110.3 
H9A C9 H9B 108.5 C9 C10 H10A 108.9 
C9 C10 H10B 108.9 C101 C10 H10A 108.9 
C101 C10 H10B 108.9 H10A C10 H10B 107.7 
 
Symmetry Operators: 
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Table 8. Torsion Angles(o) 




(1)  -X,-Y+2,-Z+1 
Table 9. Intramolecular contacts less than 3.60 Å 
Atom Atom Distance Atom Atom Distance 
O1 O8 2.4801(19) O1 C2 3.589(3) 
O1 C6 2.744(3) O8 C1 3.518(3) 
O8 C101 2.982(2) N1 C9 3.414(3) 
N7 C2 2.735(3) N7 C6 3.515(3) 
C1 C4 2.747(4) C2 C5 2.788(3) 
C3 C6 2.788(3)    
 
Symmetry Operators: 
(1)  -X,-Y+2,-Z+1 
 
 



















N7 O8 C9 C10 
-174.73 
(15)  
C9 O8 N7 N1 
-178.17 
(16)  
O1 N1 N7 O8 -0.9(3)  O1 N1 C1 C2 
159.35 
(19)  
O1 N1 C1 C6 -20.8(3)  N7 N1 C1 C2 -22.4(3)  
N7 N1 C1 C6 
157.48 
(19)  
C1 N1 N7 O8 
-179.03  
(16)  
N1 C1 C2 C3 
178.0 
(2)  
N1 C1 C6 C5 
-179.15 
(19)  
C2 C1 C6 C5 0.7(4)  C6 C1 C2 C3 -1.8(4)  
C1 C2 C3 C4 1.1(4)  C2 C3 C4 C5 0.6(4)  
C3 C4 C5 C6 -1.8(4)  C4 C5 C6 C1 1.1(4)  
O8 C9 C10 C101 67.4(2)  C9 C10 C101 C91 
180.00 
(18)  
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Atom Atom Distance Atom Atom Distance 
O1 H6 2.448 O8 H10A 2.532 
O8 H10A1 3.336 O8 H10B 3.241 
O8 H10B1 2.653 N1 H2 2.656 
N1 H6 2.574 N7 H2 2.478 
N7 H9A 2.535 N7 H9B 2.457 
C1 H3 3.248 C1 H5 3.242 
C2 H4 3.264 C2 H6 3.276 
C3 H5 3.265 C4 H2 3.269 
C4 H6 3.272 C5 H3 3.265 
C6 H2 3.275 C6 H4 3.268 
C9 H10A1 2.728 C9 H10B1 2.728 
C10 H9A1 3.387 C10 H9B1 2.704 
H2 H3 2.351 H3 H4 2.334 
H4 H5 2.337 H5 H6 2.356 
H9A H10A 2.407 H9A H10A1 3.598 
H9A H10B 2.325 H9B H10A 2.868 
H9B H10A1 2.52 H9B H10B 2.422 
H9B H10B1 2.951 H10A H10A1 2.865 














Table 11. Intermolecular contacts less than 3.60 Å 
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Atom Atom Distance Atom Atom Distance 
O1 O81 3.4504(19) O1 N71 3.241(3) 
O1 C32 3.158(3) O1 C42 3.275(3) 
O1 C53 3.590(3) O1 C91 3.582(3) 
O8 O11 3.4504(19) O8 N11 3.196(2) 
O8 C11 3.322(3) O8 C21 3.492(4) 
O8 C32 3.514(3) N1 O81 3.196(2) 
N1 N11 3.519(3) N1 N71 3.290(3) 
N1 C44 3.572(3) N1 C54 3.509(4) 
N7 O11 3.241(3) N7 N11 3.290(3) 
N7 N71 3.542(3) N7 C44 3.546(3) 
N7 C54 3.210(4) C1 O81 3.322(3) 
C1 C64 3.519(4) C1 C91 3.537(4) 
C2 O81 3.492(4) C3 O15 3.158(3) 
C3 O85 3.514(3) C4 O15 3.275(3) 
C4 N14 3.572(3) C4 N74 3.546(3) 
C5 O13 3.590(3) C5 N14 3.509(4) 
C5 N74 3.210(4) C6 C14 3.519(4) 




(1)  -X+1,-Y+1,-Z+1  (2)  X,Y+1,Z 
(3)  -X+2,-Y+1,-Z  (4)  -X+1,-Y+1,-Z 
(5)  X,Y-1,Z 
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Table 12. Intermolecular contacts less than 3.60 Å involving hydrogens 
Atom Atom Distance Atom Atom Distance 
O1 H21 3.47 O1 H32 2.483 
O1 H42 2.728 O1 H53 2.854 
O1 H9A1 2.858 O8 H21 3.439 
O8 H32 2.575 O8 H44 3.486 
O8 H54 3.524 N1 H32 3.331 
N1 H9A1 3.16 N7 H32 3.52 
N7 H54 3.068 N7 H9B5 3.217 
C1 H9A1 3.122 C1 H10A1 3.051 
C2 H36 3.292 C2 H64 3.51 
C2 H9B5 3.239 C2 H10A1 2.968 
C2 H10B5 3.118 C3 H26 3.218 
C3 H10A1 2.992 C3 H10B5 2.992 
C4 H47 3.195 C4 H57 3.321 
C4 H10A1 3.092 C5 H47 3.073 
C5 H63 3.386 C5 H9A8 3.127 
C5 H9B4 3.554 C5 H10A1 3.156 
C6 H63 3.024 C6 H9A8 3.129 
C6 H9A1 3.141 C6 H10A1 3.155 
C9 H25 3.089 C9 H59 3.445 
C9 H54 3.592 C9 H69 3.321 
C10 H25 3.288 C10 H32 3.571 
C10 H35 3.394 C10 H69 3.464 
H2 O11 3.47 H2 O81 3.439 
H2 C36 3.218 H2 C95 3.089 
H2 C105 3.288 H2 H26 3.499 
H2 H36 2.793 H2 H9A5 3.257 
H2 H9B5 2.426 H2 H10A10 3.109 
H2 H10A1 3.444 H2 H10B5 2.825 
H3 O110 2.483 H3 O810 2.575 
H3 N110 3.331 H3 N710 3.52 
H3 C26 3.292 H3 C1010 3.571 
H3 C105 3.394 H3 H26 2.793 
H3 H10A10 3.228 H3 H10A1 3.491 
H3 H10B5 2.562 H4 O110 2.728 
H4 O84 3.486 H4 C47 3.195 
H4 C57 3.073 H4 H47 2.963 
H4 H57 2.718 H4 H10A11 3.398 
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Table 12. Intermolecular contacts less than 3.60 Å involving hydrogens (continued 
Atom Atom Distance Atom Atom Distance 
H4 H10B11 3.086 H5 O13 2.854 
H5 O84 3.524 H5 N74 3.068 
H5 C47 3.321 H5 C98 3.445 
H5 C94 3.592 H5 H47 2.718 
H5 H63 3.22 H5 H9A8 2.541 
H5 H9B8 3.559 H5 H9B4 2.834 
H6 C24 3.51 H6 C53 3.386 
H6 C63 3.024 H6 C98 3.321 
H6 C108 3.464 H6 H53 3.22 
H6 H63 2.562 H6 H9A8 2.549 
H6 H9A1 3.11 H6 H10B8 2.916 
H9A O11 2.858 H9A N11 3.16 
H9A C11 3.122 H9A C59 3.127 
H9A C69 3.129 H9A C61 3.141 
H9A H25 3.257 H9A H59 2.541 
H9A H69 2.549 H9A H61 3.11 
H9A H9B5 3.438 H9B N75 3.217 
H9B C25 3.239 H9B C54 3.554 
H9B H25 2.426 H9B H59 3.559 
H9B H54 2.834 H9B H9A5 3.438 
H9B H9B5 3.314 H10A C11 3.051 
H10A C21 2.968 H10A C31 2.992 
H10A C41 3.092 H10A C51 3.156 
H10A C61 3.155 H10A H22 3.109 
H10A H21 3.444 H10A H32 3.228 
H10A H31 3.491 H10A H412 3.398 
H10B C25 3.118 H10B C35 2.992 
H10B H25 2.825 H10B H35 2.562 
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Symmetry Operators: 
(1)  -X+1,-Y+1,-Z+1  (2)  X,Y+1,Z 
(3)  -X+2,-Y+1,-Z  (4)  -X+1,-Y+1,-Z 
(5)  -X,-Y+1,-Z+1  (6)  -X+1,-Y,-Z+1 
(7)  -X+2,-Y,-Z  (8)  X+1,Y,Z-1 
(9)  X-1,Y,Z+1  (10)  X,Y-1,Z 
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AP02- HRMS of cyclohexane, formed from 104 decomposition 
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AP03- HRMS of cyclooctane, formed from 105 decomposition 
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AP04- Comparison of SNAG and cupferron compounds 
 
 
Graph 27: Comparison of SNAG and cupferron compounds 98-105 in the presence of light 
(254nm) NB: Under these conditions the parent cupferron compound 56 produced too much NO 
for the instrument to detect and is hence not included on the graph. The AUC measured has been 






























Comparison of SNAG and Cupferron derivatives in the 
presence of light (254nm) at 37°C
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Graph 28: Comparison of SNAG 19 with cupferron and its alkylated derivatives 99-105 at 37°C. 
The AUC measured has been divided by the concentration of the initial NO-donor solution to 































Comparison of SNAG 19, Cupferron and its derivatives 98-105 
under thermal conditions (37°C)
